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ABSTRACT 
Nutrient and energy partitioning toward productive processes (i.e., growth, 
reproduction, and milk production) is key to economically profitable agriculture. During 
infection, nutrients and energy are drawn away from profitable purposes to support the 
immune system. Immunological costs contribute to the economic consequences of sickness 
that include decreased growth, inefficient feed utilization, poor reproduction, and increased 
health care costs. Animals experience frequent immune challenges, as bacterial insults can 
originate from many different scenarios. Understandably, the intestinal epithelium is a 
focal point of bacterial translocation due to its “gate-keeping” role of simultaneously 
facilitating nutrient absorption while preventing bacterial infiltration into portal and 
systemic circulation. Immune insults originating from intestinal bacteria have become of 
interest as heat stress, feed restriction, and peripheral inflammation contribute to intestinal 
permeability to luminal content. Additionally, metabolic maladaptation to lactation 
following calving (i.e., ketosis) in dairy cattle is associated with inflammation, and 
intestinal-derived endotoxin may contribute to this metabolic disorder. Sickness or 
suboptimal health, regardless of origin, is an animal welfare issue and an economic burden 
to animal agriculture. The activated immune system employs a unique metabolism to 
strategically utilize substrates and ensure its quick and effective response. An activated 
immune system requires a large amount of energy, and systemic glucose homeostasis is 
markedly disrupted during endotoxemia. Specifically, activated macrophages and other 
immune cells become obligate glucose utilizers and hypoglycemia and hyperlactemia are 
characteristic hallmarks. The increased glucose requirement by the immune system occurs 
simultaneously with hypophagia and thus reduced intestinally derived carbohydrate 
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precursors. Consequently, there is a negative glucose balance that likely limits the immune 
response and certainly prevents optimal productivity. Having a better understanding of the 
nutrient requirements of an activated immune system will provide foundational 
information for developing strategies aimed at minimizing productivity losses during 
infection. Furthermore, understanding the etiology of immune system activation in various 
animal agricultural situations can aid in developing strategies to maximize protection 
against immune system over-activation.  
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CHAPTER 1: LITERATURE REVIEW 
 
Intestinal Permeability 
 
Anatomy and Physiology of the Intestinal Epithelium 
The intestinal epithelium serves a dual purpose of nutrient absorption and 
protection from numerous pathogens and other antigens present in the gastrointestinal tract 
lumen. Intestinal barrier integrity is maintained by physical and chemical means as well as 
an extensive mucosal immune system (summarized in Table 1 and Figure 1). One of the 
first physical lines of defense against foreign antigens is mucus, produced by goblet cells, 
which provides a barrier between intestinal microbiota and the mucosal epithelium and also 
acts as lubricant to keep digesta and microbes flowing continuously (McCauley and 
Guasch, 2015). There are over 20 different types of mucins produced throughout the 
gastrointestinal tract (Corfield, 2015), and absence of the major intestinal mucin, MUC2, 
can result in severe local inflammation and growth retardation (Van der Sluis et al., 2006). 
There are two distinct mucus layers in the large intestine; the inner layer is firmly attached 
to the epithelium and is mostly impenetrable to bacteria while the outer layer serves as a 
hospitable environment for some bacteria (Johansson et al., 2011). Similar to the bacterial 
load, proportions of goblet cells increase from the proximal to the distal intestine (Cheng 
and Leblond, 1974). Mucin is the glycoprotein constituent of mucus, and its secretion 
occurs in response to neuroendocrine signals, inflammatory mediators, and bacteria 
(Laboisse et al., 1996; Deplancke and Gaskins, 2001). Physiological stressors such as 
ischemia, nutrient restriction, and certain microbial enzymes can deplete the mucus layer 
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(Sherman et al., 1985; Grootjans et al., 2013; Kumar et al., 2014). Tight junctions (TJ) are 
another important aspect of the epithelial physical barrier that prevents pathogen 
infiltration while simultaneously allowing selective passage of ions and water (see review 
by Suzuki, 2013). Tight junction proteins are composed of four essential transmembrane 
proteins: occludin, claudin, junctional adhesion molecule, and tricellulin (Furuse et al., 
1993, 1998; Martìn-Padura et al., 1998; Ikenouchi et al., 2005). These transmembrane 
proteins are anchored to the cytosolic actomyosin rings via the scaffold protein zonula 
occludens (Fanning et al., 2002). Tension and contraction of the actomyosin ring is 
dependent on myosin light chain activity, and phosphorylation by myosin light chain kinase 
results in increased paracellular permeability (Cunningham and Turner, 2012). A number 
of cytokines and growth factors increase TJ permeability, including IFN-γ, TNF-α, IL-6, 
and IL-1β (Bruewer et al., 2005; Ma et al., 2005; Al-Sadi and Ma, 2007; Suzuki et al., 
2011). Conversely, there are cytokines and growth factors that aid in decreasing TJ 
permeability, including IL-10, TGF-β, and epidermal growth factor (Madsen et al., 1997; 
Howe et al., 2005; Geng et al., 2013). Ultimately, TJs and their associated intracellular 
complexes play a crucial role in maintaining barrier function, and inflammatory cytokines 
can cause alterations resulting in intestinal dysfunction. 
Interestingly, organized immune tissues were first identified in the gut of primitive 
fish, indicating the gut as the original immune system with spleen and lymph nodes 
occurring as later specializations (Matsunaga and Rahman, 2001). The gut-associated 
lymphoid tissue includes Peyer’s patches, isolated lymphoid follicles, intraepithelial 
lymphocytes, lymphocytes within the lamina propria, and plasma cells (Murphy, 2012). 
Peyer’s patches are covered by specialized M-cells which lack microvilli and are instead 
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characterized by microfolds on the apical membrane. These M-cells have a much thinner 
layer of mucus relative to enterocytes and therefore purposely endocytose more antigens 
from the lumen. In the subepithelial dome of Peyer’s patches, dendritic cells phagocytose, 
process, and present antigens to T-cells, which aids in activation and differentiation 
(Murphy, 2012). The majority of these interactions result in anti-inflammatory cytokine 
production by both macrophages and T-cells. However, when dysbiosis or pathogen 
infiltration occurs, dendritic cells switch into their pro-inflammatory phenotypes, initiating 
a pro-inflammatory response to clear invading pathogens (Murphy, 2012). 
 
Figure 1. A summary of intestinal dysfunction (Yu et al., 2016) 
 Synthesis and secretion of secretory immunoglobulin A (sIgA) is another important 
component of mucosal immunity. Plasma cells of the mucosal immune system synthesize 
and secrete sIgA into the gut lumen that binds and neutralizes antigens within the mucus 
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to inhibit propagation of an immune response (Mantis and Forbes, 2010). In addition, sIgA 
can facilitate antigen uptake into lymphoid compartments (Kadaoui and Chorthésy, 2007). 
A synergistic relationship exists between sIgA-secreting B cells and innate immune 
components of the gut associated lymphoid tissue, and knockout of either system results in 
enhanced stimulation of the other and enteric dysfunction (Slack et al., 2009; Shulzhenko 
et al., 2011). 
Table 1. Mechanisms of intestinal barrier maintenance (summarized from Murphy, 2012) 
 Defense Mechanisms Cell Types 
Mechanical 
low pH, mucins, tight junction 
proteins 
parietal cells, goblet cells, epithelial 
cells 
   
Chemical 
lysozymes, phospholipase A2, C-type 
lectins, defensins, cathelicidins, 
histatins 
Paneth cells, epithelial cells 
   
Immune 
system 
cytotoxicity, IgA, phagocytosis, 
degranulation, pathogen detection 
intraepithelial lymphocytes, plasma 
cells, macrophages, neutrophils, 
dendritic cells 
 
Failure in one or more of the aforementioned mechanisms of barrier function can lead to 
increased intestinal permeability to luminal contents and subsequent activation of the 
immune system in order to detoxify invading pathogens (see ‘Detoxification’) and is 
associated with a large energetic cost (see ‘Immune System Energetics’). 
 
Situations of Increased Intestinal Dysfunction 
Human diseases 
There are a variety of human diseases, albeit with etiological differences, where the 
common dominant pathology is impaired intestinal barrier function (i.e., leaky gut), 
including Crohn’s disease, inflammatory bowel syndrome, celiac disease, and alcoholism 
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(Draper et al., 1983; Bargiggia et al., 2003; Ludvigsson et al., 2007; McGowan et al., 2012). 
Furthermore, increased intestinal permeability has been associated with the development 
of type 1 diabetes (Bosi et al., 2006; Li and Atkinson, 2015). Incidentally, intestinal 
endotoxin infiltration contributes to hepatic steatosis (Nolan, 1975; Bargiggia et al., 2003; 
Ilan, 2012; Damms-Machado et al., 2017), and thus the aforementioned human diseases 
are often characterized by increased hepatic lipid content. In addition to the diseases 
mentioned above with various underlying etiologies, psychological stress has been 
implicated as an inducer of increased gastrointestinal tract barrier permeability (de Punder 
and Pruimboom, 2015). In fact, public speaking increases intestinal permeability, and these 
stress-induced increases in permeability are likely mediated by corticotropin-releasing 
hormone activation of mast cells (Wallon et al., 2008; Vanuytsel et al, 2014). Interestingly, 
a variety of models have demonstrated inflammation originating from non-intestinal 
sources can also impact intestinal health. Hemorrhagic shock, human immunodeficiency 
virus, burn injury, and intravenous lipopolysaccharide (LPS) all increase gastrointestinal 
tract barrier permeability (Ziegler et al., 1988; Russell et al., 1995; Hietbrink et al., 2009; 
Epple and Zeitz, 2012). Presumably this systemic effect is mediated via inflammatory 
cytokine activation of myosin light chain kinase and altered TJ proteins (Bruewer et al., 
2003; Cunningham and Turner, 2012). Thus, intestinal barrier dysfunction transcends 
species and is implicated in a variety of human disorders. While the physiology remains 
the same, the cause-effect relationship of intestinal permeability and other disorders 
remains somewhat vague in humans because of the large variation in genetic, diet, and 
lifestyle factors existing in human studies. 
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Rumen acidosis 
 The shift from a high-forage to high-concentrate diet is common practice for both 
beef and dairy cattle to provide a concentrated energy source to maximize production. 
These grains can be rapidly fermented in the rumen at a rate that exceeds the removal of 
the resulting volatile fatty acids, resulting in their accumulation and subsequent depressed 
ruminal pH (Owens et al., 1998). Broadly, rumen acidosis is a maladaptation to dietary 
changes, and the arbitrary threshold for non-physiological rumen pH is 5.5 and is defined 
as subacute rumen acidosis (SARA; Nordlund et al., 1995). Prevalence of SARA varies 
depending on herd management, but studies in Wisconsin indicate approximately 20% of 
tested commercial dairy cows had a ruminal pH below 5.5, and similar results have been 
obtained in German and Polish dairy herds (Oetzel et al., 1999; Kleen et al, 2013; Stefańska 
et al., 2016). Rumen acidosis is characterized by several negative consequences, including 
decreased dry matter intake, laminitis, liver abscesses, diarrhea, and milk fat depression 
(Kleen et al., 2003).  
Perhaps the earliest and most well-studied consequences of rumen acidosis are liver 
abscesses, which were first connected with rumen lesions by H. A. Smith in 1944 (reviewed 
by Nagaraja and Chengappa, 1998). Recently, there has been a renewed interest in rumen 
acidosis effects on epithelial barriers and consequences of bacterial translocation extending 
beyond the liver to systemic inflammation. Inducing SARA causes rapid bacterial 
proliferation and endotoxin release in the rumen (Gozho et al., 2005; Khafipour et al., 
2009a,b), and several authors have shown systemic inflammation occurs in experimentally-
induced SARA, attributable to changes in gastrointestinal tract permeability and bacterial 
endotoxin translocation (Gozho et al., 2005; Emmanuel et al., 2007b; Minuti et al., 2014; 
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Khafipour et al., 2009a). While effects of rumen acidosis on gastrointestinal permeability 
and subsequent inflammation are becoming well-established, the exact site of 
gastrointestinal permeability remains less clear. Rumen biopsies from SARA-induced 
cattle demonstrated deteriorated epithelial structural suggestive of rumen bacterial 
translocation (Steele et al., 2011). In vitro, Emmanuel and colleagues (2007a) demonstrated 
both endotoxin and low pH increased permeability of rumen and colon tissues, however, 
the concentration of LPS used to induce this change in permeability likely exceeded 
physiological concentrations. On the other hand, Khafipour et al. (2009a,b) demonstrated 
systemic inflammation occurred only when SARA was induced using a grain-based model 
and not when SARA was induced using alfalfa pellets. They speculated elevated 
inflammation in the grain-based model was due to hindgut acidosis, as high dietary starch 
levels can cause some starch to bypass pre-gastric fermentation and small intestinal 
enzymatic hydrolysis (Reynolds, 2006). Further data generated by Li et al., (2012) 
demonstrated a grain-induced model of SARA increased cecal LPS concentration and 
induced a systemic inflammatory response more than alfalfa-induced SARA; however, 
both grain- and alfalfa-based models of SARA induce similar decreases in cecal digesta 
pH, suggesting rapid bacterial proliferation and increased LPS concentrations, not altered 
pH, may be the cause of hindgut permeability. The rumen epithelium consists of four 
distinct layers (basale, spinosum, granulosum, and corneum) which together make up an 
~85 µm thick epithelial layer (Steele et al., 2016). The outer two layers of epithelial cells 
include the stratum granulosum and keratinized stratum corneum which work together to 
prevent permeability (Graham and Simmons, 2005; Elias, 2005; Steele et al., 2016). In 
contrast, the large intestine has a single layer of columnar epithelial cells ~20µm thick and 
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is protected by an inner and outer layer of mucus, the latter of which supports microbial 
habitation (Steele et al., 2016). Due to the lack of protozoa and salivary bicarbonate, the 
large intestine also possesses less buffering capacity than the rumen, despite similar 
bacterial concentrations and capacity for carbohydrate fermentation (Gressley et al., 2011). 
These differences suggest relative fragility in the hindgut compared to the rumen. 
Heat stress 
 Heat stress (HS) negatively impacts a variety of production parameters and is a 
significant financial burden (~$900 million/year for dairy in the U.S. alone; St. Pierre et 
al., 2003). Heat stress affects productivity indirectly by reducing feed intake; however, 
direct mechanisms also contribute as reduced feed intake only explains approximately 50% 
of the decreased milk yield during heat stress (Rhoads et al., 2009; Wheelock et al., 2010; 
Baumgard et al., 2011). During HS, blood flow is diverted from the viscera to the periphery 
in an attempt to dissipate heat leading to intestinal hypoxia (Hall et al., 1999). Enterocytes 
are particularly sensitive to hypoxia and nutrient restriction (Rollwagen et al., 2006), 
resulting in ATP depletion and increased oxidative and nitrosative stress (Hall et al., 2001). 
This contributes to TJ dysfunction and gross morphological changes that ultimately reduce 
intestinal barrier function (Lambert et al., 2002; Pearce et al., 2013a). As a result, HS 
increases the passage of luminal content into portal and systemic blood (Hall et al., 2001; 
Pearce et al., 2013a). Endotoxin infiltration during HS into systemic circulation was first 
observed by Graber et al. (1971) and is now commonly reported in heat stroke patients 
(Leon, 2007), and is thought to play a central role in heat stroke pathophysiology as 
survival increases when intestinal bacterial load is reduced or when plasma LPS is 
neutralized (Bynum et al., 1979; Gathiram et al., 1987).  
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Feed restriction 
There are a variety of occasions when feed intake is decreased, including gestation, 
heat stress, overcrowding, drought, shipping, poor management, and spoiled feed among 
others (Ingvartsen et al., 1992; Grant and Albright, 1995; Swanson and Morrow-Tesch, 
2001; Baumgard and Rhoads, 2013; Proudfoot et al., 2014; Hirata et al., 2015). 
Additionally, the periparturient period is a critical time of increased energy requirements, 
yet is a well-documented period of inadequate feed intake (Ingvartsen et al., 2000). While 
overlying conditions responsible for reduced feed intake can markedly affect metabolism 
and inflammation, reduced feed intake has a direct effect on intestinal integrity in pigs 
(Pearce et al., 2013a) and cattle (Zhang et al., 2013). Malnutrition-induced changes in 
intestinal permeability has been previously observed in rats, guinea pigs, and humans 
(Rodriguez et al., 1996; Welsh et al., 1998; Boza et al., 1999). Mechanistically, fasting 
reduces mucosal surface area, villus height, cell numbers, cell proliferation, and cell 
migration rates and is coupled with increased rates of cell loss, apoptosis, and mucin 
depletion, altogether contributing to increased intestinal permeability (Sherman et al., 
1985; Chappell et al., 2003; Ferraris and Carey, 2000). Although altered morphology does 
not prove increased permeability, malnutrition and intestinal permeability have been 
documented in humans and rodents (Welsh et al., 1998; Boza et al., 1999), and structural 
changes in villi morphology (i.e., decreased villus height, crypt depth, and their ratio) can 
be reflective of increased intestinal permeability (Ford et al., 1985; Pearce et al., 2013a). 
Numerous feed restriction models demonstrate detrimental effects on intestinal histology, 
including reduced villous height in feed restricted pigs (Carey et al., 1994; Pearce et al., 
2013a), chickens (Yamauchi et al., 1996), mice (Ueno et al., 2011), and rats (Holt et al., 
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1986). However, some feed restriction models indicate no effect or even an increase in villi 
height (Holt et al., 1986; Chappell et al., 2003; Hodin et al., 2011; Tůmová et al., 2015). 
Reasons for discrepant reports could be due to severity and duration of feed restriction as 
well as animal age. In particular, the effects of feed restriction in ruminants are difficult to 
assess because rumen fermentation continues for > 48 h following feed restriction 
(Bergman, 1990), and it can take over 4 d to truly fast a ruminant (Blaxter and Wainman, 
1966). Others have demonstrated an acute phase protein response to short-term feed 
restriction in beef cattle, suggesting that feed and water deprivation are the main 
contributors to the acute phase response in receiving feedlot cattle (Cappellozza et al., 
2011; Marques et al., 2012). The severity and duration of feed restriction in the literature 
vary considerably and effects on gut health are not extensively studied in the ruminant 
animal, ergo it is not clear what magnitude of feed restriction is required to dependably 
compromise intestinal barrier function and cause an inflammatory response in cattle. 
 
Modeling Intestinal Permeability in Ruminants 
  A variety of situations in animal agriculture can reduce intestinal barrier function, 
the consequences of which likely stimulate the immune system, cause inflammation, and 
eventually compromise production. Example circumstances in addition to those previously 
mentioned include weaning (Boudry et al., 2004; Moeser et al., 2007) and the periparturient 
period (Abuajamieh et al., 2016). However, a myriad of behavioral, metabolic, and 
endocrine events accompanying the aforementioned situations make it difficult to study the 
consequences of poor intestinal barrier health in isolation. Presumably an impaired 
intestinal barrier will negatively impact economically important phenotypes. However, 
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directly studying post-absorptive and production consequences of leaky gut is difficult as 
conditions thought to be responsible for reducing intestinal barrier integrity also affect 
multiple tissues and systems. Obvious examples of biologically confounding situations 
include the periparturient period and heat stress, both of which are accompanied by marked 
homeorhetic adaptations to support a new dominant physiological state (Bauman and 
Currie, 1980; Baumgard and Rhoads, 2013).  
Evaluating the metabolic, endocrine, inflammatory, and production consequences 
of intestinal dysfunction in isolation would provide insight into its direct impact on the 
pathophysiology of common on-farm disorders. Thus, there is a need to develop 
appropriate models to test potential leaky gut mitigation strategies. There are several 
chemically induced models of leaky gut (e.g., non-steroidal anti-inflammatory drugs, 
gamma-secretase inhibitors, dextran sodium sulfate; Fortun and Hawkey, 2007; Wirtz et 
al., 2007), but these approaches are associated with side effects or are logistically difficult 
to deliver, particularly in ruminants. Feed restriction provides an inviting alternative 
because it has previously been shown to cause intestinal dysfunction in a variety of species, 
including ruminants (see ‘Feed Restriction’ section), but a consistent severity and duration 
of feed restriction which causes negative effects on gut health is yet to be established. 
 
Strategies to Mitigate Intestinal Permeability 
The aforementioned situations of intestinal permeability demonstrate the fragility 
of intestinal barrier function. There are various direct strategies which have shown to 
improve intestinal barrier function, and these are highlighted in Table 2. In addition to these 
strategies specifically aimed at increasing gut barrier integrity, a number of tactics may be 
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employed to prevent the initial onset of intestinal barrier dysfunction. Rumen acidosis can 
be prevented through nutritional strategies such as bicarbonate, yeast, direct fed microbials, 
or ionophores (reviewed by Lean et al., 2014); therefore these strategies may benefit 
gastrointestinal health. Secondly, maximizing feed intake can be accomplished via feeding 
chromium or through electrolyte supplement (West et al., 1991; Hayirli et al., 2001) and 
this may help to mitigate feed restriction-induced changes in gut integrity. Both prevention 
of rumen acidosis and maximized feed intake can also be accomplished through proper 
feeding management (Zebeli et al., 2015), and an unpredictable feeding environment is 
associated with inflammation (Proudfoot et al., 2014). Lastly, improving immune function 
through immunomodulation may prevent inflammatory-induced changes in gut barrier 
function and help with efficient pathogen clearance. Dietary chromium and β-glucans 
modulate the immune system and exhibit beneficial effects on immune function (Borgs 
and Mallard, 1998; Murphy et al., 2010). Circulating immune cell numbers and function 
can also be improved with granulocyte colony-stimulating factor administration in cattle 
(Kehrli et al., 1991; Kimura et al., 2014). Dexamethasone is synthetic anti-inflammatory 
corticosteroid with the potential to reduce inflammation-induced gut barrier dysfunction 
(Chen et al., 1996). Preventing intestinal permeability should alleviate the negative effects; 
however, further research is needed on the gut-specific effects of these indirect, prevention-
based strategies. 
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Table 2. Potential strategies to ameliorate intestinal permeability 
Strategy Presumed Mechanism of Action References 
Glucagon-like peptide 2 ↑ intestinal integrity 1,2,3,27 
Glutamine ↑ intestinal integrity 4,5,6 
Zinc ↑ intestinal integrity 7,8,9,28 
Dairy products ↑ intestinal integrity 10,11,12 
Betaine ↑ intestinal integrity 13 
Butyrate ↑ intestinal integrity 14,15,16 
Vitamin A antioxidant 17,18,19,20 
Vitamin C antioxidant 21,22,23 
Vitamin E antioxidant 24,25 
Selenium antioxidant 25,26 
1Boushey et al., 1999 
2Cameron and Perdue, 2005 
3Walker et al., 2015 
4Van der Hulst et al., 1993 
5Wang et al., 2015a 
6Shu et al., 2016 
7Sanz-Fernandez et al., 2014 
8Song et al., 2015 
9Jafarpour et al., 2015 
10Playford et al., 1999 
11Prosser et al., 2004 
12Hering et al., 2011 
13Cronjé, 2005 
14Ferreira et al., 2012 
15Wang et al., 2012 
16Huang et al., 2015 
17McCollough et al., 1999 
18Warden et al., 1997 
19Thurnham et al., 2000 
 
20Elli et al., 2009 
21Buffinton and Doe, 1995 
22Inoue et al., 1998 
23Hosseinpour et al., 2012 
24Singh et al., 2012 
25Liu et al., 2016 
26Oztürk et al., 2002 
27Connor et al., 2017 
28Pearce et al., 2015 
 
 
Lipopolysaccharide 
 
Structure and Origin  
A Gram-negative bacterial cell is protected by an envelope consisting of two 
phospholipid membranes. The outermost facing membrane leaflet contains a special kind 
of glycolipid known as lipopolysaccharide (LPS), which is composed of three regions: 
lipid A, a core polysaccharide, and an O polysaccharide. Lipid A is the toxic portion of 
LPS that interacts with receptors to induce an immune response (Munford, 2005). 
Characteristics of lipid A acyl chains, such as number and length as well as phosphorylation 
state, contribute to its degree of toxicity, and the particular structure of lipid A in 
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Escherichia coli enables maximal activation with its receptor (Erridge et al., 2002). 
Interestingly, Gram-negative bacteria can modulate their lipid A-synthesizing enzyme 
expression in response to inflammation in order to reduce immune system activation and 
provide resistance to antimicrobial peptides (Cullen et al., 2015). The O polysaccharide 
region is associated with LPS virulence. The O polysaccharide can contain up to 200 sugars 
and extends beyond the cell which aids in phagocytosis resistance by white blood cells 
(Slonczewski and Foster, 2011). Changes in these sugar sequences result in different 
degrees of virulence, likely due to several factors including: adherence to certain tissues 
(i.e., epithelial tissue), resistance to phagocytes, serving as a water-solubilizing carrier for 
lipid A, protection from immune system components aimed at deactivating LPS, and 
antigenic variation allowing multiple opportunities for a pathogen to infect its host (Erridge 
et al., 2002). 
Lipopolysaccharide is present in all Gram-negative bacterial species; however, 
Escherichia coli is of particular interest in nutritional physiology because of its abundant 
presence in the intestinal lumen. Humans live continuously with over 1 g of LPS within 
the gut (Erridge et al., 2007), and bacterial load increases from the proximal to distal 
intestine (Donaldson et al., 2016). The gut lumen contains more bacteria than the human 
body has eukaryotic cells, and these bacteria play an intricate role in nutrient digestion and 
utilization (Marchesi et al., 2016). Importance of bacterial contribution to nutrient 
utilization, and therefore exposure to LPS, is certainly greater in ruminant than monogastric 
animals due to pre-gastric fermentation. Lipopolysaccharide is shed from bacterial cells 
during normal growth and division (Crutchley et al., 1968; Tsuji and Harrison, 1978), and 
administrating antibiotics can also induce LPS shedding due to bacterial death (van 
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Langevelde et al., 1998). Thus, natural exposure to endotoxin is dynamic and variable. Yet, 
one of the most common ways to model immune activation and inflammation is through 
bolus administration of LPS, which elicits a well-characterized and robust immune 
response (van Miert and Frens, 1968; Lohuis et al., 1988a,b). Human data suggest 
continuous LPS infusion prompts a less aggressive but more sustained release of 
inflammatory cytokines, likely more akin to natural LPS exposure (Taudorf et al., 2007). 
Continuous low-dose LPS exposure is not well-studied, particularly in ruminants, and 
having a better understanding how low-dose continuous LPS infusion affects metabolism 
and the immune response is critical to minimizing productivity losses when physiological 
states or environmental conditions naturally increase LPS exposure. 
 
Innate Immune Response to Lipopolysaccharide 
Recognition 
Lipopolysaccharide elicits an immune response via its recognition by Toll-like 
receptor (TLR) 4. The TLR4 complex is present on various cells including leukocytes, 
myocytes, adipocytes, and intestinal and mammary epithelial cells (Lin et al., 2000; 
Ibeagha-Awemu et al., 2008; Abreu, 2010; Frisard et al., 2010; Murphy, 2012) and elicits 
a well-characterized toxic immune response in animals (Berczi et al., 1966). Though TLR 
is present in intestinal epithelial cells, its expression is much lower in comparison with 
other tissues in order to maintain a more tolerant environment (Abreu, 2010). 
Lipopolysaccharide binding protein (LBP) facilitates the interaction of LPS and free or 
membrane-bound cluster of differentiation 14 (CD14) that in turn aids interaction of LPS 
with the TLR4 receptor complex. Jack and colleagues (1997) used LBP knockout mice to 
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demonstrate LBP’s crucial role in mounting an inflammatory reaction necessary to control 
live bacterial infection. The trans-membrane TLR4 and extracellular myeloid differential 
protein 2 (MD2) work together to recognize LPS, resulting in TLR4 dimerization and 
signal transduction using the intracellular adaptor protein myeloid differentiation factor 88 
(MyD88) and IL-1 receptor-associated kinase. This ultimately results in nuclear 
transcription factor kappa-B (NFκB) activation and an increase in inflammatory cytokine 
transcription to promote immune cell responses (Lu et al., 2008b). Alternatively, Kawai 
and colleagues (1999) found MyD88-independent responses to TLR4 dimerization that still 
led to NFκB activation in MyD88-knockout mice. However, this MyD88-independent 
pathway resulted in hyporesponsiveness to LPS; similar to the response of endotoxin 
tolerant animals (Kawai et al., 1999; see ‘Endotoxin Tolerance’ section). Ultimately, 
inflammatory cytokines produced from this activation process are what affect local and 
systemic physiology, resulting in fever, acute phase protein production, and/or metabolic 
alterations. 
Liver Response 
Traditionally, the liver is characterized as a metabolic organ; however, its role in 
immunity and endotoxin detoxification is extremely important (Strnad et al., 2017). Within 
10 min, more than 60% of i.v. injected bacteria can be found in the liver (Yan et al., 2014). 
Upon immunoactivation, the liver decreases synthesis of some proteins. These are termed 
negative acute phase proteins and include albumin, paraoxonase, and retinol binding 
protein. Positive acute phase proteins such as haptoglobin (Hp), serum amyloid A (SAA), 
and LBP aid in immune system propagation and endotoxin detoxification; thus, hepatic 
production of these proteins increases during the acute phase response (Ceciliani et al., 
31 
 
 
2012). Circulating major acute phase proteins can increase several-fold during immune 
system activation, making them attractive markers of inflammatory response. Haptoglobin 
is secreted mainly by hepatocytes and functions to bind hemoglobin released from red 
blood cell lysis (Eaton et al., 1982; Bertaggia et al., 2014). In doing so, Hp is thought to 
reduce iron availability to invasive and proliferating bacteria. Interestingly, Hp can also 
modulate the immune response through inhibiting neutrophil respiratory burst and may 
also prevent muscle atrophy during exercise or high fat diet induced oxidative stress, 
making its role in immunity complex (Oh et al., 1990; Bertaggia et al., 2014). Serum 
amyloid A has been suggested to play a role in cholesterol clearance from lysed cells, 
promotion of immune cell infiltration into tissue, upregulation of mucin expression, and 
opsonization of bacteria such as E. coli (Manley et al., 2006; Shah et al., 2006; Shigemura 
et al., 2014; Ye and Sun, 2015; Gouwy et al., 2015). Acute-phase SAA is produced in 
several isoforms by the liver (SAA1 and SAA2) as well as extrahepatic sources (SAA3) 
including adipose and mammary tissue (Ceciliani et al., 2012).  
Lipopolysaccharide binding protein was first characterized in 1986 by Tobias and 
colleagues after they noticed the rate at which LPS binds to high density lipoprotein was 
decreased in acute phase serum relative to normal serum, and that LPS-protein precipitate 
from normal serum dissolves readily in saline whereas LPS in precipitate from acute phase 
serum does not. Production of LBP mainly occurs in the liver, but it can also be synthesized 
by lung or intestinal epithelial cells, the kidney, and the reproductive tract (Wang et al., 
1998; Vreugdenhil et al., 1999; Malm et al., 2005). The primary purpose of LBP is to 
transfer LPS to the TLR4/CD14+ receptor on various immune cells in order to actuate an 
immune response (Lu et al., 2008b). Interestingly, LBP can either play a pro- or anti-
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inflammatory role following LPS activation (Gutsmann et al., 2001). Constitutive levels of 
LBP promote inflammation (Dentener et al., 1993) while acute phase levels of LBP inhibit 
LPS induced cytokine response in both mice and humans (Lamping et al., 1998; Zweigner 
et al., 2001). The anti-inflammatory effects of LBP are mediated by facilitating the transfer 
of LPS to lipoproteins which can clear LPS via non-inflammatory routes (Wurfel et al., 
1994). This makes LBP a particularly useful protein because it prevents toxic shock during 
extensive LPS infiltration and induces inflammation to control moderate bacterial infection 
(Kitchens et al., 2005). Interestingly, Jack et al., (1997) demonstrated LBP knockout mice 
administered a high i.p. LPS dose have a 100% survival rate while wild-type controls die 
quickly from septic shock. On the other hand, when gram-negative bacteria were injected 
i.p., LBP knockout mice were unable to inhibit bacterial proliferation and died within 5 d 
while most wild-type controls survived. These results indicate the significance of LBP in 
immunoactivation to clear invading pathogens and is an important concept to remember 
when considering models of immune challenges as LBP can appear detrimental in one 
model and protective in another. 
Detoxification 
Several different mechanisms exist for an organism to eliminate LPS. At the gut 
level, enterocytes can secrete alkaline phosphatase, both into the lumen and into portal 
circulation, which dephosphorylates LPS and renders it immunologically inert (Eliakim et 
al., 1991; Goldberg et al., 2008). Furthermore, dephosphorylated LPS still binds to TLR4 
(without initiating inflammation) and thus competitively inhibits intact LPS from binding 
(Lallès, 2014). Another enzyme important to LPS detoxification is acyloxyacyl hydrolase 
(AOAH), which is produced by macrophages, neutrophils, and dendritic cells (Munford 
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and Hall, 1986; Katz et al., 1999; Lu et al., 2003). Acyloxyacyl hydrolase detoxifies LPS 
by cleaving a secondary acyl group from LPS, rendering it inert and ~1% as immunogenic 
as fully acylated LPS (Munford and Hall, 1986; Lu et al., 2005). Interestingly, both LBP 
and sCD14 can rearrange LPS to better expose the lipid A portion for detoxification by 
AOAH (Gioannini et al., 2007). As stated previously, the liver’s role in immunity and 
endotoxin detoxification is extremely important (Strnad et al., 2017), and the majority of 
infiltrating pathogens end up in the liver relatively quickly (Yan et al., 2014) or originate 
from portal circulation (Jacob et al., 1977). The majority of LPS is cleared via resident liver 
macrophages (i.e., Kupffer cells) via both inflammatory and non-inflammatory 
mechanisms (which are not well-defined) and excreted back into the gastrointestinal tract 
lumen via bile (Mani et al., 2012; Guerville and Boudry, 2016). Interestingly, transition 
metals such as manganese, zinc, chromium, and copper may aid in the anti-inflammatory 
clearance by binding directly to LPS and preventing a cytokine response without affecting 
endocytosis (Thomas et al., 2008). Another major route of LPS detoxification is via 
lipoproteins, which sequester LPS quickly and are subsequently cleared via tissues 
expressing lipoprotein receptors (Munford et al., 2005). Lipopolysaccharide neutralization 
is affected by lipid emulsions (Read et al., 1995), chylomicrons (Vreugdenhil et al., 2003), 
very low density lipoproteins (VLDL; Harris et al., 1990), low density lipoproteins (LDL; 
Morel et al., 1986), high density lipoproteins (HDL; Guo et al., 2013), apolipoprotein B 
(Vreugdenhil et al., 2001), and apolipoprotein E (Rensen et al., 1997). Transfer of LPS 
from HDL to LDL can also occur, facilitated by LBP and other transfer proteins, but this 
transfer causes HDL to lose its cholesterol binding abilities and can cause dyslipidemia 
(Levels et al., 2005). Additionally, LBP and transfer proteins (e.g., phospholipid transfer 
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protein) can transfer LPS directly from bacterial membranes to lipoproteins (Vreugdenhil 
et al., 2003). The lipoprotein sequestration of LPS prevents TLR4 binding and immune 
system activation (Van Amersfoort et al., 2003), and infusing lipoproteins protects animals 
from the lethal effects of an LPS challenge (Harris et al., 1990, Casas et al., 1995; Van 
Amersfoort et al., 2003). Thus, LPS detoxification can occur via a variety of ways (both 
inflammatory and anti-inflammatory) with the ultimate end goal of neutralizing any 
infiltrating pathogens without excessive inflammation. 
Endotoxin Tolerance 
 Endotoxin tolerance is defined as a reduced inflammatory response to LPS that 
arises from repeated LPS exposure. It was first characterized in rabbits by Beeson (1946) 
who reported a diminishing fever response upon repeated E. typhosa injection. A plethora 
of modern literature exists as well; for example, rats repeatedly injected with LPS before 
subjection to a cecal ligation model of sepsis demonstrated reduced mortality relative to 
rats who were not pre-exposed to LPS (Shi et al., 2011). Tolerance is characterized by 
decreased pro-inflammatory cytokines and TLR expression as well as increased anti-
inflammatory cytokines (Biswas and Lopez-Collazo, 2009). Additionally, LPS tolerance 
increases expression of some genes termed “non-tolerizable” which are thought to protect 
against systemic infection, although this branch of tolerance is not well-studied and 
remains debated (Seeley and Ghosh, 2017). Induced tolerance in monocytes abolishes 
aerobic glycolysis normally induced during activation (Cheng et al., 2014; see ‘Immune 
System Energetics’ section), suggesting a link between tolerance, metabolic function, and 
immunity. The cellular mechanisms responsible for inducing tolerance are not well-defined 
and are currently being investigated, but may include: transcription factor and histone 
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modification, nucleosome remodeling, DNA methylation, CpG island promoters, micro 
RNAs, and long noncoding RNAs (Seeley and Ghosh, 2017). Daily LPS injections induce 
a greater degree of tolerance than weekly injections, although weekly injections are still 
effective (Beeson, 1947). Monocytes can develop LPS tolerance in as little as 1 h in vitro 
(del Fresno et al., 2009); however, endotoxin tolerance in vivo takes 24-36 h to develop. 
Once induced, tolerance can last several weeks (Beeson, 1947). How this occurs is also 
unclear, but may involve circulating microRNAs or alteration of the microbiome (Vatanen 
et al., 2016; Seeley and Ghosh, 2017). Tolerance has been described in several different 
species (van Miert and Frens, 1968) and appears to be an evolutionary advantage to limiting 
mortality due to septic shock. However, septic patient mortality is correlated with 
immunosuppression (Munoz et al., 1991; Boomer et al., 2011), and therefore contributes 
to confusion within the field. 
 
Immune System Energetics 
 
Immunometabolism 
The Warburg effect 
In normal resting cells, energy is most efficiently produced via the combined 
processes of glycolysis, the tricarboxylic acid (TCA) cycle, and oxidative phosphorylation 
which generates approximately 36 to 38 adenosine triphosphate (ATP) per molecule of 
glucose. In this process, glucose is catabolized via glycolysis to pyruvate, then to acetyl-
CoA using the enzyme pyruvate dehydrogenase (PDH). Acetyl-CoA enters the TCA cycle 
as citrate by combining with oxaloacetate to eventually produce ATP via oxidative and 
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substrate-level phosphorylation. During hypoxia, cells shunt pyruvate away from 
mitochondrial oxidative phosphorylation toward lactate production; this is known as 
anaerobic glycolysis (Berg et al., 2002). Glycolysis converts glucose into two pyruvate 
molecules, each of which are reduced to lactate molecules by the enzyme lactate 
dehydrogenase. This reaction takes place in the cytosol, generating a net two molecules of 
ATP. Regeneration of NAD+ also takes place and allows glycolysis to proceed since it 
needs NAD+ to convert glyceraldehyde 3-phosphate to 1,3 biphosphoglycerate. 
Interestingly, a switch from oxidative phosphorylation to glycolysis, even in the presence 
of oxygen, occurs in cancer cells (Warburg, 1927), preimplantation embryonic 
development (Seshagiri and Bavister, 1991; Redel, 2012), and immune cells (Warburg, 
1958; Sbarra and Karnovsky, 1959; Vander Heiden et al., 2009). This is known as the 
“Warburg Effect.” 
The Warburg Effect is named for Otto Warburg who was the first to characterize 
this metabolic phenomenon (1927) in cancer cells. Through his work, Warburg provided 
evidence that under normal conditions with adequate oxygen supply, cancer cells produced 
lactate from glucose. This phenomenon is in contrast to what was previously described in 
normal resting cells which prefer the efficiency of the TCA cycle for maximal ATP 
production. Warburg noted later (1958) that this also occurred in activated lymphocytes. 
Today, we know that the Warburg effect is not limited to cancer cells. Rapidly proliferating 
cells often utilize the Warburg effect to support rapid growth. An initial thought was that 
rate of ATP production was greater in aerobic glycolysis compared to oxidative 
phosphorylation (Nakashima et al., 1984), and is therefore able to provide a source of 
“quick energy.” However, Lunt and Vander Heiden (2011) argued that the main purpose 
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for the adjustment to glycolysis is to generate increased concentrations of glycolytic 
intermediates to support cellular anabolic processes. In a proliferating cell, approximately 
85% of glucose goes into glycolysis, 5% into oxidative phosphorylation for energy 
extraction, and 10% of the glucose is diverted into biosynthetic pathways before pyruvate 
production (Vander Heiden et al., 2009). Thus, glucose is an important substrate because 
its glycolytic intermediates are used to synthesize proteins, lipids, nucleic acids, and 
NADPH via the pentose phosphate pathway crucial for various immune cell functions 
(Palsson-McDermott and O’Neill, 2013). The ability to continually proliferate despite 
hypoxic environments is another advantage cells acquire from using glycolysis as it does 
not require oxygen consumption. Cancer cells create hypoxic environments due to rapid 
proliferation and inadequate vascularization. Further, sites of infection and inflammation 
may become nutrient or oxygen deficient due to oxygen consumption by neutrophils, 
increased metabolic activity of cells at the site, or necrosis of infected cells (Pearce et al., 
2013b). Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that responds to 
decreased oxygen availability and is also a major regulator of the Warburg effect (Semenza 
et al., 1994). Expression of glycolytic enzymes as well as glucose transporters, GLUT1 and 
GLUT3, are induced and increased via HIF-1 (Berg et al., 2002), allowing glycolysis to be 
more effective. Inducing HIF-1 occurs as a mediator of the Warburg effect in cancer 
(Maynard and Ohh, 2007) and immune cells (Imtiyaz and Simon, 2010). Even in normoxic 
conditions, succinate stabilizes HIF-1 (Selak et al., 2005) allowing HIF-1 to continue 
glycolytic regulation. A combination of all aforementioned advantages to utilizing the 
glycolytic pathway make the Warburg effect an operational method of energy extraction 
for proliferating cells independent of oxygen availability.  
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Active immune cells in both the innate and adaptive systems demonstrate the 
metabolic change from oxidative phosphorylation to glycolysis, including: dendritic cells, 
neutrophils, macrophages, T lymphocytes, and B lymphocytes (Kellett, 1966; van Raam et 
al., 2006; Krawczyk et al., 2010; Wang et al., 2011; Blair et al., 2012). The innate immune 
system is the first line of defense. Pattern recognition receptors, either membrane bound or 
in the cytosol, detect pathogen-associated molecular patterns (PAMPs) or damage-
associated molecular patterns. Binding of a ligand to the receptor causes a signaling 
cascade to occur resulting in transcription factor activation (e.g. NF-κB). Dendritic cells, 
important in cross talk between innate and adaptive immune systems, use a TLR agonist 
upon activation to change their metabolism from oxidative phosphorylation to glycolysis 
using the P13/Akt pathway, allowing for increased cellular function and synthesis and 
secretion of immune mediators (Krawczyk et al., 2010). Neutrophils are also dependent on 
aerobic glycolysis as they consume little oxygen and have few mitochondria (van Raam et 
al., 2006). Neutrophils increase NADPH generation via aerobic glycolysis and the pentose 
phosphate pathway for production of hydrogen peroxide for microbicidal function (Dale et 
al., 2008). In addition, macrophages exhibit the Warburg effect (Kellett, 1966). 
Interestingly, macrophages are able to differentiate into one of two types: M1 (classical) or 
M2 (alternative). The M1 macrophage is a “killer macrophage” stimulated by INFγ or 
particular TLR ligands. Differentiation of a macrophage to the M1 phenotype induces the 
switch to glycolysis. In contrast, the M2 macrophage only appears after cytokines such as 
IL-4, IL-13, or TGFβ stimulate development and does not switch metabolism to glycolysis 
(Palsson-McDermott and O’Neill, 2013). The M2 phenotype is a convalescent macrophage 
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which produces the anti-inflammatory cytokine IL-10 and is responsible for constructive 
processes such as wound healing (Mills, 2012). 
Primary cells of the adaptive immune system are B and T lymphocytes. T 
lymphocytes differentiate into regulatory cells, such as helper (Th) and regulatory (Treg), 
or effector cells, such as cytotoxic T (Tc), to help to provide immunity. Helper T cells 
activate the immune response and prompt differentiation of B cells. Once activated, B cells 
produce antibodies unique to the presented antigen, allowing them to bind to the antigen 
and remove it via immune effector cells and molecules. Helper T cells also stimulate 
differentiation of T lymphocytes into Tc cells utilizing cytotoxic proteins to kill infected 
cells. These Tc cells also release INFγ to inhibit viral replication and activate macrophages. 
Immune system regulation and suppression occurs via Treg cells secreting the anti-
inflammatory cytokine IL-10 to inhibit proliferation and activation of lymphocytes and 
macrophages (Borth, 2011).  
Glycolysis is necessary for B cell survival ex vivo and is stimulated via the B cell 
antigen receptor with protein kinase Cβ as a critical component (Blair et al., 2012). 
Metabolic reprogramming of T cells involving suppression of β-oxidation and stimulation 
of glycolysis is dependent on the Myc transcription factor, and may involve HIF-1 
activation to maintain glycolytic activities after initiation of the cell cycle (Wang et al., 
2011). T cells require glycolysis to be effective as a signaling mechanism to control cellular 
function through production of IFNγ. Changes in available GAPDH caused by glycolysis 
regulate cytokine mRNA translation otherwise inhibited by GAPDH binding to cytokine 
mRNA (Chang et al., 2013). This post-transcriptional control of T cell function by aerobic 
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glycolysis is a great example of how metabolism can have a profound impact on cell 
signaling. 
Alternative Role for the TCA Cycle 
Warburg’s suggestion that mitochondrial metabolism is negligible during the shift to 
glycolytic pathway has recently been challenged (Koppenol et al., 2011). In fact, when the 
Warburg effect is exhibited in cancer and immune cells, the TCA cycle can become an 
anabolic instead of catabolic process. Intermediates of the TCA cycle, such as citrate and 
succinate, have significant roles in macrophages during an LPS challenge (Infantino et al., 
2011; Selak et al., 2005). These intermediates provide substrate for biosynthesis of several 
different molecules and play an important role in inflammatory signaling (Palsson-
McDermott and O’Neill, 2013). The efflux of TCA cycle intermediates for biosynthesis is 
termed “cataplerosis” while the replenishing of intermediates is termed “anaplerosis.” 
Pyruvate, amino acids, and glutamine all contribute to anaplerosis (Owen et al., 2002). 
Recently, citrate has demonstrated importance in macrophage function. The work of 
Infantino and colleagues (2011) has demonstrated LPS-stimulated macrophages increase 
mitochondrial citrate carrier (CIC) to facilitate citrate transport from the mitochondrial 
matrix to the cytosol in exchange for malate. Upon citrate transportation into the cytosol, 
it is cleaved into acetyl-CoA and oxaloacetate by the enzyme citrate lyase. Fatty acid 
biosynthesis can then utilize acetyl-CoA for prostaglandin synthesis while oxaloacetate 
produces NADPH and H+ needed for nitric oxide (NO) generation and reactive oxygen 
species (ROS) formation via NADPH oxidase. Further, work by Infantino and colleagues 
(2011) demonstrated that CIC gene silencing and CIC inhibition reduces the production of 
nitric oxide, reactive oxygen species, and prostaglandins necessary for macrophage 
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immune function. Consequently, citrate is critical for macrophage activation by LPS and 
plays an important part in immune function. 
Macrophages stimulated by LPS also demonstrate an increase in the TCA cycle 
intermediate succinate (Tannahill et al., 2013). In addition, increased circulating succinate 
is present in rodent models of hypertension and metabolic disease (Sadagopan et al., 2007). 
Sources of succinate arise either from anaplerosis using glutamine as a substrate or 
generation through the γ-aminobutyric acid shunt (Palsson-McDermott and O’Neill, 2013). 
Succinate can be exported from the mitochondria into the cytosol in exchange for inorganic 
phosphate through the dicarboxylate carrier (Berg et al., 2002). Work done by Selak et al. 
(2005) demonstrates elevated succinate levels create negative feedback via product 
inhibition on prolyl hydroxylases (PHDs). Inhibiting PHDs stabilizes HIF-1, preventing 
its hydroxylation. Stabilization of HIF-1 allows it to continue down regulating oxidative 
phosphorylation by inducing pyruvate dehydrogenase kinase 1 and 3 that both inactivate 
PDH (Kim et al., 2006; Lu et al., 2008a; Papandreou 2006), discouraging entry of pyruvate 
into the TCA cycle and allowing for continued HIF-1 stabilization. Tannahill and 
colleagues (2013) also demonstrated HIF-1 stabilization and induction of inflammatory 
cytokine IL-1β due to succinate signaling. Increases in succinate also lead to a 
posttranslational modification known as protein lysine-succinylation (Zhang, et al., 2011). 
Not much is known about the effects of succinylation; however, it is a widespread 
posttranslational modification dependent on succinyl-CoA concentration and there is 
frequent overlap between succinylation and acetylation (Weinert et al., 2013). Succinate 
also has the ability to act as a signaling molecule in dendritic cells through the receptor 
GPR91 acting with TLRs to induce production of inflammatory cytokines (Rubic et al., 
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2008). In summary, succinate can act as a stabilizer of HIF-1, demonstrate protein 
succinylation, and activate GPR91 to induce an inflammatory response. 
Metabolism includes multifaceted and complex interactions between multiple 
systems, tissues, and organs. The Warburg effect, induced in inflammation and cancer, 
proves that metabolic pathways can be used to serve anabolic process in unexpected ways. 
Increased rates of glycolysis observed in cancer and immune cells help them not only to 
generate energy swiftly, but also to synthesize biomolecules needed for proliferation and 
other tasks. Any hypoxic environment experienced by cancer or immune cells is also 
neutralized by their ability to generate energy and molecules without oxygen. In addition, 
immune cells displaying the Warburg effect such as T cells rely on its characteristics for 
inflammatory signaling. Inhibiting the Warburg effect in inflammatory diseases is an 
exciting field of opportunity because it allows for many potential points of regulation. 
Better knowledge of the Warburg effect and its consequences on metabolism are necessary 
to developing novel approaches to mitigate inflammatory disorders. 
Glucose consumption 
Due to the shift in metabolism described in the previous sections, various in vitro 
experiments demonstrate a substantial increase in glucose consumption by activated 
immune cells as glucose is their primary fuel and an important biosynthetic precursor 
(Calder et al., 2007; Palsson-McDermott and O’Neill, 2013). Insulin, a major 
glucoregulatory hormone, positively affects function and/or glucose uptake in 
lymphocytes, neutrophils, and monocytes (Strom et al., 1975; Helderman, 1981; Daneman 
et al., 1992; Walrand et al., 2004). Furthermore, activated monocytes, T- and B-
lymphocytes, and neutrophils demonstrate increased GLUT1, GLUT3, and GLUT4 cell 
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surface expression, and insulin augments expression of GLUT3 and GLUT4 (Maratou et 
al., 2007). Monocytes from lactating dairy cows also have increased gene expression of 
GLUT3 and GLUT4 upon endotoxin stimulation in vitro (O’Boyle et al., 2012), although 
others have observed no effect (Eger et al., 2016). Both glucose and insulin levels are low 
during the periparturient period in dairy cows, but how this directly affects immune 
function is not yet clear. Kimura et al. (1999) demonstrated metabolic stress of milk 
production may contribute to immune cell dysfunction as mastectomized cows recovered 
neutrophil function more quickly than lactating cows. In vitro data suggest glucose 
supplementation to neutrophils from early and mid-lactation cows increases phagocytosis 
but has few other effects (Garcia et al., 2015).  
Previous estimates of glucose utilization in various immune cells and tissues both 
in vitro and in vivo and are summarized in Table 3. These studies firmly established that 
activated leukocytes primarily oxidize large quantities of glucose. Furthermore, the in vitro 
tissue studies firmly established tissues with a large immune compartment markedly 
increase glucose utilization. However, the extent of in vivo glucose consumption by the 
activated immune system is difficult to assess due to the ubiquitous and fluctuating 
distribution of immune cells and organ specific changes in insulin sensitivity. Furthermore, 
in vivo data are difficult to interpret due to different experimental procedures and 
conditions. Whole-body glucose utilization has been estimated using 2-deoxyglucose 
tracers in rodents by Lang et al. (1991, 1993) and in monkeys by Wannemacher et al. 
(1980). However, whole body glucose disposal measurements are governed by two 
opposing influences: tissues which increase glucose uptake and tissues which decrease 
glucose uptake. Glucose dynamics during immunoactivation involve orchestrated systemic 
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changes including peripheral insulin resistance and increased hepatic glucose output which 
successfully provides glucose in excess of immune cell utilization during the 
hyperglycemic phase of immunoactivation. Lipopolysaccharide-induced hypoglycemia 
represents the inability of glucose sparing mechanisms (reduced glucose uptake by insulin 
sensitive tissues and increased hepatic rates of glycogenolysis and gluconeogenesis) to 
keep pace with glucose utilization of the activated immune system. Thus, tissue specific 
rates of glucose utilization are currently much more informative than whole-body glucose 
disposal, and there is a need for an accurate way to specifically quantify whole-body 
immune cell glucose consumption in vivo. Furthermore, rodent models of glucose disposal 
may differ from most other species, as rodents do not seem to consistently exhibit 
hyperinsulinemia during immunoactivation (Lang et al., 1993; Table 4). Better 
understanding the impact of immunoactivation on whole-animal physiological glucose 
consumption has practical implications to animal agriculture as glucose is an important 
fuel for productive purposes. Whether glucose can become a limiting factor in the immune 
response is not clear and thus the benefits of supplemental glucose to sick animals remains 
unknown. However, from an animal production perspective, infection and inflammation 
noticeably redirect resources toward the immune system and away from utilization and 
synthesis of economically relevant products. Having a better understanding of the energetic 
and nutrient requirements of the immune response is critical to developing strategies to 
minimize productivity losses when physiological states or environmental conditions 
activate the immune system. 
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Table 3. Effect of immune activation on glucose utilization in leukocyte in vitro/ex vivo and in 
various tissues in vivo 
Leukocytes in vitro/ex vivo 
Leukocyte Response Average % Change % Change Range Reference 
T-lymphocytes ↑ +2,296% 100-5,153% 1,2,18 
B-lymphocytes ↑ +858% 150-1,400% 15,17,19 
Neutrophils ↑ +248% 142-339% 6,9,10 
Macrophages ↑ +219% 49-600% 4,5,6,7,8,9,10,16 
Dendritic cells ↑ +71% 67-80% 20,21,22 
Tissues in vivo 
Tissue Response Average % Change % Change Range Reference 
Lung ↑ +84% 60 – 140% 7,9,11,12,13,14 
Liver ↑ +153% 60 – 400% 7,9,11,12,13,14 
Ileum ↑ / = +62% 40 – 80% 7,11,12,13,14 
Spleen ↑ +92% 52 – 150% 7,9,11,12,13,14 
Skin ↑ / = +76% 50 – 125% 7,11,12,13,14 
Muscleb ↑ / ↓ / = +54% / -44% -44 – 75% 3,7,9,11,12,13,14 
Kidney ↑ / ↓ / = 75 % / -20%  11,13,14 
Adiposec ↓ / = -40%  3,11,13,14 
Brain =   11,12 
Testis =   7,9,11 
aMethods of immune activation include- 
leukocytes in vivo/ex vivo: concanavalin A, anti-Ig, lipopolysaccharide, insulin, tumor necrosis 
factor, granulocyte macrophage colony-stimulating factor, latex 
tissues in vivo: tumor necrosis factor, cecal ligation puncture, granulocyte macrophage colony-
stimulating factor, live E. coli, lipopolysaccharide 
bGastrocnemius 
cWhite adipose tissue 
1Brand, 1985 
2Greiner et al., 1994 
3Stevens et al., 2017 
4Costa Rosa et al., 1995 
5Spolarics et al., 1991a 
6Spolarics et al., 1991b 
7Spolarics et al., 1991c 
8Spolarics et al., 1992a 
9Spolarics et al., 1992b 
10Mészáros et al., 1991 
11Lang et al., 1990 
12Lang et al., 1991 
13Lang et al., 1993 
14Maitra et al., 2000 
15Caro-Maldonado et al., 2014 
16Fukuzumi et al., 1996 
17Doughty et al., 2006 
18Hume et al., 1978 
19Dufort et al., 2007 
20Jantsch et al., 2008 
21Krawczyk et al., 2010 
22Everts et al., 2012 
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Whole-body Response to Inflammation 
The energetic response to inflammation has been studied for centuries. As early as 
the 1830s, medical doctors such as Robert James Graves (for whom Graves’ disease is 
named) began teaching about the importance of maintaining energy intake during illness 
(Graves, 1842). Ever since, there has been accumulating appreciation for the complex and 
dynamic metabolic response to inflammation. Some metabolic effects of immune 
activation via endotoxin administration are highlighted in Table 3. However, it is important 
to understand metabolic responses generally exhibit a biphasic pattern during the course of 
infection. Interpreting the summary of studies listed in Table 1 is complicated by the fact 
that measurements were from samples obtained across various time points during or after 
immunoactivation. Metabolic changes are best described as a series of longitudinal 
measurements, and it is important to avoid characterizing samples obtained from one phase 
of sepsis as the overall metabolic response to sepsis. Certainly, metabolic responses and 
timing also depend largely upon the model of immunoactivation used. Lipid, protein, and 
carbohydrate metabolism are markedly altered by immunoactivation, and this is discussed 
below. 
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Table 4. The effects of endotoxin on plasma metabolites and regulatory hormones in various species 
Metabolite Species Response Reference 
Insulin Bovine ↑ / ↓ 3,4,11,19,22,23,27 / 28 
 Dogs ↑ 20 
 Horses ↑ 9 
 Pigs ↑ / ↓ 36 / 8,36 
 Rodent = / ↑↓ 38,40 / 39 
 Sheep ↑ 10,16,18 
Glucagon Bovine ↑ 3,4 
 Dogs ↑ 20 
 Rodents ↑ 38,39,40 
 Sheep ↑ 16 
Epinephrine Bovine ↑ 31 
 Human ↑ 25 
 Pigs ↑ 26 
 Rodent ↑ 39 
Cortisol Bovine ↑ 1,3,4,11,22,23,24,27,31,33 
 Human ↑ 25 
 Pig ↑ 8,26 
 Sheep ↑ 10 
Glucose Bovine ↑↓ / ↑ / ↓  1,2,3,19,23,24,27,34 / 4,6,22 / 21,28,29 
 Dogs ↓ 17,20 
 Pigs ↑↓ / ↓ 36 / 7,8 
 Rodents ↑↓ 38,39 
 Sheep/Goats ↑↓ / ↓ / ↑ 15,16,32 / 10,18,30 / 30 
NEFA Bovine ↑ / = / ↓ 2,3,5,6,23,28 / 4,19 / 11,22  
 Pigs ↑ 8,36 
 Rodents ↓ 37 
 Sheep ↓ / = 15 / 30 
BHB Bovine ↓ 3,4,5,6,22,23,24 
 Rodent ↓ 37 
 Sheep ↓ 15 
L-lactate Bovine = / ↑ 3/ 1,21,23,24,34 
 Pigs ↑ 7 
 Rodent ↑ 40 
 Sheep ↑ / = 16 / 15 
Calcium Bovine ↓ 2,12,14,34 
 Dogs ↓ 17 
 Horses ↓ 9 
 Pigs ↓ 13 
 Sheep ↓ 15 
BUN Bovine ↑ / ↓  2,19,27,28,33 / 4  
 Goat = 30,35 
 Pigs ↑ 7,36 
1 Giri et al., 1990 
2 Elsasser et al., 1996 
3 Waldron et al., 2003a 
4 Zarrin et al. 2014 
5 Graugnard et al., 2013 
6 Moyes et al., 2014 
7 Bruins et al., 2003 
8 Leininger et al., 2000 
9 Toribio et al., 2005 
10 Yates et al., 2011 
11 Vernay et al., 2012 
12 Waldron et al., 2003b  
13 Carlstedt et al., 2000 
14 Griel et al., 1975 
15 Naylor and Kronfeld, 1986 
16 Naylor and Kronfeld, 1985 
17 Holowaychuk et al., 2012 
18 Southorn and Thompson, 1986 
19 Burdick Sanchez et al., 2014 
20 Blackard et al., 1976 
21 Gerros et al., 1995 
22 Waldron et al., 2006 
23 Steiger et al., 1999 
24 Werling et al. 1996 
25 Richardson et al., 1989 
26 Williams et al., 2009 
27 Waggoner et al., 2009b  
28 Ballou et al., 2008 
29 Bieniek et al., 1998 
30 Wang et al., 2016 
31 Burdick et al., 2011 
32 Wang et al., 2015b 
33 Waggoner et al., 2009a 
34 Tennant et al., 1973 
35 van Miert et al., 1983 
36 Myers et al., 1997 
37 Kaminski et al., 1979  
38 Yamashita et al., 2015 
39 Maitra et al., 2000 
40 Lang et al., 1991 
 
48 
 
 
Carbohydrate Metabolism 
The earliest observation of altered carbohydrate metabolism during sickness 
occurred in 1926 when Francis Hector observed decreased glucose clearance following a 
glucose tolerance test in diphtheria patients (Hector, 1926). Similarly in 1928, Sweeney 
recognized impaired glucose disposal during endotoxemia. Since then, it has been well-
established that inflammatory conditions cause whole-body insulin resistance 
(McGuinness, 2005) and this has been confirmed in mid-lactation dairy cows (Vernay et 
al., 2012). Specifically, peripheral insulin resistance occurs in skeletal muscle and adipose 
tissue, the two largest “sinks” of insulin-stimulated glucose disposal (Lang et al., 1990; 
Song et al., 2006). However, some studies observe an increase in adipose tissue glucose 
utilization (Maitra et al., 2000). This is complicated by the fact that the immune system is 
ubiquitous and dynamic with leukocytes infiltrating various tissues during systemic 
inflammation (Peterson et al., 2003; Cani et al., 2007; Caesar et al., 2012; Pillon et al., 
2013). Furthermore, macrophages can make up to 40% of adipose tissue cells in obese 
individuals (Weisberg et al., 2003). To highlight cell type differences within a tissue, 
Mészáros and colleagues (1991) examined different cell fractions within the liver after an 
i.v. LPS challenge and demonstrated glucose uptake did not change in parenchymal cells 
but markedly increased in Kupffer cells (~7-fold) and neutrophils (~5-fold). In general, 
tissues with a large immune compartment (spleen, liver, lung, and ileum) increase glucose 
utilization following LPS administration (Lang et al., 1993). Collectively, this data 
suggests immune cells markedly increase glucose utilization following immunoactivation 
and changes in whole body glucose disposal are primarily due to insulin resistance in 
tissues with the largest mass (i.e., adipose and muscle). Additionally, activated immune 
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cells exploit aerobic glycolysis in order to utilize glucose, and this results in increased 
circulating lactate (see ‘Immune System Energetics’ and Table 4). Further research 
highlighting glucose utilization of different cell types within various tissues would be 
useful in better characterizing glucose utilization during immunoactivation. Synchronously 
with peripheral insulin resistance, hepatic glucose output increases via both glycogenolysis 
and gluconeogenesis, depending on the stage and severity of the infection (Filkins, 1978; 
McGuinness, 1994; Waldron 2003a). This is facilitated by characteristic increases of 
glucagon, epinephrine, and cortisol (see Table 4). Interestingly, following glucose infusion, 
there is impaired suppression of hepatic glucose output during sepsis, endotoxemia, and 
burn injuries (Long et al., 1976; Lang et al., 1987b; Wolfe and Burke, 1978). However, the 
liver is less sensitive to epinephrine-induced increases in glucose turnover (Hargrove et al., 
1989), likely because high epinephrine exposure during immunoactivation down-regulates 
adrenergic receptors and desensitizes tissues to subsequent re-exposure (Gurr and Ruh, 
1980; Snavely et al., 1985). Interestingly, increased circulating insulin is observed during 
immunoactivation. This is peculiar because glucose and glucagon typically act 
contrariwise and predominance of one over the other depends upon the prandial state. 
Endotoxin-induced hyperinsulinemia has been described in a variety of animal models (see 
Table 4). Additionally, glucose infusion can exacerbate this hyperinsulinemia (Blackard et 
al., 1976), suggesting an interaction between LPS and glucose infusion as recently 
proposed (Baumgard et al., 2016). However, it is not likely LPS-induced hyperglycemia is 
the sole cause of hyperinsulinemia during immunoactivation as prevention of 
hyperglycemia by fasting (thus depletion of hepatic glycogen storage) does not prevent 
increased circulating insulin (Hand et al., 1983; Stoakes et al., 2015a). The exact cause of 
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increased insulin secretion remains unclear, but is likely due to direct action of LPS on the 
pancreas (Vives-Pi et al., 2003; Bhat et al., 2014) or LPS-stimulated secretion of the insulin 
secretagogue glucagon-like peptide 1 (Nguyen et al., 2014). Rationale for why circulating 
insulin increases are not clear, but insulin becomes important for development and 
sensitivity to glucose uptake in immune cells during activation (Shimizu et al., 1983; 
Helderman, 1984; Calder et al., 2007; Maratou et al., 2007). Therefore, hyperinsulinemia 
coupled with peripheral insulin resistance may be a homeorhetic strategy employed to 
ensure adequate glucose delivery to the immune system. Despite the aforementioned 
efforts to spare glucose, hypoglycemia often develops following an LPS challenge, likely 
because the rate of glucose utilization by the immune system exceeds the orchestrated 
capacity of the liver to export glucose and insulin sensitive tissues to reduce glucose 
disposal (McGuinness, 2005).  
Protein Metabolism 
In 1857, Parkes first demonstrated negative nitrogen balance during immune 
activation, and Voit furthered this knowledge in 1895 by showing dietary carbohydrates 
alleviate nitrogen loss in endotoxic dogs (Beisel and Wannemacher, 1980). We now know 
that skeletal muscle is catabolized during infection to provide amino acids as substrates for 
gluconeogenesis (Wannemacher et al., 1980) as well as to provide amino acids for 
synthesis of leukocytes and acute phase proteins (Iseri and Klasing, 2013).  In humans, it 
has been estimated up to 850 mg acute phase proteins are synthesized per kg body weight 
in a typical acute phase response, and the mismatch in amino acid composition between 
muscle and acute phase proteins means more than 1,900 mg of skeletal muscle protein must 
be mobilized to provide a sufficient quantity of phenylalanine to support synthesis of the 
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acute phase proteins (Reeds et al., 1994). Thus, blood urea nitrogen consistently increases 
in monogastric models of endotoxemia (see Table 4) due to increased protein catabolism. 
Results in ruminants generally agree, but are more variable, as circulating BUN is 
complicated by the contribution of rumen urea flux and endotoxin-induced hypophagia 
reduces substrate delivery and rumen microbiota and function (Galyean et al., 1981; Jing 
et al., 2014), with the potential to mask catabolic-induced changes in BUN. Thus, it is 
important in ruminant studies to utilize pair-feeding models in order to account for 
decreased feed intake. This is again complicated by the rumen, as it takes 4 or more days 
to truly fast ruminants (Blaxter and Wainman, 1966).  
Lipid Metabolism 
Circulating levels of triglycerides and VLDLs are increased during endotoxemia in 
several monogastric species and calves (Kaufmann et al., 1976; Lanza-Jacoby et al., 1998; 
Ballou et al., 2008) due to increased hepatic triglyceride secretion or reduced lipoprotein 
lipase activity in adipose and muscle, depending on the LPS dose (Feingold et al., 1992). 
Conversely, decreased triglyceride levels in response to LPS infusion have been observed 
in heifers and goats (Steiger et al., 1999; Wang et al., 2017), although endotoxin-induced 
circulating triglyceride data in mature ruminants is scarce. Decreased circulating 
triglycerides in ruminants relative to non-ruminants may be due to the limited capacity for 
hepatic synthesis and secretion of VLDL in ruminant animals (Kleppe et al., 1988). 
Adipose tissue lipolysis during immunoactivation is variable. Some report increased 
circulating NEFA while others report decreases (see Table 4). In general, it seems 
circulating NEFA increase over time in immunoactivated animals, but this response is 
blunted when compared to pair-fed animals. Hyperinsulinemia likely contributes to 
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situations of decreased plasma NEFA observed in LPS-administered animals as insulin is 
a potent antilipolytic hormone (Vernon, 1992). Furthermore, increased circulating lactate 
during endotoxemia may contribute to the blunted lipolytic response because it mediates 
insulin’s antilipolytic effects by binding to the adipocyte G protein-coupled receptor 
GPR81 (Ahmed et al., 2010). Despite decreased circulating NEFA relative to pair-fed 
animals, NEFA accumulation into hepatic triglycerides is accelerated during 
immunoactivation (Guckian, 1973; Fiser et al., 1974; Lanza-Jacoby and Tabares, 1990) 
and a variety of infection/inflammation models have demonstrated fatty liver as a 
consequence (Hirsch et al., 1964; Ilan, 2012; Fukunishi et al., 2013; Wenfeng et al., 2014; 
Damms-Machado et al., 2017). Despite accelerated hepatic triglyceride accumulation, 
ketogenesis is compromised during infection in rodent models (Neufeld et al., 1976; 
Takeyama et al., 1990; Gitomer et al., 1995). Circulating insulin may play an important 
role in inhibiting ketogenesis during sepsis. Neufeld et al., (1980) demonstrated low blood 
ketones in infected rats was abolished when insulin production was inhibited via 
streptozotocin injection. Several ruminant models have demonstrated reduced circulating 
BHB following endotoxin administration (Waldron et al., 2003a; Graugnard et al., 2013), 
but reasons for decreased circulating ketones are less clear because a majority of circulating 
BHB during positive energy balance originates from the rumen epithelium as opposed to 
the liver (Pennington, 1952). Therefore, decreased BHB may simply be due to illness-
induced hypophagia, and this explains decreases in pair-fed animals as well. 
Administrating LPS also decreases rumen motility (Jing et al., 2014), and whether or not 
this gastrointestinal stasis affects ketone synthesis is not known. Waldron et al., (2003a) 
observed no LPS effects on ketone synthesis in incubated liver slices obtained from 
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lactating cows, indicating ketogenesis remains functional. Additionally, an increased rate 
of BHB infusion was required to maintain hyperketonemia in lactating cows challenged 
with LPS (Zarrin et al., 2014), indicating increased circulating BHB clearance and 
peripheral tissue utilization could help explain the decrease as this may be a strategy 
utilized to spare glucose for immune cells. Furthermore, we have shown increased BHB 
levels in cows infused continuously with LPS for 7 d relative to pair-fed controls (see 
chapter 6). Because ruminant lipid metabolism differs markedly from rodents and humans, 
a better understanding of how endotoxemia specifically influences ruminant metabolism 
has obvious practical implications to a variety of dairy cow pathological conditions.  
 
Conclusion 
Immunoactivation can be caused by a variety of situations, but intestinal 
permeability is gaining rapid attention, as a wide variety of situations can lead to 
compromised intestinal barrier function and subsequent endotoxin translocation into portal 
and systemic circulation. Immune insults originating from intestinal bacteria have become 
of interest as heat stress, feed restriction, and peripheral inflammation contribute to 
increased intestinal permeability. While much attention has been paid to obvious sources 
of inflammation, relatively little is known about intestinal dysfunction and its contribution 
to immunoactivation, particularly in ruminants. A partial objective of this dissertation was 
to determine, in lactating dairy cows, if feed restriction causes intestinal dysfunction and 
to determine metabolic consequences of intentionally-induced intestinal dysfunction 
(Chapter 2 and 3).  
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Intestinal dysfunction can result in translocation of PAMPs which activate the 
immune system and cause an inflammatory situation. This has obvious implications to 
animal agriculture, as homeorhetic adaptation in support of an immune response takes 
precedence over energy directed towards economically productive purposes. Glucose 
metabolism is especially altered during inflammation, and this is mainly due to the 
increased requirement by immune cells coupled with peripheral insulin resistance. 
Accurately quantifying the amount of glucose the immune system diverts from milk or lean 
tissue synthesis would provide a greater understanding of practical dietary requirements 
and management strategies to better maintain glucose homeostasis in immune-challenged 
animals. Ultimately, the experiments within this dissertation will provide valuable and 
pragmatic information enabling us to model dietary requirements during times of infection. 
This will allow nutritionists and producers to more efficiently predict and compile least 
costs rations to maximize productivity and profitability while simultaneously promoting 
optimal animal health. Therefore, another objective of this dissertation was to determine 
the glucose requirements of an activated immune system (Chapter 4 and 5). Finally, current 
knowledge of endotoxin effects on metabolism are limited to bolus or short term LPS 
infusion models, yet during natural infection, endotoxin release is concomitant with 
dynamics of bacterial growth and proliferation. Key knowledge gaps remain in 
distinguishing how accurate single or repeated LPS boluses mimic chronic, naturally-
occurring exposure and therefore a final objective to this dissertation was to observe if 
chronically administered endotoxin would also result in detrimental metabolic changes 
similar to bolus models (Chapter 6).   
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CHAPTER 2: INTENTIONALLY INDUCED INTESTINAL BARRIER 
DYSFUNCTION CAUSES INFLAMMATION, AFFECTS METABOLISM, AND 
REDUCES PRODUCTIVITY IN LACTATING HOLSTEIN COWS 
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Abstract 
Study objectives were to evaluate the effects of intentionally reduced intestinal 
barrier function on productivity, metabolism, and inflammatory indices in otherwise 
healthy dairy cows. Fourteen lactating Holstein cows (parity 2.6 ± 0.3; 117 ± 18 days in 
milk) were enrolled in two experimental periods. Period 1 (P1; 5 d) served as the baseline 
for period 2 (P2; 7 d) during which cows received one of two i.v. treatments twice daily: 
1) sterile saline or 2) gamma-secretase inhibitor (GSI; 1.5 mg/kg body weight). Gamma-
secretase inhibitor reduces intestinal barrier function via inhibiting crypt cell differentiation 
into absorptive enterocytes. During P2, control cows receiving sterile saline were pair-fed 
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(PF) to the GSI-treated cows and all cows were euthanized at the end of P2. Administering 
GSI increased goblet cell area 218, 70, and 28% in jejunum, ileum, and colon, respectively. 
In the jejunum, GSI-treated cows had increased crypt depth and reduced villus height, 
villus height-to-crypt depth ratio, cell proliferation, and mucosal surface area. Plasma 
lipopolysaccharide binding protein increased with time, and tended to be increased 42% in 
GSI-treated cows relative to PF-controls on d 5-7. Circulating haptoglobin and serum 
amyloid A concentrations increased (585 and 4.4 fold, respectively) similarly in both 
treatments. Administering GSI progressively reduced dry matter intake (66%) and, by 
design, the pattern and magnitude of decreased nutrient intake was similar in PF-controls. 
A similar progressive decrease (42%) in milk yield occurred in both treatments, and there 
were no treatment effects detected on milk components. Cows treated with GSI tended to 
have increased plasma insulin (68%) and decreased circulating non-esterified fatty acids 
(29%) compared to PF cows. For both treatments, plasma glucose decreased with time 
while β-hydroxybutyrate progressively increased. Liver triglycerides increased 221% from 
P1 to sacrifice in both treatments. No differences in liver weight, liver moisture, or body 
weight change were detected. In summary, intentionally compromising intestinal barrier 
function caused inflammation, altered metabolism and markedly reduced feed intake and 
milk yield. Further, we have demonstrated that progressive feed reduction appears to cause 
leaky gut and inflammation. 
Keywords: inflammation, insulin, intestinal integrity, lipopolysaccharide 
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Introduction 
There is an increasing appreciation for the importance of proper intestinal barrier 
function in domestic farm animals. The gastrointestinal tract’s (GIT) luminal content 
technically remains extrinsic to the animal, and thus the GIT serves a dual role of absorbing 
valuable nutrients while simultaneously preventing infiltration of unwanted compounds 
and molecules (Mani et al., 2012). The human GIT has a surface area of ~400 m2, which 
is 200 times greater than skin (Murphy, 2012), and is continuously subjected to potentially 
pathogenic microorganisms and toxins (Mani et al., 2012). Barrier importance is 
heightened in cattle as both the size of the GIT and potential toxin exposure are more 
extensive in ruminants due to pre-gastric fermentation compartments.  Therefore, it is not 
surprising that a large majority of the immune system resides in the splanchnic bed (van 
der Heijden et al., 1987).  
There are a variety of diseases, albeit with etiological differences, where the 
common dominant pathology is impaired intestinal barrier function (i.e., leaky gut), 
including Crohn’s disease, inflammatory bowel syndrome, celiac disease, and alcoholism 
(Draper et al., 1983; Bargiggia et al., 2003; Ludvigsson et al., 2007; McGowan et al., 2012). 
Recognized circumstances in animal agriculture where GIT barrier function is 
compromised include weaning (Boudry et al., 2004; Moeser et al., 2007), heat stress 
(Baumgard and Rhoads, 2013; Pearce et al., 2013a), and rumen acidosis (Emmanuel et al., 
2007a,b; Khafipour et al., 2009; Minuti et al., 2014). Additionally, reduced feed intake has 
been shown to decrease barrier integrity in humans (Welsh et al., 1998) and farm animals 
(Pearce et al., 2013a; Zhang et al., 2013; Stoakes et al., 2015b). Further, we have 
preliminary evidence strongly implicating leaky gut as the etiological origin of ketosis in 
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transitioning dairy cows (Abuajamieh et al., 2016). Accordingly, there are multiple 
situations experienced by farm animals with the potential to induce leaky gut.  
Presumably an impaired intestinal barrier will negatively impact economically 
important phenotypes. However, directly studying post-absorptive and production 
consequences of leaky gut is difficult as conditions thought to be responsible for reducing 
intestinal barrier integrity also affect multiple tissues and systems. Obvious examples of 
biologically confounding situations include the periparturient period and heat stress, both 
of which are accompanied by marked homeorhetic adaptations to support a new dominant 
physiological state (Bauman and Currie, 1980; Baumgard and Rhoads, 2013). Evaluating 
the metabolic, endocrine, inflammatory, and production consequences of leaky gut in 
isolation would provide insight into its direct impact on the pathophysiology of common 
on-farm disorders.  
We hypothesized that intestinal tract barrier dysfunction (in apparently otherwise 
healthy animals) would detrimentally affect production parameters, metabolic variables, 
and inflammatory indices, and that these post-absorptive consequences would resemble 
characteristic biomarkers in the aforementioned disorders. To test this, we utilized gamma-
secretase inhibitor (GSI) to decrease intestinal barrier integrity. Administrating GSI causes 
intestinal metaplasia of mucus secreting goblet cells from crypt cells via Notch pathway 
interference (Milano et al., 2004; van Es et al., 2005), which is necessary for normal 
absorptive enterocyte maturation and proliferation (Okamoto et al., 2009). Disrupting 
ordinary crypt cell differentiation using GSI severely damages intestinal structures (Wong 
et al., 2004) and inhibiting the Notch pathway decreases epithelial cell turnover and 
increases intestinal permeability (Obata et al., 2012). 
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Materials and Methods 
Animals and Sampling 
 The Institutional Animal Care and Use Committee at Iowa State University (ISU) 
approved all procedures involving animals. Fourteen lactating Holstein cows (117 ± 18 
DIM; 666 ± 14 kg BW; parity 2.6 ± 0.3) were housed at the ISU Dairy Farm and enrolled 
in two experimental periods. Period 1 (P1) lasted 4-5 d and served as the baseline (data 
generated for covariate analysis) for period 2 (P2). Period two lasted 7 d during which 
cows received one of two i.v. treatments twice daily at 0600 and 1800 h: 1) control (1 L 
sterile saline; n = 7) or 2) GSI (1.5 mg/kg BW semagacestat dissolved in 1 L sterile saline; 
LY-450139; Eli Lilly and Company, Indianapolis, IN; n = 7). The GSI dose was selected 
from a preliminary dose response trial where 1 mg/kg/d BW did not induce overt 
phenotypic responses while 6 mg/kg/d caused a severe and rapid decrease in feed intake 
(data not shown). Control animals were pair-fed (PF) to the GSI-treated cows to eliminate 
the confounding effects of dissimilar nutrient intake as we have previously described 
(Wheelock et al., 2010). 
All cows were individually fed a TMR once daily at 0800 h, and orts were recorded 
daily prior to feeding. The TMR was formulated by Nutrition Professionals, Inc. (Neenah, 
WI) to meet or exceed the predicted requirements of energy, protein, minerals, and 
vitamins (NRC, 2001; Table 5). Reductions in daily feed intake by GSI-treated cows in P2 
were determined as a percentage of their mean daily ad libitum intake during P1. Initiation 
of P2 for the PF cows occurred 1 d later to allow for pair-feeding calculations and 
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implementation. For tissue collection consistency, PF and GSI cows were euthanized after 
morning blood samples of the same calendar day (P2D8 for GSI-treated cows and P2D7 
for PF cows).  
Throughout the experiment, cows were milked twice daily at 0500 and 1700 h, and 
yields were recorded at each milking. Individual milk samples for composition analysis 
were obtained daily during both periods at the AM milking. Samples were stored at 4˚C 
with a preservative (bronopol tablet; D & F Control System, San Ramon, CA) until analysis 
by Dairy Lab Services (Dubuque, IA) using AOAC approved infrared analysis equipment 
and procedures. 
Heart rate, respiration rate, rectal temperature, and manure score were measured 
twice daily at 0700 and 1900 h. Heart rate and respiration rate were measured as beats or 
flank movements during a 15 s interval and were later transformed to beats/min and 
breaths/min, respectively. Rectal temperatures were measured using a digital thermometer 
(GLA M700, San Luis Obispo, CA). Manure score for each animal was determined based 
on a scale of 1 (liquid) to 5 (firm) using the manure scoring system by Skidmore and 
colleagues (1996). Body weights were recorded on d 5 of P1 to calculate GSI dosage and 
again immediately preceding sacrifice. 
Jugular catheters were inserted into all cows as previously described (Baumgard et 
al., 2002b) prior to P1 for blood sampling and a second catheter was inserted 1 d before P2 
for GSI or saline administration. Serum and plasma samples were collected daily at 0500 
h during both periods using an empty glass tube and a glass tube containing 50 µL sterile 
heparin (Sagent Pharmaceuticals, Schaumburg, IL), respectively. Pyrogen free serum 
samples were collected on d 3 and 5 of P1 and d 1, 3, 5, and 7 of P2. Prior to collection, 
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the coccygeal area was scrubbed with alcohol soaked gauze and the sample was collected 
via venipuncture into evacuated sterile serum collection tubes (BD Vacutainer, Franklin 
Lakes, NJ) and handled in sterile conditions from then on. Serum samples were allowed to 
clot for one hour at room temperature. Plasma and serum were harvested following 
centrifugation at 1500 x g for 15 min at 4°C, and subsequently frozen at -20°C until 
analysis. 
 
Tissue Collection 
Liver biopsies were collected on d 3 of P1 and d 5 of P2 as previously described 
(Rhoads et al., 2004). Briefly, the area was shaved, disinfected, and locally anesthetized 
using lidocaine before performing a percutaneous biopsy with a trocar. Four samples (~20 
mg each) were collected, snap frozen in liquid nitrogen and stored at -80°C until analyzed. 
Incisions were then sutured and topically treated with AluShieldTM (Neogen Corp., 
Lexington, KY). 
Cows were euthanized with a CASH Special captive bolt gun (Accles & Shelvoke 
Ltd., Sutton Coldfield, West Midlands) using a large animal charge followed by 
exsanguination completed by severing the carotid arteries bilaterally. Liver and intestinal 
tissues were harvested immediately and liver and spleen weights were recorded. A liver 
sample was collected from ~20 cm dorsal to the ventral liver margin (a location anticipated 
to be where the liver biopsies were obtained) and was snap frozen in liquid nitrogen and 
stored at -80°C until further analysis. A jejunum segment was collected ~5.5 m proximal 
to the ileocecal junction. An ileum segment was collected immediately proximal to the 
ileocecal junction. A colon segment was collected ~1.5 m proximal to the pelvic inlet. 
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Jejunum, ileum, and colon segments (~20-30 cm) were flushed with cold PBS to remove 
intestinal content. A transversal section was collected from each sample and subsequently 
fixed in 10% neutral buffered formalin for later histological analysis. 
 
Blood Analyses 
 Plasma insulin, non-esterified fatty acids (NEFA), glucose, BHB, LPS-binding 
protein (LBP), serum amyloid A (SAA), haptoglobin, and BUN concentrations were 
determined using commercially available kits validated for use in our laboratory (insulin, 
Mercodia AB, Uppsala, Sweden; NEFA, Wako Chemicals USA, Richmond, VA; glucose, 
Wako Chemicals USA Inc., Richmond, VA; BHB, Pointe Scientific Inc., Canton, MI; LBP, 
Hycult Biotech, Uden, Netherlands; SAA, Tridelta Development Ltd., Kildare, Ireland; 
haptoglobin, Immunology Consultants Laboratory Inc., Portland, OR; BUN, Teco 
Diagnostics Anaheim, CA). The inter- and intra-assay coefficients of variation for insulin, 
NEFA, glucose, BHB, SAA, LBP, and BUN assays were 6.7 and 17.5%, 7.1 and 7.3%, 6.9 
and 5.9%, 14.3 and 4.6%, 27.3 and 5.3%, and 5.8 and 1.9%, respectively. Serum LPS was 
analyzed in triplicate using sterile procedures and a PyroGene endotoxin detection assay 
(Lonza, Walkersville, MD); inter- and intra-assay coefficient were 64.9 and 29.7%, 
respectively. 
 
Liver Analyses 
 Portions of the liver samples (~5.0 g) were weighed, dried in an oven for 18 h at 
102°C, and reweighed after cooling in order to determine liver moisture percentage. To 
determine liver triglyceride content, a portion (~20 mg) was weighed and homogenized 
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with 500 µL chilled PBS. The homogenate was then centrifuged at 8,000 x g for 2 min at 
4°C. Free glycerol was immediately determined using 10 µL of supernatant via enzymatic 
glycerol phosphate oxidase method (Sigma-Aldrich, St. Louis, MO). An additional 300 µL 
of supernatant was removed and incubated with 75 µL lipase (MP Biomedicals, Solon, 
OH) at 37°C for 16 h before determining total glycerol using the same enzymatic glycerol 
phosphate oxidase method. Free glycerol (before lipase digestion) was subtracted from 
total glycerol (after lipase digestion) in order to determine triglyceride content, and this 
was expressed as a percentage of wet weight of the original sample before homogenization. 
The intra-assay coefficient of variation for free glycerol and total glycerol was 1.9 and 
0.8%, respectively. 
 
Histological Analyses 
For histological analysis, 10% neutral buffered formalin-fixed jejunum, ileum, and 
colon were sectioned and periodic acid-Schiff (PAS) stained at the ISU Veterinary 
Diagnostic Laboratory for morphological and goblet cell area quantification. One slide per 
cow per tissue was generated. For histological and goblet cell analysis, a microscope 
(Leica® DMI3000 B Inverted Microscope, Bannockburn, IL) with an attached camera 
(QImaging® 12-bit QICAM Fast 1394, Surrey, BC) was used to obtain images from five 
non-overlapping fields per slide at 100X magnification. All morphological measurements 
were obtained using ImageJ (1.48b, National Institutes of Health, USA). For villus 
measurements, one villus per image was measured for a total of five measurements per 
cow. Total mucosal area was determined after subtracting luminal area, and area of PAS 
stain was measured using the ImageJ color deconvolution tool with H PAS vector. Goblet 
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cell area was expressed as percentage of the total mucosal area stained by PAS. Villus 
height was measured from the villus tip to the villus-crypt interface. Villus width was 
measured at mid-villus height. Crypt depth was measured from the villus-crypt opening to 
the laminae propria. Crypt width was measured at the villus-crypt interface level. A 
mucosal surface area estimate was obtained using the mucosal-to-serosal amplification 
ratio M as previously reported by Kisielinski and colleagues (2002), where: 
𝑀 =  
(𝑣𝑖𝑙𝑙𝑢𝑠 𝑤𝑖𝑑𝑡ℎ × 𝑣𝑖𝑙𝑙𝑢𝑠 𝑙𝑒𝑛𝑔𝑡ℎ) + (
𝑣𝑖𝑙𝑙𝑢𝑠 𝑤𝑖𝑑𝑡ℎ
2 + 
𝑐𝑟𝑦𝑝𝑡 𝑤𝑖𝑑𝑡ℎ
2 )
2
− (
𝑣𝑖𝑙𝑙𝑢𝑠 𝑤𝑖𝑑𝑡ℎ
2 )
2
(
𝑣𝑖𝑙𝑙𝑢𝑠 𝑤𝑖𝑑𝑡ℎ
2 +  
𝑐𝑟𝑦𝑝𝑡 𝑤𝑖𝑑𝑡ℎ
2 )
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Immunofluorescence Staining 
 For immunofluorescence analysis, 10% neutral buffered formalin-fixed jejunum, 
ileum, and colon were sectioned at 5 microns thickness and mounted in the histology 
laboratory at the ISU Veterinary Diagnostic Laboratory. Slides were deparaffinized using 
Citrisolv™ Hybrid Solvent (Fisher Scientific), rehydrated by incubation for 3 min twice in 
100% ethanol, 95% ethanol for 1 min, 80% ethanol for 1 min, followed by rinsing in 
distilled and deionized water. Antigen retrieval was performed by incubating slides in 
citrate buffer (Sodium Citrate, Citric Acid, Tween20, water) at 95˚C for 30 min. Tissue 
sections were blocked in 5% BSA (Sigma Aldrich) in PBS for 90-180 min. Primary 
antibody against proliferating cell nuclear antigen (PCNA; PC10 mAb, Cell Signaling 
Technology #2586; 1:200 dilution), a marker of cellular proliferation, was applied to each 
section and incubated overnight at 4˚C. Slides were washed thrice in PBS and incubated in 
fluorescent secondary antibody (anti-mouse IgG (H+L) F(ab’)2 Fragment, AlexaFluor® 
488 conjugate, Cell Signaling Technology #4408; 1:1000 dilution) for 1 h at room 
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temperature. Slides were washed thrice in PBS and 4',6-diamidino-2-phenylindole stain 
was applied to each section. Slides were stored in the dark at 4˚C to prevent fading. To 
decrease variability due to staining day, each tissue type was stained on the same day, and 
slides were imaged within a 6 h timeframe. For each animal, five images from each tissue 
were collected on a Leica fluorescent microscope at 100X magnification. To ensure 
antibody binding specificity, negative controls omitted either the primary antibody, 
secondary antibody, or both. Mouse IgG was used in place of the primary antibody to 
control for antibody isotype nonspecific binding. The fluorescence signaling was obtained 
for one individual villi per image in the jejunum and ileum samples while the total 
fluorescence of each colon image was performed using integrated density quantification in 
ImageJ software. 
 
Statistical Analyses 
 For production and blood parameters, effects of treatment, day, and treatment by 
day interaction were assessed using PROC MIXED (SAS Inst. Inc., Cary, NC) using 
repeated measures analysis with an autoregressive covariance structure and day as the 
repeated effect. Each specific variable’s P1 value (when available) served as a covariate. 
For post-mortem data, the effect of treatment was assessed using PROC MIXED. 
Immunofluorescence staining data was analyzed using the unpaired t-test function in 
GraphPad Prism. Irrespective of treatment, Pearson correlation analysis between intestinal 
parameters and the change in circulating inflammatory parameters (P2D5-P2D7 average 
minus P1 average) was conducted using PROC CORR of SAS. Data are reported as 
LSmeans and considered significant if P ≤ 0.05 and a tendency if 0.05 < P ≤ 0.15. 
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Results 
 During P2, GSI administration progressively decreased DMI (P < 0.01; Figure 2A), 
and feed intake was reduced 66% by the end of the study. By experimental design, the 
pattern and extent of feed intake reduction was similar in PF cows (P = 0.96; Figure 2A). 
There was a similar and progressive decline in milk yield for both treatments during P2 (P 
< 0.01; Figure 2B), whereby milk yield was reduced 42% by the end of the study. There 
were no differences in milk components between treatments; however, there was a 
tendency for milk SCC and MUN to be increased in GSI-treated cows (144 and 22%, 
respectively, P ≤ 0.08; Table 6). Milk fat content increased (45%) over time for both PF 
and GSI treatments (P = 0.05; Table 6). 
 Manure score was decreased 29% in GSI-treated cows (P = 0.03; Figure 2C) due 
to a progressive reduction that did not occur in PF-controls. Overall, GSI-treated cows had 
slightly increased heart rate and respiration rate in comparison with PF cows (8 beats/min 
and 7 breaths/min, respectively; P ≤ 0.01; Table 6). There was a tendency for GSI-treated 
cows to have an increased rectal temperature compared to PF-controls (38.6 vs. 38.4°C; P 
= 0.06; Table 6).  
 Plasma glucose concentrations decreased slightly with time (P = 0.05; Figure 3A) 
in both treatments. Cows treated with GSI tended to have increased plasma insulin (68%) 
and decreased circulating NEFA (29%) compared to PF-controls (P ≤ 0.07; Figure 3B and 
3C). Circulating NEFA increased with time in both treatments (P < 0.01; Figure 3C) 
whereby at the end of P2, NEFA were increased 5.2 and 2.2 fold relative to baseline values 
in PF and GSI-treated cows, respectively. There was a tendency for a treatment by day 
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interaction in plasma BHB due to a more pronounced increase in GSI-treated cows (124% 
increase on d 7 from baseline; Figure 3D) compared to PF controls (81% increase on d 6 
from baseline) over time. No differences in circulating BUN were detected (data not 
shown). Cows treated with GSI tended to have a 70% decrease in circulating LPS on d 5 
and 7 relative to PF cows (P = 0.12; Figure 4A). Plasma LBP increased with time (P < 
0.01; Figure 4B) and tended to be increased 42% in GSI-treated cows compared to PF-
controls on d 5-7 (P = 0.14; Figure 4B). Haptoglobin and SAA progressively increased 
similarly in both treatments and were 585 and 4.4 fold higher, respectively, at the end of 
P2 relative to baseline (P < 0.01; Figure 4C and 4D). 
 Compared to PF controls, administering GSI increased goblet cell area 218, 70, and 
28% in jejunum, ileum, and colon, respectively (P ≤ 0.02; Figure 5A and Figure 8). 
Jejunum villus height, villus height-to-crypt depth ratio, and mucosal surface area were 
reduced (21, 36, and 21%, respectively) in GSI-treated cows while jejunum crypt depth 
was increased 43% compared to PF controls (P < 0.01; Figure 5B, 5D, and 5E). Jejunum 
villus width was not affected by treatment. Crypt depth tended to be increased 21% in the 
ileum of GSI-treated animals relative to controls (P = 0.06; Figure 5C), but there were no 
other detectable effects on ileum morphology. Intestinal cellular proliferation, as measured 
by PCNA, was decreased 27% in the jejunum of GSI-treated cows relative to PF controls 
(P < 0.01), but no differences were observed in the ileum or colon (Figure 5F & Figure 7).  
Irrespective of treatment, change in circulating LBP (P2D5-7 average minus P1 
average) was correlated with the jejunum villus height-to-crypt-depth ratio (r = -0.89, P < 
0.01; Figure 6) as well as jejunum crypt depth and villus height (r = 0.84 and -0.69, 
respectively, P ≤ 0.01; data not shown). Change in circulating SAA was correlated with 
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jejunum villus width (r = 0.64, P =0.03) and tended to be correlated with the villus height-
to-crypt depth ratio and mucosal surface area (r = -0.47 and -0.53, respectively, P ≤ 0.13; 
data not shown). Circulating haptoglobin change tended to be correlated with jejunum 
villus width and jejunum mucosal surface area (r = 0.50 and -0.44, P ≤ 0.15; data not 
shown). In the ileum, there were no correlations between changes in acute phase proteins 
and intestinal morphology parameters. 
 Liver triglyceride content was increased 221% at sacrifice relative to baseline in 
both treatments (P < 0.01; Figure 7). There were no treatment differences in liver weight, 
liver moisture percentage, liver or spleen weight as a percentage of BW, or change in 
overall BW (Table 7). 
 
Discussion 
 A variety of situations in animal agriculture can reduce intestinal barrier function- 
the consequences of which likely stimulate the immune system, cause inflammation, and 
eventually compromise production. Example circumstances include weaning (Boudry et 
al., 2004; Moeser et al., 2007), heat stress (Baumgard and Rhoads, 2013; Pearce et al., 
2013a), rumen acidosis (Emmanuel et al., 2007a,b; Khafipour et al., 2009; Minuti et al., 
2014), and the periparturient period (Abuajamieh et al., 2016). However, a myriad of 
behavioral, metabolic, and endocrine events accompanying the aforementioned situations 
make it difficult to study the consequences of poor intestinal barrier health in isolation. To 
our knowledge, a controlled experiment intentionally reducing intestinal barrier integrity 
has never been performed in ruminants. Our objectives were to elucidate the inflammatory, 
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production, and metabolic consequences of intestinal barrier dysfunction in otherwise 
healthy mid-lactation dairy cows.  
Administering GSI in the current experiment disturbed intestinal architecture, 
changes likely reflective of leaky gut (Ford et al., 1985; Pearce et al., 2013a). Crypt cell 
Notch signaling is inhibited by GSI (De Strooper et al., 1999), and altering this pathway 
increases intestinal permeability (Obata et al., 2012). Furthermore, GSI decreases 
absorptive enterocyte proliferation and causes goblet cell hyperplasia (van Es et al., 2005), 
which was evident in the current study by the decrease in jejunal cell proliferation and 
increase in goblet cell area in jejunum, ileum, and colon. Effects of GSI were particularly 
evident in the jejunum as changes in villus height, crypt depth and their ratio, and mucosal 
surface area are indicative markers of damaged epithelium (van der Hulst et al., 1998; 
Pearce et al., 2013a). It is unknown why the jejunum was more sensitive to GSI than the 
ileum and colon, but a plausible explanation is the larger proportion of absorptive 
enterocytes in jejunum villi relative to other segments of the GIT (Cheng and Leblond, 
1974). Additionally, goblet cell hyperplasia likely contributed to the progressive decrease 
in manure scores (indicative of increased fecal moisture) due to increased mucus 
production.  
The direct consequence of intestinal barrier dysfunction is the increased leakage of 
luminal antigens into the blood stream with the potential to initiate an inflammatory 
response. Elevated rectal temperature, heart rate, and respiration rate are indicative of 
immunoactivation (Jacobsen et al., 2005), and these were increased in cows administered 
GSI, suggesting a greater degree of inflammation. To further assess inflammation, we 
measured three acute phase proteins (APP): haptoglobin, SAA, and LBP. The liver 
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produces APP as a secondary (non-local) response to toxic stimuli, and they have been 
widely acknowledged as markers of systemic inflammation (Ceciliani et al., 2012). 
Admittedly, APP production is a non-specific response to endotoxin infiltration which 
could originate from a wide variety of sources (e.g., uterus, mammary, etc.). However, in 
the present study, because of the localized intestinal effects of GSI and lack of overt extra-
intestinal infection, intestinal barrier dysfunction is the ostensible source of the APP 
response. All three APP measured increased from P1 to P2 in both GSI and PF cows. The 
increased circulating APP in PF cows was not unexpected as reduced nutrient intake has 
been reported to compromise intestinal integrity in rodent, pig, and human models 
(Rodriguez et al., 1996; Welsh et al., 1998; Pearce et al., 2013a), and we have previously 
demonstrated reduced feed intake negatively affects ileum morphology in lactating cows 
(Stoakes et al., 2015b). After 5 d of treatment, LBP levels tended to be increased in GSI-
treated cows compared to PF-controls (Figure 4B). Interestingly, the magnitude of 
increased circulating LBP in GSI-infused cows mirrors the increase observed in cows with 
ketosis and rumen acidosis (Abuajamieh et al., 2016; Khafipour et al., 2009), indicating a 
similar inflammatory response to seemingly differing and unconnected disorders. 
Incidentally, this is also the period of time (near the end of P2) when treatment differences 
in LPS were largest (Figure 4A). Binding of LBP to LPS is essential for the activation of 
its receptor TLR-4 and the subsequent production of inflammatory mediators (Lu et al., 
2008b). Therefore, LPS clearance partially depends on LBP and interpreting changes in 
both variables can be difficult when considered independently. Changes in circulating LBP 
were well-correlated with jejunal intestinal morphology parameters of villus height, crypt 
depth, and the villus height-to-crypt depth ratio, suggesting changes in circulating LBP are 
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responsive to the degree of intestinal damage and decreased barrier function (i.e., ~79% of 
the variation in circulating LBP changes can be explained by the jejunum villus height-to-
crypt depth ratio). Reasons why LBP could be a more sensitive marker of leaky gut-induced 
inflammation than the other APPs measured remains unknown, but is likely due to the fact 
the LBP is specific for LPS clearance while SAA and haptoglobin play more broad roles 
in combating infection (Ceciliani et al., 2012). The increased LBP levels during the end of 
P2 coupled with the histological data suggests GSI treatment had a more detrimental effect 
on intestinal integrity, resulting in increased luminal content leakage into the portal blood, 
and perhaps a more robust response to detoxify LPS compared to PF cows. 
Utilizing the pair-feeding design allows us to discriminate between direct effects of 
GSI and indirect effects of GSI-mediated reduced DMI. Hence, the GSI-treated cows had 
a progressive and marked decrease in DMI and, by design, the PF-controls had a similar 
pattern and magnitude of feed intake reduction. The GSI treatment induced a steady 
decrease in milk yield, but this appeared to be mostly related to inadequate feed 
consumption as the PF cows had a comparable decrease in both pattern and severity. For 
the current experiment, we assume decreased DMI is a consequence of GSI-induced leaky 
gut, but we acknowledge GSI may alter appetite by some extra-intestinal unknown 
mechanism. Regardless, decreased feed intake and/or milk yield is characteristic of 
inflammatory situations such as weaning, heat stress, transition period disorders, and 
rumen acidosis. While the magnitude of decreased DMI and milk yield in the current study 
is more extensive than the majority of these circumstances, the post-absorptive metabolism 
and inflammatory responses underpinning the aforementioned disorders share similarities 
to what is described herein. 
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The metabolic profile of the current model resembles conditions involving immune 
system activation, further evidence supporting the hypothesis that leaky gut is the cause of 
many on-farm disorders. For example, despite marked reductions in feed intake, plasma 
insulin levels remained unchanged from P1 in the GSI-treated cows, but progressively 
decreased as expected in the PF cows. By d 5-7 of P2, insulin concentrations were increased 
79% in GSI-treated cows compared to PF-controls. The increased insulin (a potent anabolic 
hormone) in GSI-treated cows is energetically difficult to explain as feed intake was 
severely depressed and cows were obviously in an intensely catabolic condition (i.e., > 40 
kg BW loss). However, this unusual temporal pattern is similar to increased insulin levels 
experienced by a variety of species exposed to heat stress, another leaky gut-inducing and 
catabolic condition (Baumgard and Rhoads, 2013). The insulin differences may be partially 
explained by LPS, as infusing LPS into the mammary gland increased circulating insulin 
in lactating cows (Waldron et al., 2006), and we have demonstrated increased circulating 
insulin in pigs, calves, and lactating cows infused i.v. with LPS (Rhoads et al., 2009; 
Stoakes et al., 2015a; Kvidera et al., 2016a, 2017a). The changes in insulin were not 
reflected in circulating glucose, which similarly decreased over time for both treatments, 
suggesting that GSI-treated cows may have become slightly insulin resistant. This profile 
fits with a status of immunoactivation which is characterized by hyperinsulinemia and 
whole-body insulin resistance (Lang et al., 1990; McGuinness et al., 2005; Kvidera et al., 
2016a, 2017b) which redirects glucose away from major disposal sites (i.e., muscle and 
adipose) towards the immune system, a substantial insulin-induced and insulin independent 
glucose utilizer upon activation (Lang et al., 1990; Maratou et al., 2007; Palsson-
McDermott and O’Neill, 2013). We have previously established an intensely activated 
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immune system of a lactating dairy cow requires over 1 kg glucose in a 12 h period 
(Kvidera et al., 2017a), and this highlights the fact that immune stimulation comes at a 
huge glucose cost. Thus, the aforementioned changes in carbohydrate metabolism appear 
to be a strategy to both “spare glucose” (muscle and adipose tissue insulin resistance) and 
activate/provide fuel for the immune system (hyperinsulinemia). 
As expected, considering inadequate energy intake, there was a progressive and 
marked increase in plasma NEFA levels during P2 in both treatment groups; however, GSI 
cows tended to have a 41% decrease in circulating NEFA on d 5-7 compared to PF cows. 
The treatment differences in insulin likely explain the differences in circulating NEFA as 
insulin is a potent anti-lipolytic signal (Vernon, 1992), and these insulin/NEFA 
idiosyncrasies mimic the metabolic fingerprint of multiple heat-stressed species 
(Baumgard and Rhoads, 2013). Despite tending to have decreased NEFA concentrations 
during the end of P2, GSI-administered cows had a higher peak BHB relative to PF-
controls (124 versus 81% increase from baseline, respectively). Interestingly, during the 
periparturient period, NEFA and BHB are not well-correlated, and dairy cows diagnosed 
with ketosis have increased BHB levels despite similar NEFA concentrations (McCarthy 
et al., 2015; Zhang et al., 2016). Similarly, BHB are elevated in heat-stressed pigs despite 
a blunted response to lipolytic signals (Sanz Fernandez et al., 2015). Reasons for discordant 
patterns in NEFA and BHB are not clear, but increased circulating NEFA certainly cannot 
fully explain increased circulating BHB observed in GSI-treated cows. Despite marked 
treatment differences in circulating NEFA, liver triglyceride content increased similarly in 
both treatments from what is considered “normal” during P1 to “mildly fatty” at sacrifice 
(Bobe et al., 2004). Incidentally, intestinal endotoxin infiltration contributes to hepatic 
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steatosis (Ilan, 2012), and fatty liver is characteristic of both ketotic and heat-stressed 
transitioning dairy cows (Bobe et al., 2004; Bernabucci et al., 2010). Thus, it is not 
surprising GSI-infused cows had increased liver fat content despite ~40% less circulating 
NEFA.  
To our knowledge, this is the first study utilizing GSI in a ruminant model. 
Therefore, our understanding is limited regarding its direct influence on metabolic or 
endocrine systems. Potential toxicity issues arise with GSI due to their inhibition of Notch 
cleavage which is associated with alteration of lymphopoiesis in addition to intestinal 
toxicity (Wong et al., 2004). However, clinical trials for the specific GSI used in the present 
study have been conducted successfully in mice, dogs, and guinea pigs with few negative 
side effects (Hyslop et al., 2004; May et al., 2004; Lanz et al., 2006), and multiple human 
studies have been conducted by Siemers and colleagues (2005, 2006, 2007). Furthermore, 
goblet cell metaplasia may be a limitation to our study as increased mucus production may 
have partially limited bacterial translocation into portal and systemic circulation. However, 
due to the temporal increase in both circulating biomarkers of leaky gut and metabolic 
alterations, we consider this unlikely. Lastly, our experimental design is complicated by 
the fact that both treatments negatively affected intestinal health during P2. Fortunately, 
neither treatment was implemented during P1, and each treatment’s repeatedly measured 
parameters can be compared back to its respective baseline value. Regrettably, this type of 
comparison cannot be accomplished for the intestinal morphology and organ data as these 
variables were only measured at sacrifice. However, the detrimental effect of GSI on 
jejunal intestinal morphology (coupled with differences in LBP and insulin) despite similar 
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feed restriction to the controls indicates a more severe effect of GSI on intestinal integrity 
than feed restriction alone. 
Conclusions 
 In summary, administrating GSI appeared to induce intestinal damage and 
compromise intestinal permeability. This reduced barrier integrity had production, 
metabolic, and inflammatory consequences including decreased DMI, decreased milk 
yield, hyperinsulinemia, increased circulating ketones, and increased APP. Further, feed 
restriction appears to directly cause intestinal barrier dysfunction. Consequently, we now 
have strong evidence to suggest intestinal barrier dysfunction directly affects traditional 
production, metabolic, and inflammatory parameters and many of these changes are 
strikingly similar to the phenotypes observed in both heat-stressed and ketotic dairy cows. 
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Table 5. Ingredients and composition of diet1 
Composition % of DM2 
Ingredient  
    Corn Silage 33.6 
    Alfalfa Hay 19.8 
    Rolled Corn 17.1 
    Ground Corn 13.7 
    Whole Cotton 8.6 
    Soy Plus®3 4.2 
    High Protein Soybean Meal4 3.0 
  
Chemical analysis, % of DM  
    CP 15.7 
    NDF 31.6 
    ADF 22.7 
    NEL Mcal/kg DM 1.6 
1Values represent an average of samples collected and 
composited throughout the trial. Dry matter averaged 
53%. 
2Average nutrient levels: 5.74% Fat, 0.84% Ca, 0.34% 
P, 0.37% Mg, 0.19% S, 1.1% K, 0.44% Na, 0.47% Cl, 
56.30 ppm of Zn, 60.08 ppm of Mn, 95.76 ppm of Fe, 
17.28 ppm of Cu, 0.19 ppm of Co, 0.28 ppm Se, 43.68 
ppm of I, 4475.9 IU/kg of vitamin A, 1438.8 IU/kg of 
vitamin D, and 26.95 IU/kg of vitamin E 
3Cooker-expeller processed soybean meal produced by 
West Central Cooperative, Ralston, IA, containing 
46.6% CP, 60% RUP (% CP); DM basis). 
4Solvent-extracted soybean meal containing 54.5% CP, 
35% RUP (% CP); DM basis). 
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Table 6. Effects of gamma-secretase inhibitor or pair-feeding on production variables 
and vital measurements 
 Treatment  P 
Parameter PF1 GSI2 SEM TRT3 Day 
TRT3 x 
Day 
Milk components       
    Milk fat, % 4.2 4.4 0.4 0.65 0.05 0.51 
    Lactose, % 4.8 4.8 0.1 0.92 0.11 0.99 
    Protein, % 2.6 2.7 0.1 0.61 0.17 0.73 
    Total solids, % 12.4 12.9 0.2 0.28 0.18 0.37 
    Other solids, % 5.7 5.7 0.1 0.98 0.10 0.99 
    SCC, *1000/mL 54 132 27 0.07 0.32 0.30 
    MUN, mg/dL 11.5 14.0 0.9 0.08 0.10 0.28 
Rectal temperature, °C 38.4 38.6 0.1 0.06 0.31 0.48 
Respiration rate, 
breaths/min 
33 40 2 0.01 0.01 0.36 
Heart rate, beats/min 66 74 2 <0.01 <0.01 0.24 
1Cows pair-fed to gamma-secretase inhibitor treatment and administered 1 L saline 
twice daily 
2Cows administered 1.5 mg/kg BW gamma-secretase inhibitor twice daily 
3Treatment 
 
 
 
 
Table 7. Effects of gamma-secretase inhibitor or pair-feeding on liver and spleen 
measurements post-mortem and body weight change 
 Treatment  P 
Parameter PF1 GSI2 SEM Treatment 
Liver      
      Weight, kg 9.5 10.6 0.5 0.19 
      Liver, % of BW3 1.6 1.8 0.1 0.42 
      Moisture, % 68.6 71.0 1.0 0.14 
Spleen     
      Weight, kg 1.20 1.05 0.05 0.73 
      Spleen, % of BW 0.18 0.16 0.01 0.28 
Body weight     
      BW change, kg4 -48.2 -65.2 17.7 0.53 
1Cows pair-fed to gamma-secretase inhibitor treatment and administered 1 L saline 
twice daily 
2Cows administered 1.5 mg/kg BW gamma-secretase inhibitor twice daily 
3Percentage of BW 
4BW change over duration of treatment administration 
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Figure 2. Effects of gamma-secretase inhibitor (GSI) or pair-feeding (PF) on (A) DMI, (B) 
milk yield, and (C) manure score in lactating Holstein cows. Values for P1 represent the 
period 1 average that was statistically used as a covariate. †Indicates a significant treatment 
effect (P ≤ 0.05). 
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Figure 3. Effects of gamma-secretase inhibitor (GSI) or pair-feeding (PF) on plasma 
metabolites (A) glucose, (B) insulin, (C) non-esterified fatty acids (NEFA), and (D) BHB 
in lactating Holstein cows. Values for P1 represent the period 1 average that was 
statistically used as a covariate. †Indicates a significant treatment effect (P ≤ 0.05). 
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Figure 4. Effects of gamma-secretase inhibitor (GSI) or pair-feeding (PF) on blood acute 
phase proteins (A) lipopolysaccharide, (B) lipopolysaccharide binding protein (LBP), (C) 
haptoglobin, and (D) serum amyloid A (SAA) in lactating Holstein cows. Values for P1 
represent the period 1 average that was statistically used as a covariate. †Indicates a 
significant treatment effect (P ≤ 0.05). 
0
2000
4000
6000
8000
10000
P1 1 3 5 7
L
P
S
 (
E
U
/m
L
)
Day
(A) P=0.12
0
2
4
6
8
10
12
14
P1 2 3 4 5 6 7
L
B
P
 (
µ
g
/m
L
)
Day
(B) Day: P<0.01
P=0.14
-500
0
500
1000
1500
2000
2500
3000
P1 2 3 4 5 6 7
H
ap
to
g
lo
b
in
 (
µ
g
/m
L
)
Day
(C) Day: P<0.01
0
200
400
600
800
1000
1200
1400
P1 2 3 4 5 6 7
S
A
A
 (
µ
g
/m
L
)
Day
(D) Day: P<0.01
81 
 
 
 
 
 
Figure 5. Effects of gamma-secretase inhibitor (GSI) or pair-feeding (PF) on (A) goblet 
cell area as a percentage of epithelial area in jejunum, ileum, and colon, (B) jejunum villus 
morphology, (C) ileum villus morphology, (D) villus height-to-crypt depth ratio in jejunum 
and ileum, (E) mucosal surface area in jejunum and ileum, and (F) intensity of PCNA 
protein in jejunum, ileum, and colon. *Indicates a tendency for a treatment effect (P ≤ 
0.15). †Indicates a significant treatment effect (P ≤ 0.05). Mucosal surface area is 
expressed as an M-index as described by Kisielinski et al., 2002. 
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Figure 6.  Correlation between the jejunum villus height-to-crypt depth ratio and the 
change in circulating lipopolysaccharide binding protein (LBP; P2D5-7 average minus the 
P1 average). Analysis includes the combination of cows administered 1.5 mg/kg BW 
gamma-secretase inhibitor 2x/d and cows pair-fed to gamma-secretase inhibitor treatment 
and administered 1 L saline 2x/d.  
R² = 0.7891
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Figure 7. Effects of gamma-secretase inhibitor (GSI) or pair-feeding (PF) on liver 
triglyceride as a percentage of wet weight. *Due to logistical constraints, animals were 
sacrificed on the same calendar day (P2D7 and P2D8 for PF and GSI animals, 
respectively). 
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Figure 8. Representative images of periodic acid-Schiff stained (A) jejunum, (B) ileum, 
and (C) colon of pair-fed controls (PF) and (D) jejunum, (E) ileum, and (F) colon of cows 
administered gamma-secretase inhibitor (GSI). Dark purple stain is positive for 
mucosubstances.  
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Figure 9. Representative image of PCNA protein intensity in jejunum of a pair-fed control 
(PF; A) and a cow administered gamma-secretase inhibitor (GSI; B). Negative controls are 
primary antibody omitted (C), IgG serum in place of primary antibody (D). Nuclear stain 
is blue while PCNA stain is green. 
  
A B 
C D 
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CHAPTER 3: CHARACTERIZING EFFECTS OF FEED RESTRICTION AND 
GLUCAGON-LIKE PEPTIDE 2 ADMINISTRATION ON BIOMARKERS OF 
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Abstract 
Objectives were to characterize how progressive feed restriction (FR) affects inflammation, 
metabolism, and intestinal morphology, and to investigate if glucagon-like peptide 2 
(GLP2) administration influences the aforementioned responses. Twenty-eight Holstein 
cows (157 ± 9 days in milk) were enrolled in 2 experimental periods. Period 1 (5 d of ad 
libitum [AL] feed intake) served as baseline for period 2 (P2; 5 d), during which cows 
received 1 of 6 treatments: 1) 100% of AL feed intake (AL100), 2) 80% of AL feed intake, 
3) 60% of AL feed intake, 4) 40% of AL feed intake (AL40), 5) 40% of AL feed intake + 
GLP2 administration (AL40G; 75 µg/kg BW s.c. 2x/d), or 6) 20% of AL feed intake 
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(AL20). As the magnitude of FR increased, body weight and milk yield decreased linearly. 
Blood urea nitrogen and insulin decreased while non-esterified fatty acids and liver 
triglyceride content increased linearly with progressive FR. Circulating endotoxin, 
lipopolysaccharide binding protein, haptoglobin, serum amyloid A, and lymphocytes 
increased or tended to increase linearly with advancing FR. Circulating haptoglobin 
decreased (76%) and serum amyloid A tended to decrease (57%) in AL40G relative to 
AL40 cows. Cows in AL100, AL40, and AL40G treatments were sacrificed to evaluate 
intestinal histology. Jejunum villus width, crypt depth, and goblet cell area, as well as ileum 
height, crypt depth, and goblet cell area were reduced (36, 14, 52, 22, 28, and 25%, 
respectively) in AL40 cows compared to AL100 controls. Ileum cellular proliferation 
tended to be decreased (14%) in AL40 vs. AL100 cows. Relative to AL40, AL40G cows 
had improved jejunum and ileum morphology, including: increased villus height (46 and 
51%), villus height to crypt depth ratio (38 and 35%), mucosal surface area (30 and 27%), 
cellular proliferation (43 and 36%), and goblet cell area (59 and 41%). Colon goblet cell 
area was also increased (48%) in AL40G relative to AL40 cows. In summary, progressive 
FR increased circulating markers of inflammation which we speculate is due to increased 
intestinal permeability as demonstrated by intestinal architecture deterioration. 
Furthermore, GLP2 improved intestinal morphology and ameliorated circulating markers 
of inflammation. Consequently, FR is a viable model to study consequences of intestinal 
barrier dysfunction and administering GLP2 appears to be an effective mitigation strategy 
to improve gut health. 
Keywords: feed restriction, glucagon like-peptide 2, gut health 
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Introduction 
There are various situations in animal agriculture where feed intake is suboptimal 
either due to feed unavailability (e.g., shipping, drought, overcrowding) or as a result of an 
adaptive response (e.g., heat stress, immunoactivation). The decrease in energy and 
nutrient intake constrains animal performance below its genetic potential and jeopardizes 
efficiency and profitability. However, inadequate feed intake might impact productivity by 
mechanisms other than reduced substrate availability. Specifically, feed restriction (FR) 
and malnutrition cause intestinal barrier dysfunction in rodents, chickens, pigs, and humans 
(Rodriguez et al., 1996; Yamauchi et al., 1996; Welsh et al., 1998; Boza et al., 1999, Pearce 
et al., 2013); and we and others have demonstrated that this is also the case in ruminants 
(Zhang et al., 2013; Kvidera et al., 2017b). Thus, FR’s deleterious impact on the intestinal 
barrier appears to transcend species. Mechanistically, how FR negatively affects barrier 
integrity remains ill-defined, but fasting and malnutrition reduce intestinal epithelial cell 
numbers, proliferation, migration rates, and villus height as well as increase intestinal cell 
loss rate and apoptosis (Ferraris and Carey, 2000). Furthermore, FR decreases 
antimicrobial secreting Paneth cell function which compromises the gut’s immune defense 
capacity and alters the microbiome (Hodin et al., 2011; Le Floc'h et al., 2014). Due to its 
impact on intestinal barrier function, FR increases the risk of endotoxin translocation from 
the gut lumen into systemic circulation (Deitch et al., 1990), with the potential to activate 
the immune system. 
Endotoxin infiltration of the intestinal barrier activates the immune system and 
causes a well-characterized inflammatory response (van Miert and Frens, 1968; Lohuis et 
al., 1988) coupled with a large glucose requirement by stimulated leukocytes (Kvidera et 
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al., 2016, 2017a). Immunoactivation rearranges the hierarchy of nutrient partitioning away 
from economically important phenotypes, contributing to a reduction in profitability. Thus, 
there is a need to develop appropriate models to test potential “leaky gut” mitigation 
strategies. There are several chemically-induced models of leaky gut (e.g., non-steroidal 
anti-inflammatory drugs, gamma-secretase inhibitors, dextran sodium sulfate; Fortun and 
Hawkey, 2007; Wirtz et al., 2007; Kvidera et al., 2017b), but these approaches are 
associated with side effects or are logistically difficult to deliver, particularly in ruminants. 
Consequently, we and others have observed negative effects of FR on barrier function and 
inflammation (Zhang et al., 2013; Kvidera et al., 2017), making it a simple and appealing 
model for intestinal barrier dysfunction. The severity and duration of FR in the 
aforementioned literature varies considerably and its effects on gut health are not 
extensively studied in the ruminant animal, ergo it is not clear what magnitude of FR is 
required to dependably compromise intestinal barrier function. Consequently, a primary 
objective of the current experiment was to identify a FR level that induces an inflammatory 
response mirroring the physiological characteristics of on-farm situations that cause leaky 
gut. 
A potential mitigation strategy to improve intestinal barrier function is glucagon-
like peptide 2 (GLP2) administration. Endogenous GLP2 is secreted by enteroendocrine 
cells in response to luminal nutrients and has trophic effects on intestinal growth (Drucker 
and Yusta, 2014). Exogenous GLP2 administration prevents increased intestinal 
permeability in mouse models (Benjamin et al., 2000; Cameron and Perdue, 2005). Further, 
GLP2 administration improved expression of tight junction proteins, small intestine blood 
flow and growth, and reduced acute phase proteins in calves (Taylor-Edwards et al., 2011; 
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Walker et al., 2015; Connor et al., 2017). Thus, a second objective was to evaluate whether 
GLP2 treatment ameliorates the negative impact of FR on intestinal health and systemic 
inflammation. 
 
Materials and Methods 
Animals and Sampling 
Iowa State University Institutional Animal Care and Use Committee approved all 
procedures involving animals. Twenty-eight lactating Holstein cows (157 ± 9 DIM, 713 ± 
10 kg BW, parity 2 to 4) were utilized in an experiment conducted in two replications. 
Cows were housed in individual box-stalls (4.57 m by 4.57 m) at the Iowa State University 
Dairy Farm. Throughout the experiment, cows were milked twice daily (0600 and 1800 h) 
and yields was recorded at each milking. Cows were individually fed a TMR formulated 
by Nutrition Professionals, Inc. (Neenah, WI) to meet or exceed the predicted requirements 
(NRC, 2001) of energy, protein, minerals and vitamins (Table 1). Energy balance was 
calculated using the following equations: EBAL = energy intake - energy output, where 
energy intake = 1.6 Mcal/kg x DMI and energy output = (NEM = 0.08 Mcal/kg x BW0.75) 
+ [NEL = milk yield x (0.029 x fat % + 0.0547 x protein % + 0.0395 x lactose %)]. 
The trial consisted of two experimental periods within each replication. Period 1 
(P1) lasted 5 d and served as the baseline which yielded data for covariate analysis. During 
P1, cows were fed ad libitum; feed was distributed once daily (0800 h) and orts were 
collected before the AM feeding. Period 2 (P2) lasted 5 d during which cows were allocated 
to one of six FR treatments: 1) ad libitum feed intake (AL100; n = 3), 2) 80% of P1 feed 
intake (AL80; n = 5), 3) 60% of P1 feed intake (AL60; n = 5), 4) 40% of P1 feed intake + 
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saline administration (AL40; ~ 3 mL s.c. at 0700 and 1900 h; n = 5), 5) 40% of P1 feed 
intake + GLP2 administration (AL40G; 75 µg bovine GLP2/kg BW at 0700 and 1900 h; 
Elanco Animal Health, Greenfield, IN; n = 5), or 6) 20% of P1 feed intake (AL20; n = 5).  
Daily feed intake during P2 was determined by applying the desired percentage of 
FR to each cow’s mean daily intake during P1. The calculated amount of feed was divided 
into three equal portions during P2 (0800, 1300, and 1800 h) in order minimize metabolic 
variation due to gorging. During both P1 and P2, vitals were recorded twice daily at 0700 
and 1900 h. Heart rate (HR) and respiration rate (RR) were measured as beats or flank 
movements during a 15 s interval and were later transformed to beats/min and breaths/min, 
respectively. Rectal temperatures (Tr) were measured using a digital thermometer (GLA 
M700, San Luis Obispo, CA). Individual milk samples for composition analysis were 
obtained daily during both periods from the PM milking. Samples were stored at 4˚C with 
a preservative (bronopol tablet; D & F Control System, San Ramon, CA) until analysis by 
Dairy Lab Services (Dubuque, IA) using AOAC approved infrared analysis equipment and 
procedures. Body weights determined on d 1 of acclimation were utilized for calculating 
the GLP2 dose. Body weights were obtained again on d 5 of P2. 
A jugular catheter was implanted in all cows prior to P1. Blood samples were 
collected daily at 1730 h during both periods into an empty glass tube and a glass tube 
containing 50 µL sterile heparin (Sagent Pharmaceuticals, Schaumburg, IL). Pyrogen free 
serum samples were collected on d 2 and d 4 of both P1 and P2 via coccygeal venipuncture. 
Prior to collection, the coccygeal area was scrubbed with alcohol soaked gauze and the 
sample was collected into evacuated sterile serum collection tubes (BD Vacutainer, 
Franklin Lakes, NJ) and subsequently handled in sterile conditions. Serum samples were 
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allowed to clot at room temperature for one hour prior to centrifugation. Plasma and serum 
were harvested following centrifugation at 1,500 x g for 15 min at 4°C, and subsequently 
frozen at -20°C until analysis. Samples for complete blood count analysis were collected 
on d 2 of P1 and d 4 of P2 via coccygeal venipuncture (3 ml Vacuette® EDTA tubes; 
Greiner Bio-One, Monroe, NC), kept overnight at 4˚C, and submitted to the Iowa State 
Department of Veterinary Pathology for analysis. 
Tissue Collection 
Liver biopsies were collected from all animals on d 2 of P1 and d 5 of P2 as 
previously described (Rhoads et al., 2004). Briefly, the area was shaved, disinfected, and 
locally anesthetized using lidocaine before performing a percutaneous biopsy with a trocar. 
Samples were snap frozen in liquid nitrogen and stored at -80°C until analysis. Incisions 
were then sutured and topically treated with AluShield (Neogen Corp., Lexington, KY). 
At the end of P2, cows were either returned to the ISU dairy herd or were 
transported to the Iowa State Livestock Infectious Disease Isolation Facility and euthanized 
via captive bolt gun followed by exsanguination. A total of 13 cows from AL100 (n = 3), 
AL40 (n = 5) and AL40G (n = 5) were sacrificed. Liver and intestinal tissues were 
harvested within 15 min of euthanasia. Intestinal samples (25 cm segments) were collected 
as follows: jejunum was collected 1 m proximal to the ileocecal junction, ileum was 
collected 18 cm proximal to the ileocecal junction, and descending colon was collected 50 
cm proximal to the rectum. All intestinal segments were flushed with cold PBS to remove 
luminal content and a 4 cm section from the middle of the segment was collected and fixed 
in 10% neutral buffered formalin for later histological analysis. 
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Laboratory Analyses 
Plasma insulin, non-esterified fatty acids (NEFA), glucose, BHB, 
lipopolysaccharide-binding protein (LBP), serum amyloid A (SAA), haptoglobin, and 
BUN concentrations were determined using commercially available kits validated in our 
laboratory (insulin, Mercodia AB, Uppsala, Sweden; NEFA, Wako Chemicals USA, 
Richmond, VA; glucose, Wako Chemicals USA Inc., Richmond, VA; BHBA, Pointe 
Scientific Inc., Canton, MI; LBP, Hycult Biotech, Uden, Netherlands; SAA, Tridelta 
Development Ltd., Kildare, Ireland; haptoglobin, Immunology Consultants Laboratory 
Inc., Portland, OR; BUN, Teco Diagnostics Anaheim, CA). Pyrogen free serum samples 
were analyzed in duplicate using sterile procedures and a Pierce® Limulus Amebocyte LAL 
Chromogenic Endotoxin Quantitation Kit (No. 88282; Thermo Scientific, Rockford, IL). 
Portions of the liver samples (~5.0 g) were weighed, dried for 18 h at 102°C, and 
reweighed after cooling in order to determine liver moisture percentage. Hepatic 
triglyceride (TG) content was measured using a method adapted from (Morey et al., 2011). 
A ~20 mg liver sample was weighed and homogenized with 500 µL chilled PBS. The 
homogenate was then centrifuged at 8,000 x g for 2 min at 4°C. Free glycerol was 
immediately determined using 10 µL of supernatant via enzymatic glycerol phosphate 
oxidase method (Sigma-Aldrich, St. Louis, MO). An additional 300 µL of supernatant was 
removed and incubated with 75 µL lipase (MP Biomedicals, Solon, OH) at 37°C for 16 h 
before determining total glycerol using the same method. Free glycerol (before lipase 
digestion) was subtracted from total glycerol (after lipase digestion) in order to determine 
TG content, and this was expressed as a percentage of wet weight of the original sample. 
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The intra-assay coefficient of variation for free glycerol and total glycerol was 1.9 and 
0.8%, respectively. 
Histological Analysis 
For histological analysis, 10% neutral buffered formalin-fixed ileum, jejunum, and 
colon samples were submitted to the Iowa State University Veterinary Diagnostic 
Laboratory for sectioning and periodic acid-Schiff (PAS) staining for goblet cell area and 
villi morphology quantification. One slide per cow per tissue was generated. Using a 
microscope (Leica® DMI3000 B Inverted Microscope, Bannockburn, IL) with an attached 
camera (QImaging® 12-bit QICAM Fast 1394, Surrey, BC), five images per section of 
intestine were obtained at 50X magnification. All image processing and quantification was 
done using ImageJ 1.48v (National Institutes of Health, USA). PAS stain was measured 
using the Image J color deconvolution tool with H PAS vector. Goblet cell area was 
expressed as a percentage of the total mucosal area stained by PAS. For villus 
measurements, two villi per image were measured for a total of ten measurements per cow. 
Villus height was measured from the tip to the villus-crypt interface. Villus width was 
measured at mid height. Crypt depth was measured from the villus-crypt opening to the 
laminae propria. Crypt width was measured at the villus-crypt interface level. A mucosal 
surface area estimate was obtained using the mucosal-to-serosal amplification ratio M as 
previously reported by Kisielinski and colleagues (2002), where: 
𝑀 =  
(𝑣𝑖𝑙𝑙𝑢𝑠 𝑤𝑖𝑑𝑡ℎ × 𝑣𝑖𝑙𝑙𝑢𝑠 𝑙𝑒𝑛𝑔𝑡ℎ) + (
𝑣𝑖𝑙𝑙𝑢𝑠 𝑤𝑖𝑑𝑡ℎ
2 + 
𝑐𝑟𝑦𝑝𝑡 𝑤𝑖𝑑𝑡ℎ
2 )
2
− (
𝑣𝑖𝑙𝑙𝑢𝑠 𝑤𝑖𝑑𝑡ℎ
2 )
2
(
𝑣𝑖𝑙𝑙𝑢𝑠 𝑤𝑖𝑑𝑡ℎ
2 +  
𝑐𝑟𝑦𝑝𝑡 𝑤𝑖𝑑𝑡ℎ
2 )
2  
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Immunofluorescence Staining 
For immunofluorescence analysis, 10% neutral buffered formalin-fixed jejunum, 
ileum, and colon were sectioned at 5 microns thickness and mounted in the histology 
laboratory at the University of Iowa. Slides were deparaffinized using Citrisolv™ Hybrid 
Solvent (Fisher Scientific), rehydrated by 100%, 95% and 80% ethanol for 5 min each, 
followed by rinsing in distilled water. Antigen retrieval was performed by incubating slides 
in citrate buffer (Sodium Citrate, Citric Acid, Tween20, water) in a laboratory microwave 
for 8 min and then slides were allowed to cool down for 20 min. Tissue sections were 
blocked in 5% BSA (Sigma Aldrich) in PBS for 90-180 min. Primary antibody against 
proliferating cell nuclear antigen (PCNA; PC10 mAb, Cell Signaling Technology #2586; 
1:200 dilution), a marker of cellular proliferation, was applied to each section and 
incubated overnight at 4˚C. Slides were washed thrice in 1XPBS for 10 min each and 
incubated in fluorescent secondary antibody (anti-mouse IgG (H+L) F(ab’)2 Fragment, 
AlexaFluor® 488 conjugate, Cell Signaling Technology #4408; 1:1000 dilution) for 1 h at 
room temperature. Slides were washed thrice in 1XPBS for 10 min each and 4',6-
diamidino-2-phenylindole stain was applied to each section. Slides were stained with BSA/ 
BSA, primary antibody/BSA, BSA/secondary antibody for negative control. Images were 
collected on a Leica fluorescent microscope at 100X magnification. The relative intensity 
of the PCNA staining was analyzed (3 animals per treatment and 10 villi per animal) using 
integrated density quantification in ImageJ software. 
Statistical Analyses 
The effects of FR on most variables progressed with time, and thus data from P2 
d5 were statistically analyzed using PROC MIXED of SAS (SAS Institute Inc., Cary, NC) 
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with extent of FR as the fixed effect. Linear and quadratic effects of AL100, AL80, AL60, 
AL40, and AL20 treatments (not AL40G) were analyzed using preplanned orthogonal 
contrasts. In addition, a preplanned contrast of AL40 and AL40G treatments was included. 
For endotoxin analysis, both P2D2 and P2D4 data were used but the effects of day and 
treatment by day interaction were not significant and were therefore removed from the 
model. For post-mortem organ and histology data, preplanned contrasts of AL100 versus 
AL40 and AL40 versus AL40G were utilized. For liver TG, effect of treatment, period, 
and treatment by period interaction were assessed as well as linear and quadratic effects. 
Effect of replicate was included in the model and was removed if not significant. Each 
specific variable’s P1 value (when available) served as a covariate. Results are reported as 
least squares means and considered different when P ≤ 0.05 and tend to differ if P < 0.15. 
 
Results 
As dictated by experimental design, DMI linearly declined with increasing FR (P 
< 0.01; Figure 1A). Similarly, there was a linear decrease in both milk yield (Figure 1B) 
and EBAL (Table 2). There were no DMI, milk yield, or EBAL differences detected 
between cows assigned to the AL40G and AL40 treatments (P > 0.10). A linear increase 
in milk fat content occurred with increased severity of FR (P = 0.01; Table 2). Advancing 
FR linearly decreased MUN, protein, and lactose content (P < 0.01; Table 2). There were 
no differences in milk composition between cows in the AL40 and AL40G treatments. 
Heart and respiration rate declined linearly with FR (P < 0.05; Table 2). Cows in 
the AL40G treatment had increased HR (7 bpm) and Tr (0.3°C) compared to AL40 controls 
(P ≤ 0.05; Table 2). Unexpectedly, AL100 cows lost weight (28 kg), but body weight loss 
97 
 
 
increased with advancing FR severity (linear: P < 0.01; Table 2). Body weight loss tended 
to be greater in AL40G relative to AL40 cows (60 vs. 40 kg; P = 0.09). Body weight loss 
data should be interpreted with caution because cows were not weighed at a similar time 
relative to either milking or feeding due to logistical issues. 
Overall, there was no difference in circulating glucose (P = 0.33; Figure 2A). Both 
circulating insulin and BUN decreased linearly (P < 0.01; Figure 2B and 2C) while plasma 
NEFA increased linearly (P < 0.01; Figure 2D) with increasing FR. Circulating BHB 
tended to differ (P = 0.07) between treatments with AL20 cows having the highest levels 
(51% above AL100 controls; Figure 2E). Relative to AL40 cows, AL40G cows tended to 
have decreased circulating glucose (60 vs. 66 mg/dL; P = 0.08; Figure 2A) and had 
increased circulating BUN (27%; P = 0.03; Figure 2C). 
Circulating endotoxin, haptoglobin, SAA, and LBP increased or tended to increase 
linearly with advancing FR (P ≤ 0.08; Figure 3A-D,). A quadratic effect was detected for 
the insulin-to-DMI ratio where AL100 and AL20 treatments did not differ and AL80 and 
AL60 treatments were decreased ~50% relative to AL100 and AL20 (P < 0.01; Figure 3E). 
Circulating lymphocytes increased with advancing FR (P = 0.05; Figure 3F), but there were 
no treatment or contrasts effects on any other immune cell parameters, including total white 
blood cells, neutrophils, monocytes, eosinophils, and basophils (data not shown). In 
comparison with AL40 controls, AL40G cows had similar circulating endotoxin, but had 
decreased haptoglobin (76%; P = 0.01; Figure 3B) and tended to have decreased SAA 
levels (57%; P = 0.11; Figure 3C). Circulating LBP did not differ between AL40G cows 
and AL40 controls (P = 0.34; Figure 3D).  
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Relative to AL100 cows, AL40 cows had decreased jejunum villus width, jejunum 
crypt depth, ileum villus height, and ileum crypt depth (36, 14, 22, and 28%, respectively; 
P < 0.01; Figure 4A and 4B), and ileum mucosal surface area tended to be decreased (12%; 
P = 0.08; Figure 4D). Intestinal cellular proliferation, as measured by PCNA staining, 
tended to be decreased 14% in the ileum of AL40 relative to AL100 cows (P = 0.06; Figure 
4E). Goblet cell area was decreased 52 and 25% in the jejunum and ileum (P ≤ 0.01) and 
tended to be decreased 17% in the colon of AL40 compared to AL100 cows (P = 0.06; 
Figure 4F). No differences in villus height to crypt depth ratio between AL100 and AL40 
treatments were detected (P > 0.10; Figure 4C). In comparison with the AL40 treatment, 
cows treated with GLP2 (AL40G) had increased jejunum and ileum villus height (46 and 
51%, respectively) and increased ileum crypt depth (17%; P ≤ 0.01; Figure 4A and 4B). In 
both jejunum and ileum, AL40G cows had increased villus height to crypt depth ratios and 
mucosal surface area (38 and 35%, respectively and 30 and 29%, respectively; P < 0.01; 
Figure 4C and 4D). Relative intensity of PCNA protein was increased in both jejunum 
(43%) and ileum (36%) of AL40G cows relative to AL40 controls (P < 0.01; Figure 4E). 
Goblet cell area from AL40G cows was increased 59, 41, and 48% in the jejunum, ileum, 
and colon, respectively, relative to AL40 controls (P < 0.01; Figure 4F). 
Liver TG did not differ during P1 (P > 0.10). At the end of P2, liver TG were 
increased linearly with increased severity of FR (P = 0.01), and this was mainly due to a 
~88% increase in AL40 and AL20 relative to AL100 cows (Figure 5). 
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Discussion 
There is increasing appreciation for how intestinal barrier integrity influences 
performance in animal agriculture. Circumstances where the gastrointestinal barrier is 
compromised include weaning (Boudry et al., 2004; Moeser et al., 2007), heat stress 
(Baumgard and Rhoads, 2013; Pearce et al., 2013), rumen acidosis (Emmanuel et al., 2007; 
Khafipour et al., 2009; Minuti et al., 2014), and the periparturient period (Abuajamieh et 
al., 2016). Thus, identifying a mitigation strategy that could improve or ameliorate leaky 
gut would presumably enhance production efficiency in a variety of species. However, a 
standardized and easily implemented model to identify potential target molecules has not 
been established. Reduced feed intake causes intestinal barrier dysfunction in humans 
(Welsh et al., 1998), rodents (Holt et al., 1986; Ueno et al., 2011), chickens (Yamauchi et 
al., 1996), pigs (Carey et al., 1994; Pearce et al., 2013), and ruminant models (Zhang et al., 
2013). Further, our preliminary data suggest that this is also the case in lactating cows 
(Kvidera et al., 2017b). Therefore, our objectives were to identify a magnitude of FR that 
affects circulating biomarkers reflective of leaky gut, and to evaluate GLP2 administration 
as a potential mitigation strategy in lactating cows. 
As expected, FR reduced milk yield and energy balance and increased BW loss, 
and this demonstrates that we successfully implemented the experimental design. Further, 
milk yield and energy balance decreases were similar to other studies of comparable length 
and degree of restriction (Carlson et al., 2006; Ferraretto et al., 2014). Metabolic changes 
observed during the current study are consistent with the well-known hallmarks of reduced 
feed intake in ruminants, including: reduced circulating insulin (de Boer et al., 1985; 
Carlson et al., 2006; Ferraretto et al., 2014) and BUN (Bjerre-Harpøth et al., 2012; Lérias 
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et al., 2015) and increased circulating NEFA (de Boer et al., 1985; Carlson et al., 2006; 
Ferraretto et al., 2014). Additionally, liver fat content was increased in animals restricted 
to 40 or 20% ad libitum intake, which agrees with similar models (Carlson et al., 2003) 
while less severe or more chronic FR models do not observe such effects (Gross et al., 
2013). 
In the current study, there were no overt health disorders, so the increase in 
circulating inflammatory biomarkers observed ostensibly originated from the translocation 
of gut luminal content into circulation due to reduced intestinal barrier integrity. 
Circulating endotoxin was elevated with increasing severity of FR, and levels were similar 
to those observed by Khafipour and colleagues (2009). However, endotoxin data should be 
treated with caution as the Limulus Amebocyte Lysate assay measures endotoxin 
biological activity and not LPS bound to inflammatory mediators such as soluble CD14 or 
LBP (Guerville and Boudry, 2016). Perhaps better markers of gut luminal content 
infiltration are acute phase proteins (APP), which are produced by the liver as a secondary 
(non-local) response to toxic stimuli and have been widely utilized as markers of systemic 
inflammation (Ceciliani et al., 2012). Acute phase proteins LBP, SAA, and haptoglobin 
were increased with progressive FR, indicating an inflammatory response. Others have 
demonstrated an APP response to short-term FR in beef cattle, suggesting that feed and 
water deprivation are the main contributors to the APP response in receiving feedlot cattle 
(Cappellozza et al., 2011; Marques et al., 2012). It is unclear why AL20 cows had 
decreased levels of APP relative to less severe restricted cows. However, the magnitude of 
APP production can be impaired during malnourishment (Doherty et al., 1993; Reid et al., 
2002), yet remains responsive (Ling et al., 2004), and perhaps restricting feed to less than 
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40% of ad libitum limits the APP response. Circulating insulin is also acutely increased 
during times of inflammation (Baumgard et al., 2016; Kvidera et al., 2017a,b); however, 
differences in feed intake (and thus circulating nutrients, a major driver of insulin secretion) 
make this interpretation difficult. Utilizing an insulin-to-DMI ratio allows us to quantify 
the amount of circulating insulin per unit of DMI. The insulin-to-DMI ratio reached its 
nadir in the AL60 treatment before increasing to the point where AL20 cows do not differ 
from the AL100 cows. In the current study, the quadratic effect of FR on the insulin-to-
DMI ratio further confirms the most severely feed restricted treatments were experiencing 
inflammation.  
Reduced feed intake has deleterious effects on intestinal health (Ferraris and Carey, 
2000). In the current study, FR to 40% of ad libitum intake for 5 d negatively impacted 
intestinal architecture, particularly reducing the villus height and crypt depth in the ileum. 
The decreased villus height is likely due to the 14% decrease in cellular proliferation 
(Figure 4E). Numerous other FR models demonstrate detrimental effects on intestinal 
histology, including reduced villus height in feed restricted pigs (Carey et al., 1994; Pearce 
et al., 2013), chickens (Yamauchi et al., 1996), mice (Ueno et al., 2011), and rats (Holt et 
al., 1986). However, some FR models indicate no effect or even an increase in villi height 
(Holt et al., 1986; Chappell et al., 2003; Hodin et al., 2011; Tůmová et al., 2015). Reasons 
for discrepancy between results could be due to severity and duration of FR as well as the 
intestinal segment examined and its relative importance to that species. Mechanistically, 
fasting reduces intestinal epithelial cell numbers, cellular proliferation, and cellular 
migration rates, and this is coupled with increased rates of cellular loss and apoptosis, 
altogether contributing to changes in intestinal architecture and increased epithelial 
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permeability (Chappell et al., 2003; Ferraris and Carey, 2000). Although altered 
morphology does not prove decreased barrier function, malnutrition and increased 
intestinal permeability have been reported in numerous species (Holt et al., 1986; Welsh et 
al., 1998; Boza et al., 1999). Further, altered intestinal barrier function has been 
demonstrated in studies where structural changes in villi morphology were similar to those 
observed in the current study (Ford et al., 1985; Pearce et al., 2013). 
The importance of proper barrier function cannot be understated as the intestine is 
continuously exposed to potential pathogens and toxins (Mani et al., 2012). The human 
gastrointestinal tract has a surface area of ~400m2 (Murphy, 2012) and is continuously 
subjected to potentially pathogenic microorganisms and toxins (Mani et al., 2012). 
Pathogen exposure is certainly more extensive in ruminants due to pre-gastric fermentation 
compartments and the relative size of the gastrointestinal tract. The direct consequence of 
intestinal barrier dysfunction is increased leakage of luminal antigens into the submucosa 
and portal blood stream with the potential to initiate an inflammatory response. This can 
undoubtedly compromise production as immunoactivation is an energetically expensive 
process which redirects energy away from agriculturally productive purposes and 
compromises animal welfare (Kvidera et al., 2017a). Therefore, researching molecules or 
nutritional strategies to ameliorate gut barrier dysfunction, including exogenous GLP2, has 
been gaining recent attention in production agriculture (Thymann et al., 2014; Connor et 
al., 2016). Endogenous GLP2 is a proglucagon-derived peptide secreted by 
enteroendocrine L cells in response to luminal nutrients (Drucker and Yusta, 2014). The 
trophic effects of GLP2 on intestine are mediated through increased mesenteric blood flow, 
greater nutrient uptake, and release of growth factors such as IGF-1, IGF-2, keratinocyte 
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growth factor, and epidermal growth factor-ErbB family members (Connor et al., 2016). 
Exogenous GLP2 administration reduced intestinal permeability, hepatic bacterial cultures, 
and intestinal crypt apoptosis in stressed mouse models (Boushey et al., 1999; Cameron 
and Perdue, 2005). The authors are unaware of previous literature examining GLP2’s effect 
in lactating dairy cattle; however, GLP2 receptors have been characterized in the lactating 
cow gastrointestinal tract (Connor et al., 2010). In calves, GLP2 administration improved 
small intestine tight junction protein expression, blood flow, and growth and reduced 
circulating acute phase proteins (Taylor-Edwards et al., 2011; Connor et al., 2013; Walker 
et al., 2015; Connor et al., 2017). In the current study, administrating GLP2 increased ileum 
villus height above the ad libitum controls. Negative effects of FR on ileum mucosal area 
and goblet cell area of all three segments were also rescued or even improved by GLP2 
administration. Though FR did not affect villus height to crypt depth ratios, jejunum villus 
height, or jejunum mucosal surface area, GLP2 increased each of these parameters ~30-
50% above ad libitum control cows. Increased villus height in animals administered GLP2 
is likely explained by the 43 and 36% increase in cellular proliferation observed in both 
the jejunum and ileum. It is unclear why FR impacted the ileum more than the jejunum, 
but may be due to diminished nutrient availability from the proximal to distal intestine. 
Subtle changes in jejunum intestinal architecture also may not be detected due to the low 
number of cows utilized in this study. Regardless, these data clearly demonstrate the 
beneficial effects of GLP2 on the intestine in both stressed and non-stressed sections of the 
intestine (i.e., both jejunum and ileum), which agrees with Hu et al. (2010) who also 
observed GLP2’s trophic effects in both heat-stressed and healthy chickens. Further, 
administering GLP2 lowered circulating haptoglobin and serum amyloid A 76 and 57%, 
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respectively. A reduced circulating serum amyloid A response to coccidial infection was 
also observed in calves administered GLP2 (Connor et al., 2017). Despite not being able 
to establish causation, we hypothesize GLP2’s positive effects on intestinal integrity and 
subsequent prevention of endotoxin infiltration play a role in the APP reduction. Glucagon 
like peptide 2 may also have a direct role in inhibiting inflammation because it stimulates 
antimicrobial peptide secretion by Paneth cells in the intestinal epithelium (Lee et al., 2012) 
which may reduce microbial load and subsequent microbial component leakage into 
systemic circulation. Furthermore, GLP2 has the ability to suppress the pro-inflammatory 
response of macrophages to LPS (Xie et al., 2014). Collectively, the histology and changes 
in acute phase protein profile strongly suggest that GLP2 improved gut barrier function. 
Despite its beneficial effects on intestinal health, GLP2 administration did not 
improve production parameters, as evidenced by similar milk yield and composition 
between AL40 and AL40G cows. This is not entirely surprising, as the experiment was 
knowingly underpowered to detect production differences. Additionally, the FR model 
limits any positive effects GLP2 may have on feed intake. It would be of interest to study 
GLP2 administration during a natural model of stress with objectives of determining if 
GLP2 has a beneficial effect on feed intake or production and if this further improves 
intestinal growth and integrity. It is unclear whether the GLP2-induced decrease in 
circulating glucose is of biological relevance (66 vs. 60 mg/dL), but it may be related 
GLP2’s neuroendocrine role in the gut-brain axis which can result in suppression of hepatic 
glucose production and increased glucose tolerance (Guan, 2014). Injecting GLP2 did not 
influence circulating insulin, and this is not surprising as GLP2 does not directly modulate 
insulin secretion (Schmidt et al., 1985). Interestingly, GLP2 administration increased BUN 
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by 27%. Reasons behind this effect are not clear, but interpreting BUN in ruminants is 
difficult because it originates from both skeletal muscle catabolism and excessive rumen 
ammonia production. 
Decreased intestinal barrier integrity has several negative consequences and thus 
research into ruminant intestinal health has gained recent attention (Connor et al., 2016; 
Steele et al., 2016). However, it is difficult to model leaky gut in order to test potential 
mitigation strategies. Various models exist to pharmaceutically induce intestinal barrier 
dysfunction, including non-steroidal anti-inflammatory drugs, gamma-secretase inhibitors, 
and dextran sodium sulfate (Fortun and Hawkey, 2007; Wirtz et al., 2007; Kvidera et al., 
2017b), but these approaches are difficult to administer in ruminants and are often 
associated with side effects. As previously mentioned, the severity and duration of FR in 
literature varies considerably and its effects on gut health are not extensively studied in the 
ruminant animal, ergo it is not clear what magnitude of FR is required to dependably 
compromise intestinal barrier function. In the current study, animals restricted to 40% of 
their ad libitum intake for 5 days exhibited a well-defined increase in inflammatory 
parameters. Deterioration of intestinal architecture accompanied this inflammation, giving 
us confidence that intestinal dysfunction was likely the cause. One drawback to our model 
is the limitation of beneficial effects a mitigation strategy may have on feed intake. Despite 
this, GLP2 administration improved intestinal health and subsequently reduced 
inflammatory parameters independently of any changes in feed intake. 
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Conclusions 
Increasing severity of FR reduced milk yield and increased circulating endotoxin 
and APP as well as liver TG. It appears that cows fed 40% of their ad libitum intake were 
most affected, and this treatment showed obvious signs of intestinal dysfunction, including 
reduced ileum villus height, mucosal surface area, and cellular proliferation as well as 
reduced goblet cell area in all three intestinal sections. Administering GLP2 had a 
substantial effect on intestinal growth, morphology, and reduced circulating APP in 
comparison with cows on a similar plane of nutrition. In conclusion, FR had detrimental 
effects on intestinal barrier integrity and administering GLP2 alleviates these negative 
effects.   
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Table 8. Ingredients and composition of diet 
Ingredient % of DM2 
Corn Silage 42.8 
Alfalfa Hay 19.7 
Rolled Corn 18.1 
Whole Cotton 8.6 
High Protein Soybean Meal3 5.4 
Soy Plus®4 3.0 
Ground Corn 2.3 
  
Chemical analysis, % of DM  
CP 16.7 
NDF 32.1 
ADF 21.8 
NEL Mcal/kg DM 1.6 
1Values represent an average of ration nutrient 
summary reports collected throughout the trial.   
Diet moisture averaged 43.56%. 
2Average nutrient levels: 4.41% Fat, 0.84% Ca, 
0.47% P, 0.37% Mg, 0.20% S, 1.20% K, 0.45% 
Na, 0.48% Cl, 56.58 ppm of Zn, 64.85 ppm of 
Mn, 136.46 ppm of Fe, 17.91 ppm of Cu, 0.22 
ppm of Co, 0.27 ppm Se, 0.85 ppm of I, 4402.2 
IU/kg of vitamin A, 1438.8 IU/kg of vitamin D, 
and 24.2 IU/kg of vitamin E 
3Solvent-extracted soybean meal containing 54.5% 
CP, 35% RUP (% CP; DM basis). 
4Cooker-expeller processed soybean meal 
produced by West Central Cooperative, Ralston, 
IA, containing 46.6% CP, 60% RUP (% CP; DM 
basis). 
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Table 9. Effects of 5 d of incremental feed restriction and GLP2 treatment on milk and health parameters  
 Treatment1    P  Contrasts 
Parameter AL100 AL80 AL60 AL40 AL40G AL20  SEM  Treatment  Linear2 Quadratic2 
AL40 v 
AL40G 
Milk parameters               
Fat, % 3.9 4.3 4.1 4.4 4.6 5.4  0.3  0.07  0.01 0.22 0.68 
Lactose, % 4.8a 4.6ab 4.6ab 4.5ab 4.4bc 4.2c  0.1  0.01  <0.01 0.69 0.47 
Protein, % 3.2 3.0 3.0 2.9 2.8 2.9  0.1  0.08  0.04 0.25 0.36 
TS, % 12.8 13.0 12.5 12.7 13.1 13.4  0.4  0.55  0.41 0.24 0.49 
MUN, mg/dL 14.6a 14.1ab 12.7bc 11.6c 12.2c 11.3c  0.5  <0.01  <0.01 0.76 0.41 
Milk SCC, *1000/mL 82 84 256 130 153 411  92  0.12  0.03 0.48 0.86 
Health parameters               
EBAL, Mcal/d 11.2a 2.6b 0.0b -5.0c -6.4c -10.5d  1.2  <0.01  <0.01 0.32 0.49 
Tr3, °C 38.3 38.5 38.3 38.1 38.4 38.3  0.1  0.24  0.17 0.99 0.05 
RR4, breaths/min 42 45 39 38 43 36  3  0.13  0.04 0.69 0.15 
Heart rate, beats/min 71a 69ab 64b 58c 65ab 65ab  2  0.01  0.01 0.05 0.02 
BW loss, kg 28c 25c 36c 40bc 60ab 69a  8  <0.01  <0.01 0.09 0.09 
1Treatments: AL100 = ad libitum intake; AL80 = restricted to 80% of ad libitum intake; AL60 = restricted to 60% of ad libitum intake; AL40 = 
restricted to 40% of ad libitum intake + saline (3 mL s.c. twice daily); AL40G = restricted to 40% of ad libitum intake + glucagon-like peptide 2 (75 
µg/kg BW s.c. twice daily); AL20 = restricted to 20% of ad libitum intake 
2Assessed using AL100, AL80, AL60, AL40, and AL20 treatments 
3Rectal temperature 
4Respiration rate 
1
0
8
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Figure 10. Effects of incremental feed restriction and GLP2 treatment on (A) dry matter intake 
and (B) milk yield on d 5 of treatment. Treatments include: AL100 = ad libitum intake, AL80 = 
restricted to 80% of ad libitum intake, AL60 = restricted to 60% of ad libitum intake, AL40 = 
restricted to 40% of ad libitum intake + saline (3 mL s.c. twice daily), AL40G = restricted to 40% 
of ad libitum intake + glucagon-like peptide 2 (75 µg/kg BW s.c. twice daily), and AL20 = 
restricted to 20% of ad libitum intake. a-eValues with differing superscripts denote differences (P 
≤ 0.05) between treatments. 
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Figure 11. Effects of incremental feed restriction and GLP2 treatment on circulating (A) glucose, 
(B) insulin, (C) BUN, (D) non-esterified fatty acids (NEFA), and (E) BHB on d 5 of treatment. 
Treatments include: AL100 = ad libitum intake, AL80 = restricted to 80% of ad libitum intake, 
AL60 = restricted to 60% of ad libitum intake, AL40 = restricted to 40% of ad libitum intake + 
saline (3 mL s.c. twice daily), AL40G = restricted to 40% of ad libitum intake + glucagon-like 
peptide 2 (75 µg/kg BW s.c. twice daily), and AL20 = restricted to 20% of ad libitum intake. a-
eValues with differing superscripts denote differences (P ≤ 0.05) between treatments. 
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Figure 12. Effects of incremental feed restriction and GLP2 treatment on (A) circulating 
endotoxin, (B) haptoglobin, (C) serum amyloid A (SAA), (D) LPS-binding protein (LBP), (E) 
insulin-to-dry matter intake ratio (Insulin:DMI), and (F) lymphocytes. Treatments include: AL100 
= ad libitum intake, AL80 = restricted to 80% of ad libitum intake, AL60 = restricted to 60% of 
ad libitum intake, AL40 = restricted to 40% of ad libitum intake + saline (3 mL s.c. twice daily), 
AL40G = restricted to 40% of ad libitum intake + glucagon-like peptide 2 (75 µg/kg BW s.c. twice 
daily), and AL20 = restricted to 20% of ad libitum intake. a-cValues with differing superscripts 
denote differences (P ≤ 0.05) between treatments. 
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Figure 13. Effects of incremental feed restriction and GLP2 treatment on (A) jejunum villus 
morphology, (B) ileum villus morphology, (C) villus height-to-crypt depth ratio in jejunum and 
ileum, (D) mucosal surface area in jejunum and ileum, (E) intensity of PCNA protein in jejunum 
and ileum, and (F) goblet cell area as a percentage of epithelial area in jejunum, ileum, and colon. 
Treatments include: AL100 = ad libitum intake, AL40 = restricted to 40% of ad libitum intake + 
saline (3 mL s.c. twice daily), and AL40G = restricted to 40% of ad libitum intake + glucagon-like 
peptide 2 (75 µg/kg BW s.c. twice daily). a-cValues with differing superscripts denote differences 
(P ≤ 0.05) between treatments. Mucosal surface area is expressed as an M-index as described by 
Kisielinski et al., 2002. 
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Figure 14. Effects of incremental feed restriction and GLP2 treatment on liver triglyceride (TG) 
content. Treatments include: AL100 = ad libitum intake, AL80 = restricted to 80% of ad libitum 
intake, AL60 = restricted to 60% of ad libitum intake, AL40 = restricted to 40% of ad libitum 
intake + saline (3 mL s.c. twice daily), AL40G = restricted to 40% of ad libitum intake + glucagon-
like peptide 2 (75 µg/kg BW s.c. twice daily), and AL20 = restricted to 20% of ad libitum intake. 
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Figure 15. Representative images of periodic acid-Schiff stained (A) AL100 jejunum, (B) 
AL40 jejunum, (C) AL40G jejunum, (D) AL100 ileum, (E) AL40 ileum, (F) AL40G ileum, 
(G) AL100 colon, (B) AL40 colon, (I) AL40G colon. Dark purple stain is positive for 
mucosubstances. 
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Figure 16. Representative image of PCNA protein intensity in (A) AL100 jejunum, (B) 
AL40 jejunum, (C) AL40G jejunum, (D) AL100 ileum, (E) AL40 ileum, (F) AL40G ileum. 
Negative controls are (F) BSA/BSA, (G) primary antibody alone, (H) secondary antibody 
alone. Nuclear stain is blue while PCNA stain is green. 
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CHAPTER 4: TECHNICAL NOTE: ESTIMATING GLUCOSE 
REQUIREMENTS OF AN ACTIVATED IMMUNE SYSTEM IN HOLSTEIN 
STEERS 
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Abstract 
Infection and inflammation impede efficient animal productivity. The activated 
immune system ostensibly requires large amounts of energy and nutrients otherwise 
destined for synthesis of agriculturally relevant products. Accurately determining the 
immune system’s in vivo energy needs is difficult, but a better understanding may facilitate 
developing nutritional strategies to maximize productivity. The study objective was to 
estimate immune system glucose requirements following an i.v. lipopolysaccharide (LPS) 
challenge. Holstein steers (148 ± 9 kg; n=15) were jugular catheterized bilaterally and 
assigned to 1 of 3 i.v. treatments: control (CON; 3 mL saline; n=5), LPS-administered 
controls (LPS-C; E. coli 055:B5; 1.5 μg/kg BW; n=5), and LPS + euglycemic clamp (LPS-
Eu; 1.5 μg/kg BW; 50% dextrose infusion to maintain euglycemia; n=5). In LPS-Eu steers, 
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post-bolus blood samples were analyzed for glucose every 10 min. Dextrose infusion rates 
were adjusted to maintain euglycemia for 720 min. All steers were fasted during the 
challenge. Samples for later analysis were obtained at 180, 360, 540, and 720 min relative 
to LPS administration. Rectal temperature was increased ~0.5°C in both LPS treatments 
relative to CON steers (P = 0.01). Steers in both LPS treatments were hyperglycemic for 
~3 h post-bolus; thereafter, blood glucose was markedly decreased (30%; P < 0.01) in LPS-
C relative to both CON and LPS-Eu steers. A total of 516 ± 65 g of infused glucose was 
required to maintain continuous euglycemia in LPS-Eu steers. Circulating insulin increased 
in LPS-C and LPS-Eu steers relative to CON (~70% and ~20 fold, respectively; P < 0.01). 
Circulating NEFA increased similarly with time for both CON and LPS-C compared to 
LPS-Eu steers (~43%; P < 0.01). Plasma L-lactate and LPS binding protein increased 
(~198 and ~90%, respectively; P < 0.01) and ionized calcium decreased (18%; P < 0.01) 
in both LPS treatments relative to CON steers. Circulating white blood cells decreased 
initially in LPS-Eu and LPS-C relative to controls (180 min; 85%) followed by a 
progressive increase with time (P = 0.02). Blood neutrophils followed the same pattern, 
however, at 720 min, neutrophils were decreased in LPS-Eu compared to LPS-C, resulting 
in a decreased neutrophil-to-lymphocyte ratio (54%; P = 0.03). The large amount of 
glucose needed to maintain euglycemia indicates extensive repartitioning of nutrients away 
from growth and the importance of glucose as a fuel for the immune system. 
Key words: glucose homeostasis, immune challenge, lipopolysaccharide  
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Introduction 
 Infection and inflammation have negative economic consequences on animal 
agriculture due to decreased production, inefficient feed utilization, poor reproduction, and 
increased health care costs. An activated immune system demands a large amount of 
energy and nutrients (Lochmiller and Deerenberg, 2000; Johnson, 2012) which 
reprioritizes the hierarchy of nutrient partitioning away from productive purposes. For 
instance, glucose homeostasis is markedly disrupted during an endotoxin (e.g., 
lipopolysaccharide; LPS) challenge and hypoglycemia and hyperlactemia are 
characteristic hallmarks (Filkins, 1978; McGuinness, 2005; Michaeli et al., 2012). In 
addition, in vitro experiments suggest activated immune cells experience a substantial 
increase in glucose consumption and utilize glucose as their primary source for the 
generation of energy, biosynthetic precursors, and signaling intermediates (Calder et al., 
2007; Palsson-McDermott and O’Neill, 2013). The extent of immune cell glucose 
consumption in vivo is difficult to assess due to the ubiquitous and fluctuating distribution 
of immune cells and organ specific changes in insulin sensitivity; however, better 
understanding the impact on energy status has practical implications to animal agriculture 
as glucose is obviously an important fuel for productive purposes. 
Despite the increase in glucose requirements, an activated immune response is often 
accompanied by anorexia and thus decreased diet-derived glucose or glucose precursors. 
To ensure an adequate nutrient supply to the immune system, hepatic glucose output can 
increase via both glycogenolysis and gluconeogenesis (Filkins, 1978; McGuinness, 1994). 
Concurrently, there is an increase in peripheral insulin resistance leading to decreased 
glucose uptake by skeletal muscle and adipose tissue (Lang et al., 1990; Song et al., 2006). 
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Despite the homeorhetic efforts to spare glucose for the immune system, hypoglycemia 
often develops following a LPS challenge, likely because the immune system’s rate of 
glucose utilization exceeds the synchronized capacity of the liver to export glucose and 
insulin sensitive tissues to reduce glucose disposal (McGuinness, 2005). Therefore, the 
experimental objective was to estimate the amount of glucose needed to maintain 
euglycemia following an LPS challenge as a proxy for the amount of glucose required to 
fuel an acute immune response. 
 
Materials and Methods 
 All procedures were approved by the Iowa State University Institutional Animal 
Care and Use Committee. Fifteen Holstein steers (148 ± 9 kg) were randomly assigned to 
individual pens at the Iowa State University Zumwalt Climatic Research Station (Ames, 
IA). Steers were allowed 5 d to acclimate during which they were implanted with bilateral 
jugular catheters and fed ad libitum once daily (0600 h) a diet formulated to meet or exceed 
the predicted requirements (NRC, 2001) of energy, protein, minerals, and vitamins. Steers 
were randomly assigned to 1 of 3 i.v. bolus treatments: control (CON; 3 mL sterile saline; 
n=5), LPS-administered controls in which hypoglycemia was allowed to develop (LPS-C; 
1.5 μg/kg BW LPS; n=5), and LPS-administered in which euglycemia was maintained 
(LPS-Eu; 1.5 μg/kg BW LPS; n=5). The LPS dose used was selected based on Waggoner 
et al. (2009b) and their observation of a 30% decrease in circulating glucose 4 h post-LPS. 
Lipopolysaccharide (Escherichia coli O55:B5; Sigma Aldrich, St. Louis, MO) was 
dissolved in sterile saline at a concentration of 75 μg/mL and passed through a 0.2 μm 
sterile syringe filter (Thermo Scientific; Waltham, MA). The total volume of LPS solution 
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administered was approximately 3 mL. In the LPS-Eu treatment, we performed a 
euglycemic clamp where 50% dextrose (VetOne, Boise, ID) was i.v. infused at a known 
and adjustable rate utilizing a modular pump (Deltec 3000, Deltec Inc., St. Paul, MN) in 
order to maintain the pre-LPS infusion blood glucose levels. 
Feed was removed ~1 h prior to treatment administration and animals remained 
fasted during the 720 min data collection period. Baseline blood samples were obtained -
30, -20, and 0 min relative to bolus administration to establish baseline glucose levels. Each 
respective treatment bolus was administered immediately following the 0 min blood 
sample collection. For LPS-Eu steers, post-bolus blood samples (1 mL) were collected 
every 10 min and immediately analyzed for glucose (TRUEbalance glucometer; 
McKesson, San Francisco, CA). Dextrose infusion began when blood glucose content 
declined below baseline levels, and its rate of infusion was adjusted as necessary to 
maintain blood glucose concentration at baseline levels (± 10%). The rate of 50% dextrose 
infusion (mL/h) was transformed to rate of glucose infusion (ROGI; g/h). The total glucose 
infused for each steer was calculated using the ROGI for each 10 min interval (72 intervals 
in total) according the following equation: 
∑ 𝑅𝑂𝐺𝐼 (
𝑔
ℎ
)
𝑖
72
𝑖=0
∗
1 ℎ
60 𝑚𝑖𝑛
∗ 10 𝑚𝑖𝑛 
Blood glucose was measured every 30 min in CON and LPS-C steers for the first 300 min 
and every 60 min thereafter. Additional serum and plasma samples (~10 mL each) for 
further analysis were collected from all treatments at -30, 0, 180, 360, 540, and 720 min 
relative to LPS administration. Rectal temperatures were obtained -30 and 0 min relative 
to bolus administration, every 30 min for the first 300 min, and every 60 min thereafter 
using a digital thermometer (GLA M700, San Luis Obispo, CA). 
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 Insulin, glucose, NEFA, β-hydroxy butyrate (BHB), LPS binding protein (LBP), 
L-lactate, serum amyloid A (SAA), haptoglobin, and blood urea nitrogen (BUN) 
concentrations were determined using commercially available kits according to 
manufacturers’ instructions (insulin, Mercodia AB, Uppsala, Sweden; glucose, Wako 
Chemicals USA Inc., Richmond, VA; NEFA, Wako Chemicals USA, Richmond, VA; 
BHB, Pointe Scientific Inc., Canton, MI; LBP, Hycult Biotech, Uden, Netherlands; L-
lactate, Biomedical Research Service Center, Buffalo, NY; SAA, Tridelta Development 
Ltd., Kildare, Ireland; haptoglobin, Immunology Consultants Laboratory Inc., Portland, 
OR; BUN, Teco Diagnostics Anaheim, CA). The inter- and intra-assay coefficients for 
haptoglobin, insulin, NEFA, BHB, L-lactate, SAA, LBP, and BUN assays were 14.0 and 
10.2%, 12.6 and 7.0%, 9.9 and 3.9%, 3.8 and 2.3%, 7.1 and 2.9%, 14.2 and 6.2%, 33.0 and 
2.6%, and 12.2 and 5.2%, respectively. Ionized blood calcium was measured using an i-
STAT handheld machine and cartridge (CG8+; Abbott Point of Care, Princeton, NJ). For 
white blood cell (WBC) count, a 3 mL blood sample was collected (K2EDTA; BD Franklin 
Lakes, NJ) and stored at 4°C for 12 h before submission to the Iowa State Department of 
Veterinary Pathology for complete blood count analysis. 
  Post-bolus blood glucose was divided into two phases: a hyperglycemic (0-180 
min) and hypoglycemic (180-720 min) phase which were statistically analyzed separately. 
Rectal temperature and ROGI were analyzed for the entire post-bolus period. Remaining 
parameters were analyzed for the hypoglycemic phase (180-720 min, during which blood 
samples were obtained). Each animal’s respective parameter was analyzed using repeated 
measures with an autoregressive covariance structure for blood parameters and spatial 
power law for rectal temperature and blood glucose. The repeated effect was minute after 
122 
 
 
bolus administration. Each specific variable’s pre-bolus value served as a covariate. Effects 
of treatment, time, and treatment by time interaction (except for ROGI, where only the 
effect of time within the LPS-Eu treatment was analyzed) were assessed as a completely 
randomized design using PROC MIXED (SAS Inst. Inc., Cary, NC). Pre-formed contrasts 
were used to estimate differences between CON and LPS-infused steers (LPS-C and LPS-
Eu) as well as between the two LPS-infused treatments (LPS-C vs. LPS-Eu). Data are 
reported as LSmeans and considered significant if P ≤ 0.05 and a tendency if 0.05 < P ≤ 
0.10. 
 
Results 
 Rectal temperature was increased ~0.5°C in both LPS treatments relative to CON 
steers (P = 0.01; Table 10). Both LPS-infused treatments (LPS-C and LPS-Eu), had ~100% 
increased circulating glucose for 180 min following LPS-administration relative to CON 
steers (P = 0.04; Figure 17A). From 180 to 720 min, there was a 30% decrease in blood 
glucose in LPS-C steers relative to CON and LPS-Eu steers (P < 0.01; Figure 17A). No 
differences in blood glucose were observed between CON and LPS-Eu treatments (P = 
0.59) following the 180th min, indicating euglycemia was successfully maintained. Glucose 
infusion began 178 ± 17 min post-LPS administration (range 150-230 min). The ROGI 
increased with time (P < 0.01) and 516 ± 65 g of glucose were infused to maintain 
euglycemia (Figure 17B) from the 180th to 720th min.  
Insulin increased 25.5-fold in LPS-Eu steers compared to CON steers (P < 0.01; 
Figure 17C). Ad hoc analysis also indicated that LPS-C steers had a 70% increase (P < 
0.05) in circulating insulin compared to controls (data not shown). Circulating NEFA and 
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BHB were reduced (43 and 33%, respectively) in LPS-Eu versus CON and LPS-C steers 
(P ≤ 0.01; Table 10). Compared to CON, steers in both LPS treatments had a similar 
increase in circulating BUN (53%; P = 0.03; Table 10), L-lactate (199%; P = 0.01; Figure 
18A), LBP (90%; P < 0.01; Figure 18B), and a tendency for increased SAA (26%; P = 
0.10; Table 10). Ionized calcium decreased 16% in both LPS treatments relative to CON 
steers (P < 0.01; Table 10). 
There was a treatment by time interaction (P = 0.02; Figure 18C) for WBC counts 
as LPS steers experienced an initial decrease in cell number (180 min; 85%) followed by a 
progressive increase with time and WBC counts were similar to CON levels by 720 min. 
Cell types primarily contributing to the WBC temporal changes were neutrophils, 
lymphocytes, monocytes, and basophils which were initially reduced (9, 85, 91, and 79%, 
respectively; P ≤ 0.08) at 180 min post-LPS and gradually increased thereafter (Table 10). 
The progressive increase in neutrophils tended to be reduced in LPS-Eu steers (P = 0.08; 
Table 10), resulting in a 63% decrease in neutrophil number by min 720 compared to LPS-
C steers. This resulted in a 100% decrease in the neutrophil-to-lymphocyte ratio (NLR) in 
LPS-Eu relative to LPS-C steers (P = 0.03; Table 10). Eosinophils increased 76% and 
platelets decreased 52% in both LPS treatments relative to CON steers (P < 0.05; Table 
10). 
 
Discussion 
 Animal productivity is suboptimal during infection and inflammation due to 
increased energy requirements and subsequent nutrient partitioning towards the immune 
system and away from agriculturally important products (e.g., skeletal muscle, milk, fetus, 
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etc.). For example, skeletal muscle proteolysis is an important source of amino acids 
needed for acute phase protein synthesis, and this has been studied extensively (Klasing 
and Austic, 1984a,b; Reeds et al., 1994; Grimble and Grimble, 1998; Reeds and Jahoor, 
2001; Li et al., 2007; Johnson, 2012). However, quantifying nutrient requirements of the 
immune system is difficult due to its dynamic and ubiquitous distribution throughout 
tissues. In terms of bioenergetics, both whole body energy expenditure and glucose 
utilization are estimated to increase approximately 50% during an infection (Lang and 
Dobrescu, 1991; Lang et al., 1993; Plank et al., 1998). This is likely because immune cells 
become substantial glucose consumers in order to support the energetic and substrate needs 
of activation (Calder et al., 2007; Maratou et al., 2007; Maciver et al., 2008; Palsson-
McDermott and O’Neill, 2013; Kelly and O’Neill, 2015). For instance, in tissues with a 
large immune compartment (spleen, liver, lung, and ileum) LPS increases glucose 
utilization which is enhanced by euglycemia (Lang et al., 1993). Determining energetic 
requirements of the immune system in vivo is arduous as immune cells are present in 
virtually every tissue. Furthermore, the distribution of immune cells throughout different 
tissues is dynamic and can change rapidly as demonstrated by leukopenia observed in this 
and other studies (Griel et al., 1975; Bieniek et al., 1998). Despite its obvious difficulty, 
accurately estimating energetic and nutrient requirements of an activated immune response 
is essential for developing strategies to optimize productivity in immune-challenged 
animals. Herein, we propose using a euglycemic clamp after LPS administration in order 
to estimate the amount of glucose utilized during an intense immune response. 
 In the current study, we successfully induced an immune response by LPS injection 
as indicated by pyrexia and increased circulating levels of acute phase proteins LBP and 
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SAA (26 and 90% for SAA and LBP, respectively; Table 10 and Figure 18B). While the 
increase in acute phase proteins is consistent with other ruminant literature, there is 
substantial variation in baseline values and magnitudes of change (Carroll et al., 2009; 
Schroedl et al., 2001; Graugnard et al., 2013; Plessers et al., 2015). This is likely due to 
differences in models, route of LPS administration, and/or laboratory procedures, but 
differences in baseline values have even been reported within labs (Khafipour et al., 
2009a,b). Severe hypoglycemia (30% decrease; Figure 17A) began ~180 min post bolus 
and continued through 720 min. Hyperlactemia (~200% increase; Figure 18A) was also 
evident in LPS-infused steers, especially at 180 min, and declined slightly with time. 
Additionally, circulating ionized calcium decreased (18%) which agrees with others (Griel 
et al., 1975; Carlstedt et al., 2000; Waldron et al., 2003b) and may be due to calcium’s 
involvement with immune system activation (Hendy and Canaff, 2016). The 
aforementioned observations are indicative of an aggressive and sustained immune 
response and are similar to other models of endotoxemia (Filkins, 1978; Lang et al., 1993; 
Waldron et al., 2003b; Michaeli et al., 2012). Dextrose infusion initiation, coinciding with 
the development of hypoglycemia, was fairly consistent between steers (178 ± 17 min post-
LPS; range 150-230 min). The ROGI increased steadily over time before plateauing at 
~650 min post-LPS. From the accumulated ROGI, we estimate the activated immune 
system uses approximately 516 g of glucose in a 720 min period. However, as further 
discussed below, this calculation is likely underestimated as it does not incorporate glucose 
use by immune cells during the hyperglycemic phase. 
 Nevertheless, the current experimental design has some limitations. Firstly, the 
extent of peripheral tissue glucose consumption limits our capacity to accurately estimate 
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immune system’s glucose utilization. However, many studies demonstrate reduced insulin-
sensitivity and/or glucose utilization in both muscle and adipose tissue during endotoxemia 
both in vivo (Raymond et al., 1981; Ling et al., 1994; Poggi et al., 2007; Mulligan et al., 
2012) and in vitro (Song et al., 2006; Liang et al., 2013). Lang and colleagues (1993) 
obtained similar results in a rodent model of endotoxemia; however, when providing 
glucose to maintain euglycemia, glucose utilization increased in skeletal muscle and 
adipose tissue. Nonetheless, in tissues with a large immune compartment (spleen, liver, 
lung, and ileum) glucose utilization was increased in LPS-hypoglycemic rats and the 
increase was even more pronounced in LPS-euglycemic conditions, acknowledging the 
relative importance of activated immune cells to whole-body glucose consumption. 
Additionally, endotoxemia likely causes macrophage infiltration into adipose and muscle 
(Caesar et al., 2012; Pillon et al., 2013), highlighting the difficulty to pinpoint glucose 
consumption by the immune system using 2-deoxyglucose, a non-metabolizable marker of 
glucose uptake, as immune cells are located in essentially every tissue. Immune cell 
distribution radically changes after LPS administration as demonstrated by leukopenia 
observed in this and other studies (Figure 18C; Griel et al., 1975; Bieniek et al., 1998), 
which is likely due to extravasation of leukocytes into tissues, especially those with 
important immune functions such as liver, kidney, spleen, and lung (Mészáros et al., 1991; 
Lang and Dobrescu, 1991). In agreement, Mészáros and colleagues (1991) examined 
different cell fractions within the liver after an i.v. LPS challenge and demonstrated glucose 
uptake did not change in parenchymal cells but markedly increased in Kupffer cells and 
neutrophils. A potential refinement to the current experimental design would be to 
incorporate tracers in order to measure glucose uptake by individual tissues during sepsis. 
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However, an accurate measurement would still require isolating and studying different cell 
types within a given tissue. The aforementioned studies demonstrate glucose incorporation 
into immune cells increases while extra-immune cells decrease glucose utilization during 
LPS infusion and supports our assumption that infused glucose was primarily utilized by 
immune cells rather than peripheral tissue.  
A second limitation to our experimental design is the lack of hepatic glucose output 
measurements which prevents us from estimating the liver’s contribution to the circulating 
glucose pool. However, increased glycogenolysis and gluconeogenesis following 
endotoxin administration has been reported in ruminants (Waldron et al., 2003a) and other 
species (Wolfe et al., 1977; Filkins, 1978; Spitzer et al., 1985; Lang et al., 1985; 
McGuinness, 1994; McGuinness, 2005). Hepatic glycogenolysis is likely a large 
contributor to the hyperglycemic period post-LPS bolus in the current study (Figure 17A), 
and we are unable to calculate the amount of endogenous glucose utilized by the immune 
system prior (~180 min) to dextrose infusion. The hyperglycemic phase is a consequence 
of orchestrated systemic changes including peripheral insulin resistance and increased 
hepatic glucose output which successfully provides glucose in excess of immune cell 
utilization. The LPS-induced hypoglycemia represents the inability of glucose sparing 
mechanisms (reduced glucose uptake by insulin sensitive tissues and increased hepatic 
rates of glycogenolysis and gluconeogenesis) to keep pace with the activated immune 
system’s glucose utilization. If increased rates of hepatic glycogenolysis and 
gluconeogenesis described in ruminant and non-ruminant models hold true in the current 
model, then we are underestimating the amount of glucose entering the circulating pool 
and subsequently the total amount of glucose utilized by the activated immune system. 
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 Interestingly, differences between the LPS-C and LPS-Eu steers were mostly 
related to metabolism rather than immunity. Particularly, the magnitude of insulin increase 
in LPS-Eu steers is remarkable, but not unprecedented, as similar results have been 
described in dogs (Blackard et al., 1976). This suggests an interaction between LPS and 
glucose infusion as recently proposed (Baumgard et al., 2016). Further, severe 
hyperinsulinemia likely contributes to the decrease in plasma NEFA and BHB observed in 
LPS-Eu cows, as insulin is a potent antilipolytic hormone (Vernon, 1992). Regardless of 
exogenous glucose infusion, hyperinsulinemia following an LPS challenge has been 
previously observed in cattle (Waldron et al., 2003a,b; Burdick Sanchez et al., 2013), and 
might be explained by LPS’s amplifying role in glucose-stimulated insulin release reported 
in various in vitro experiments (Vives-Pi et al., 2003; Bhat et al., 2014). Furthermore, 
insulin becomes important for immune cell glucose uptake and development during 
activation (Shimizu et al., 1983; Helderman, 1984; Calder et al., 2007; Maratou et al., 
2007). 
Another hallmark of endotoxemia is hyperlactemia (Wolfe et al., 1977; Michaeli et 
al., 2012), which is likely due to the increase glucose utilization via aerobic glycolysis of 
immune cells after activation (Palsson-McDermott and O’Neill, 2013). In agreement, in 
the current study, LPS-Eu steers experienced a numerical 48% increase in plasma L-lactate 
compared to LPS-C steers, which likely represents an increase in glucose utilization by 
immune cells when glucose supply is not a limiting factor. Other potential sources include 
skeletal muscle, which may export L-lactate as an oxidative fuel for non-immune cells in 
an attempt to “spare” glucose for the immune system, a process akin to the Warburg Effect 
(Tannahill and O’Neill, 2011). Other adaptations to support the innate immune response 
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demand for energy and biosynthetic precursors include muscle proteolysis (Klasing and 
Austic, 1984a; Doyle et al., 2011; Michaeli et al., 2012, Johnson, 2012), which also likely 
occurred in the current experiment based on the increase in circulating BUN in LPS-infused 
steers. Interestingly, insulin normally inhibits skeletal muscle proteolysis (Allen, 1988), 
but insulin’s inhibitory effect on muscle proteolysis is compromised during sepsis 
(Hasselgren et al., 1987) and may be due to LPS-induced insulin resistance and increased 
glucocorticoids taking primary control of muscle (Hall-Angerås et al., 1991).  
Regarding immune parameters, leukopenia was evident at 180 min post-LPS and 
WBC count gradually increased to baseline levels by 720 min. Leukopenia has been 
observed in other endotoxemia studies (Griel et al., 1975; Bieniek et al., 1998) and is likely 
due to leukocyte extravasation into tissues. The NLR was increased in LPS-C steers and 
similar results were observed in LPS-infused rodents (Rose et al., 2007). The NLR is a 
marker of systemic inflammation as well as a predictor of mortality in various diseases 
involving the liver and cardiovascular system (Núñez et al., 2008; Leithead et al., 2015). 
Infusing glucose in LPS-Eu steers attenuated the increase in NLR and perhaps 
demonstrates a benefit of supplemental glucose to the innate immune system’s ability to 
detoxify LPS. 
In conclusion, our experiment demonstrates the induction of acute endotoxemia 
causes hypoglycemia within 3 hours and this likely results from the immune systems rate 
of glucose utilization exceeding whole-body glucose sparing mechanisms. From the ROGI, 
we estimate the activated immune system uses approximately 516 g of glucose in a 720 
min period. This is ostensibly underestimated because we are unable to account for immune 
cell glucose utilization during the acute hyperglycemic phase and the liver’s increased 
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contribution to the circulating pool as described in ruminant and non-ruminant models 
following LPS infusion. Regardless, on a metabolic bodyweight basis, the requirement for 
glucose is approximately 1.0 g/kg BW0.75/h which is comparable with data we have 
generated in other LPS-euglycemic clamp experiments in growing pigs and lactating cows 
(1.1 and 0.64 g/kg BW0.75/h, respectively; Kvidera and Baumgard, unpublished data). The 
consistency in calculated glucose utilization despite different ages, physiological status, 
and species suggests the reprioritization and extent of fuel utilization by immune cells upon 
severe activation might be a conserved response. Whether glucose can become a limiting 
factor in immune response and the benefit of supplemental glucose is not clear. However, 
from an animal production perspective, infection and inflammation redirect resources 
toward the immune system and away from utilization and development of economically 
relevant tissues. Having a better understanding of the energetic and nutrient requirements 
of the immune response is critical in order to develop strategies to minimize productivity 
losses when physiological states or environmental conditions activate the immune system. 
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Figure 17. (A) Blood glucose levels in steers administered a bolus of saline (CON), 
lipopolysaccharide (LPS-C), or lipopolysaccharide accompanied with a euglycemic clamp 
(LPS-Eu) during both hyperglycemic (0-150 min) and hypoglycemic (180-720 min) 
phases, (B) the average rate of glucose infusion in LPS-Eu steers, and (C) circulating 
insulin levels in CON, LPS-C, and LPS-Eu steers during the hypoglycemic phase (180-720 
min).  
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Figure 18. Circulating (A) L-lactate, (B) lipopolysaccharide binding protein (LBP), and 
(C) white blood cell count (WBC) during the hypoglycemic period (180-720 min) in steers 
given a bolus of saline (CON), lipopolysaccharide (LPS-C), or lipopolysaccharide 
accompanied with a euglycemic clamp (LPS-Eu).  
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Table 10. Blood parameters in steers given a bolus of saline (CON), lipopolysaccharide (LPS-C), or lipopolysaccharide accompanied 
with a euglycemic clamp (LPS-Eu) during the hypoglycemic phase 180-720 min post-LPS administration 
 Treatment1    P-value  Contrasts 
Parameter CON LPS-C LPS-Eu  SEM  Treatment Time 
Treatment 
x Time 
 
CON v 
LPS2 
LPS-C v 
LPS-Eu 
Rectal Temperature, °C 38.7a 39.2b 39.2b  0.1  0.02 <0.01 0.34  0.01 0.95 
Metabolites             
NEFA, mEq/L 340a 352a 197b  28  <0.01 <0.01 <0.01  0.08 <0.01 
BHB3, mg/dL 4.3a 3.8a 2.7b  0.3  0.01 0.09 0.19  0.02 0.03 
Blood urea N, mg/dL 6.7 10.4 10.1  1.1  0.08 0.01 0.34  0.03 0.84 
Haptoglobin, μg/mL 136 170 152  65  0.95 0.19 0.41  0.75 0.87 
LBP4, μg/mL 6.9a 14.0b 12.2b  1.0  <0.01 <0.01 <0.01  <0.01 0.27 
SAA5, μg/mL 87 117 103  11  0.22 <0.01 0.32  0.10 0.47 
Ionized Calcium, mmol/L 1.40a 1.16b 1.19b  0.02  <0.01 0.01 0.02  <0.01 0.38 
Complete Blood Count             
Neutrophils, x103/μL 4.4 3.8 1.6  1.1  0.25 0.01 0.08  0.21 0.21 
Lymphocytes, x103/μL 6.0a 2.9b 2.8b  0.6  0.01 <0.01 0.01  <0.01 0.89 
Monocytes, x103/μL 0.57a 0.20b 0.18b  0.10  0.03 0.02 0.06  0.01 0.83 
Eosinophils, x103/μL 0.29 0.56 0.46  0.06  0.06 0.05 0.17  0.03 0.27 
Basophils, x103/μL 0.13 0.08 0.07  0.02  0.07 <0.01 0.04  0.03 0.53 
Red blood cells, x106/μL 9.0 9.4 9.6  0.2  0.26 0.02 0.03  0.11 0.65 
Platelets, x103/μL 553a 274b 256b  31  <0.01 0.15 0.68  <0.01 0.71 
NLR6 0.8 1.2 0.6  0.2  0.07 0.12 0.24  0.81 0.03 
1CON = saline bolus; LPS-C = LPS bolus; LPS-Eu = LPS bolus and euglycemic clamp 
2LPS-C and LPS-Eu treatments 
3β-hydroxy butyrate 
4Lipopolysaccharide binding protein 
5Serum amyloid A 
6Neutrophil-to-lymphocyte ratio 
a-c Means with different letters differ (P ≤ 0.05) 
1
3
3
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CHAPTER 5: ESTIMATING GLUCOSE REQUIREMENTS OF AN ACTIVATED 
IMMUNE SYSTEM IN LACTATING HOLSTEIN COWS 
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Abstract 
Accurately quantifying activated immune system energy requirements in vivo is 
difficult, but a better understanding may advance strategies to maximize animal 
productivity. Study objectives were to estimate whole-body glucose utilization following 
an i.v. endotoxin challenge. Lactating Holstein cows were jugular catheterized and 
assigned 1 of 3 bolus treatments: control (CON; 5 mL saline; n = 6), lipopolysaccharide 
(LPS)-administered (LPS-C; 1.5 μg/kg BW; E. coli 055:B5; n = 6), and LPS + euglycemic 
clamp (LPS-Eu; 1.5 μg/kg BW; 50% glucose solution infusion; n = 6). After LPS 
administration, blood glucose was determined every 10 min and glucose infusion rates 
were adjusted in LPS-Eu cows to maintain euglycemia for 720 min. Blood samples were 
obtained 180, 360, 540, and 720 min postbolus for further analysis. Cows were milked 360 
and 720 min postbolus. Blood glucose was increased 84% in LPS-administered cows for 
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up to 150 min postbolus; thereafter, circulating glucose was decreased 30% in LPS-C 
relative to LPS-Eu and CON cows. Mild hyperthermia (+0.5°C) occurred between 30 and 
90 min postbolus in LPS-administered relative to CON cows; thereafter, rectal temperature 
did not differ between treatments. Milk yield and lactose percentage were decreased 80 
and 11%, respectively, in LPS-administered relative to CON cows. Circulating insulin was 
increased 4-fold and non-esterified fatty acids, β-hydroxybutyrate, and ionized Ca were 
decreased ~50% in LPS-administered compared to CON cows. Plasma L-lactate, 
haptoglobin, and serum amyloid A increased ~160, 260, and 75%, respectively, in LPS-
administered relative to CON cows. Overall, LPS binding protein was increased 87% in 
LPS-administered relative to CON cows; however, at 720 min, it was decreased 25% in 
LPS-Eu compared to LPS-C cows. White blood cell count decreased ~90% in LPS-
administered cows at 180 min and progressively increased to ~50% of CON values by 720 
min. Total glucose deficit during the 720 min following LPS administration was calculated 
as the decrease in the amount of glucose required to synthesize milk (due to the decrease 
in MY relative to prebolus levels) plus the amount of glucose infused to maintain 
euglycemia (in LPS-Eu cows only) and was 461, 1259, and 1553 g for CON, LPS-C, and 
LPS-Eu cows, respectively. Our data indicate an acutely activated immune system uses >1 
kg of glucose within 720 min and maintaining euglycemia did not rescue milk synthesis. 
Key words: glucose homeostasis, inflammation, insulin, lipopolysaccharide 
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Introduction 
 Maximizing nutrient and energy partitioning toward productive processes is key to 
economically profitable animal agriculture. Immunoactivation is characterized by 
decreased milk and lean tissue synthesis, inefficient feed utilization, and poor reproduction 
presumably due to immune system nutrient consumption (Lochmiller and Deerenberg, 
2000; Johnson, 2012). Farm animals experience frequent immune challenges, and obvious 
sources in dairy cattle include metritis and mastitis (Sheldon et al., 2008; Ballou, 2012). A 
more inconspicuous source of inflammation is increased gastrointestinal permeability 
which can be a consequence of different stressors including dietary changes (e.g., grain-
induced acidosis; Khafipour et al., 2009a), systemic inflammation (Hietbrink et al., 2009), 
or environmental factors like heat stress (Baumgard and Rhoads, 2013). Immunoactivation 
begins when molecular patterns from invading pathogens (e.g., bacteria, viruses, yeast, 
parasites) are recognized by immune cells, eliciting the transcription and production of 
inflammatory cytokines which results in an acute phase response characterized by fever, 
changes in circulating leukocyte numbers, and hepatic acute phase protein synthesis 
(Ceciliani et al., 2012). Immunoactivation can be experimentally modeled by 
administrating lipopolysaccharide (LPS), a cell wall component of Gram-negative bacteria 
which elicits a well-characterized and robust immune response (van Miert and Frens, 1968; 
Lohuis et al., 1988b). However, the response can vary in magnitude as repeated or 
continuous exposure to endotoxin results hyporesponsiveness (i.e., tolerance; Beeson, 
1947). 
Immunoactivation markedly disrupts glucose homeostasis and is characterized by 
hypoglycemia and hyperlactemia (Filkins, 1978; McGuinness, 2005; Michaeli et al., 2012). 
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In vitro experiments demonstrate a substantial increase in glucose consumption by 
activated immune cells as glucose is their primary fuel and an important biosynthetic 
precursor (Calder et al., 2007; Palsson-McDermott and O’Neill, 2013). Despite the increase 
in glucose requirements, anorexia accompanies immunoactivation which decreases diet-
derived glucose or glucose precursors. Decreased milk synthesis is one of the first 
observable signs of infection/inflammation in dairy cattle and this presumably represents a 
strategy to spare glucose for the immune system. To further ensure an adequate fuel supply 
for the immune system, hepatic glucose output increases via both glycogenolysis and 
gluconeogenesis (Filkins, 1978; McGuinness, 1994; Waldron 2003a). Synchronously, 
peripheral insulin resistance occurs leading to decreased glucose uptake by skeletal muscle 
and adipose tissue (Lang et al., 1990; Song et al., 2006). These metabolic adaptations are 
indicative of homeorhetic partitioning towards a new dominant physiological state of 
immunoactivation. Despite the aforementioned efforts to spare glucose, hypoglycemia 
often develops following a LPS challenge, likely because the immune system’s rate of 
glucose utilization exceeds the orchestrated capacity of the liver to export glucose and 
insulin sensitive tissues to reduce glucose disposal (McGuinness, 2005). 
The extent of in vivo glucose consumption by the activated immune system is 
difficult to assess due to the ubiquitous and fluctuating distribution of immune cells and 
organ specific changes in insulin sensitivity; however, better understanding its impact on 
bioenergetics is a prerequisite to developing strategies aimed at minimizing production 
losses in immunoactivated animals. Therefore, the experimental objective was to estimate 
the amount of glucose needed to maintain euglycemia following an LPS challenge as a 
proxy for the amount of glucose required to fuel an acute immune response. 
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Materials and Methods 
Animals and Experimental Design 
All procedures were approved by the Iowa State University Institutional Animal 
Care and Use Committee. Eighteen Holstein cows (718 ± 16 kg; 169 ± 7 DIM; parity 2 or 
3) were utilized and housed in individual box-stalls (4.57 m by 4.57 m) at the Iowa State 
University Dairy Farm. Due to space constraints, the study was conducted in two 
replications occurring 14 d apart with 9 different cows in each replication. Treatment was 
balanced within each replication. Cows were allowed 5 d to acclimate during which they 
were implanted with bilateral jugular catheters. Cows were fed ad libitum once daily (0600 
h) a diet formulated to meet or exceed the predicted requirements (NRC, 2001; Table 11) 
of energy, protein, minerals, and vitamins. Cows were milked four times daily (0000, 0600, 
1200, 1800 h) throughout the experiment. During the final 3 d of acclimation, milk yields 
were recorded and a sample for composition analysis was obtained at each milking. To 
estimate the glucose requirements of an activated immune system we employed an LPS-
euglycemic clamp technique as we have recently described (Kvidera et al., 2016a). Cows 
were randomly assigned to 1 of 3 i.v. bolus treatments administered immediately after the 
0600 h milking: 1) control (CON; 3 mL sterile saline; n = 6), 2) LPS-administered controls 
in which hypoglycemia was allowed to develop (LPS-C; 1.5 μg/kg BW LPS; n = 6), and 
3) LPS-administered in which euglycemia was maintained (LPS-Eu; 1.5 μg/kg BW LPS; 
n = 6). Selection of the LPS dose was influenced by the magnitude of hypoglycemia 
observed in earlier reports (Giri et al., 1990; Waldron et al., 2003a; Waggoner et al., 
2009b). Lipopolysaccharide (Escherichia coli O55:B5; Sigma Aldrich, St. Louis, MO) was 
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dissolved in sterile saline at a concentration of 200 μg/mL and passed through a 0.2 μm 
sterile syringe filter (Thermo Scientific; Waltham, MA). The total volume of LPS solution 
administered was approximately 5 mL. In the LPS-Eu treatment, we performed a 
euglycemic clamp where a 50% glucose solution (as dextrose; VetOne, Boise, ID) was i.v. 
infused at a known and adjustable rate utilizing a modular pump (Deltec 3000, Deltec Inc., 
St. Paul, MN) in order to maintain the pre-LPS administration blood glucose 
concentrations. 
Cows were tethered during the 12 h challenge (but allowed to stand up and lay 
down) to allow for frequent sampling. Water was provided ad libitum and feed was 
removed ~1 h prior to treatment administration and animals remained fasted during the 720 
min data collection period in order to eliminate the confounding effect of dissimilar nutrient 
intake. Cows were milked immediately prior to administration (0600 h) and continued to 
be milked every 360 min (6 h) with yields and samples for composition analysis obtained 
at each milking. Samples were stored at 4°C with a preservative (bronopol tablet; D & F 
Control System, San Ramon, CA) until analysis by Dairy Lab Services (Dubuque, IA) 
using AOAC approved infrared analysis equipment and procedures.  
Blood samples were obtained at -30, -20, and 0 min relative to LPS administration 
to establish baseline glucose levels. Each respective treatment bolus was administered 
immediately following the 0 min blood sample collection. For LPS-Eu cows, postbolus 
blood samples (1 mL) were collected every 10 min and immediately analyzed for glucose 
concentration (TRUEbalance glucometer; McKesson, San Francisco, CA). Glucose 
infusion began when blood glucose concentration declined below baseline levels, and its 
rate of infusion was adjusted as necessary to maintain blood glucose concentration at 
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baseline levels (± 10%). The rate of 50% glucose solution infusion (mL/h) was transformed 
to rate of glucose infusion (ROGI; g/h). The total glucose infused for each cow was 
calculated using the ROGI for each 10 min interval (72 intervals in total) according to the 
following equation: 
∑ 𝑅𝑂𝐺𝐼 (
𝑔
ℎ
)
𝑖
72
𝑖=0
∗
1 ℎ
60 𝑚𝑖𝑛
∗ 10 𝑚𝑖𝑛 
Blood glucose was measured every 30 min in CON and LPS-C cows for the first 
300 min and every 60 min thereafter. Additional plasma and serum samples (~10 mL each) 
were collected from all treatments at -30, 0, 180, 360, 540, and 720 min relative to LPS 
administration. Plasma and serum were harvested following centrifugation at 1500 x g for 
15 min at 4°C and were subsequently frozen at -20°C until analysis. Urine was collected 
at 0, 180, 360, 540, and 720 min relative to LPS administration and was frozen at -20°C 
until analysis. Rectal temperatures were measured at -30 and 0 min relative to LPS 
administration, every 30 min for the first 300 min postbolus, and every 60 min thereafter 
using a digital thermometer (GLA M700, San Luis Obispo, CA). 
Plasma insulin, non-esterified fatty acids (NEFA), BHB, LPS binding protein 
(LBP), L-lactate, serum amyloid A (SAA), haptoglobin, and BUN as well as urine glucose 
concentrations were determined using commercially available kits according to 
manufacturers’ instructions (insulin, Mercodia AB, Uppsala, Sweden; NEFA, Wako 
Chemicals USA, Richmond, VA; BHB, Pointe Scientific Inc., Canton, MI; LBP, Hycult 
Biotech, Uden, Netherlands; L-lactate, Biomedical Research Service Center, Buffalo, NY; 
SAA, Tridelta Development Ltd., Kildare, Ireland; haptoglobin, Immunology Consultants 
Laboratory Inc., Portland, OR; BUN, Teco Diagnostics, Anaheim, CA; glucose, Wako 
Chemicals USA Inc., Richmond, VA). The inter- and intra-assay coefficients of variation 
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for haptoglobin, insulin, NEFA, BHB, L-lactate, SAA, LBP, and BUN assays were 1.2 and 
26.1%, 8.3 and 13.8%, 6.7 and 2.0%, 10.5 and 5.3%, 18.3 and 10.2%, 43.0 and 20.8%, 
12.1 and 7.4%, and 2.8 and 3.7%, respectively. The intra-assay coefficient of variation for 
urine glucose was 4.9%. Blood ionized calcium was measured using an i-STAT handheld 
machine and cartridge (CG8+; Abbott Point of Care, Princeton, NJ). For white blood cell 
(WBC) count, a 3 mL blood sample was collected (K2EDTA; BD Franklin Lakes, NJ) and 
stored at 4°C for ~12 h before submission to the Iowa State University’s Department of 
Veterinary Pathology for complete blood count analysis. 
Calculations and Statistical Analyses  
Administration of LPS decreased milk yield and therefore decreased glucose 
utilized for milk synthesis. The decrease in milk yield allows us to estimate the amount of 
glucose conserved (milk glucose deficit) and channeled toward the activated immune 
system in LPS-administered cows. As described in the results section, the CON cows also 
reduced their milk yield due to fasting, allowing us to account for the milk glucose deficit 
due to reduced feed intake alone. The amount of glucose utilized for milk synthesis was 
calculated for each milking based on Kronfeld’s (1982) estimation of 72 g glucose required 
to synthesize 1 kg of milk. Milk glucose utilization values obtained prior to the challenge 
were averaged in order to establish a baseline value. Milk glucose utilization at both 360 
and 720 min was subtracted from the baseline in order to calculate the milk glucose deficit. 
For CON and LPS-C cows, milk glucose deficit was solely used to calculate total glucose 
deficit. For LPS-Eu cows, milk glucose deficit plus the amount of glucose infused to 
maintain euglycemia were combined to obtain total glucose deficit. 
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The temporal pattern of postbolus blood glucose was divided into two phases: a 
hyperglycemic (0-150 min) and hypoglycemic (180-720 min) phase which were 
statistically analyzed separately. Rectal temperature and ROGI were analyzed for the entire 
postbolus period. Remaining parameters were analyzed for the hypoglycemic phase (180-
720 min, during which blood samples, milk yield, and milk composition were obtained). 
Each animal’s respective parameter was analyzed using repeated measures with an 
autoregressive covariance structure for blood and milk parameters and spatial power law 
for rectal temperature and blood glucose. The repeated effect was minute after LPS 
administration. Each specific variable’s prebolus value (when available) served as a 
covariate. Effects of treatment, time, treatment by time interaction, and replicate (except 
for ROGI, where only the effect of time within the LPS-Eu treatment was analyzed) were 
assessed as a completely randomized design using PROC MIXED (SAS Inst. Inc., Cary, 
NC). Pre-formed contrasts were used to estimate differences between CON and LPS-
administered cows (LPS-C and LPS-Eu) as well as between the two LPS-administered 
treatments (LPS-C vs. LPS-Eu). Data are reported as LSmeans and considered significant 
if P ≤ 0.05 and a tendency if 0.05 < P ≤ 0.10. 
 
Results 
 Overall rectal temperature did not differ between treatments (P = 0.94); however, 
mild hyperthermia (+0.5°C) was observed between 30 to 90 min postbolus in LPS-
administered relative to CON cows (P = 0.04; Figure 19). Cows treated with LPS (LPS-C 
and LPS-Eu) anecdotally developed visible symptoms of immunoactivation within 120 
min postbolus, including lethargy, drooping ears, and diarrhea. Cows administered LPS 
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had increased (84%) circulating glucose from 0-150 min postbolus relative to CON cows 
(P < 0.01; Figure 20A). From 180 to 720 min, LPS-C cows had 30% decreased blood 
glucose compared to CON and LPS-Eu cows. There were no differences in circulating 
glucose between CON and LPS-Eu cows from 180-720 min (P = 0.26), indicating 
successful maintenance of euglycemia in LPS-Eu cows. There were no treatment 
differences detected in urine glucose (<1.5 mg/dL; P = 0.29; data not shown). Glucose 
infusion began 143 ± 18 min post-LPS administration (range 60-170) and increased with 
time (P < 0.01; Figure 20B). An average of 265 ± 98 g of glucose were infused to maintain 
euglycemia during the entire 720 min clamp.  
 Milk yield decreased ~80% for both LPS treatments relative to CON cows at both 
360 and 720 min postbolus (P < 0.01; Figure 21A). Relative to the baseline value, milk 
yield of CON cows was decreased at both 360 and 720 min (21%; P = 0.07 and 39%; P < 
0.01, respectively), and this can be attributed to fasting. Milk lactose percentage decreased 
11% in LPS-treated cows relative to CON cows (P = 0.01; Table 12). Milk fat percentage 
increased in all treatments with time (36%; P = 0.02; Table 12), and there were no effects 
on milk protein percentage (P > 0.10; Table 12). There was a progressive increase in MUN 
(~20%) for all treatments (P < 0.01; Table 12). Overall, somatic cell count increased 100% 
in LPS-C relative to CON cows while LPS-Eu cows did not differ from either treatment (P 
= 0.03; Table 12). The milk glucose deficit accumulated over 720 min was increased 
~175% in LPS-administered cows relative to controls (P < 0.01; Figure 21B). Total glucose 
deficit accumulated over 720 min differed between all treatments with CON, LPS-C, and 
LPS-Eu cows having a 461, 1259, and 1553 g glucose deficit, respectively (P < 0.01; Figure 
21B).  
144 
 
 
Insulin increased 4-fold in LPS relative to CON cows (P = 0.01; Figure 22A). 
Circulating NEFA and BHB were decreased 46 and 53%, respectively, in LPS versus CON 
cows (P < 0.01; Figure 22B and 22C). Blood urea nitrogen increased ~30% in all treatments 
over time (P = 0.01; data not shown). Ionized calcium decreased 46% in both LPS 
treatments relative to CON cows (P < 0.01; Figure 22D). Compared to CON cows, L-
lactate, haptoglobin, and SAA increased ~160, 260, and 75%, respectively, in LPS-treated 
cows (P ≤ 0.01; Figure 23A, 23B, and 23C). Overall, an 87% increase in LBP was observed 
in LPS compared to CON cows, and by 720 min, LBP was reduced 25% in LPS-Eu relative 
to LPS-C cows (P < 0.01; Figure 23D).  
 There was a treatment by time interaction (P < 0.01; Figure 24A) for WBC counts 
as LPS-administered cows experienced an initial decrease in cell number (180 min; 90%) 
followed by a progressive increase with time, and WBC counts were 54% of the CON 
values by 720 min. Lymphocytes, neutrophils, and monocytes primarily contributed to the 
WBC temporal changes as they were initially reduced (86, 98, and 85%, respectively; P < 
0.01) at 180 min post-LPS administration and gradually increased to 50, 53, and 47% of 
CON values, respectively, by 720 min (Figure 24B and 24C; Table 13). The neutrophil to 
lymphocyte ratio (NLR) decreased 80% at 180 min in LPS-administered cows relative to 
controls and returned to baseline levels by 540 min (P = 0.02; Table 13). Red blood cells, 
hemoglobin, and hematocrit increased in LPS-administered cows relative to CON (6, 8, 
and 10%; P ≤ 0.01; Table 13). Platelets were decreased 63% in LPS-administered cows 
relative to controls while mean platelet volume was increased 105% (P < 0.01; Table 13). 
There were no differences observed between LPS-C and LPS-Eu cows for any complete 
blood count parameter. 
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Discussion 
Accurately determining nutrient requirements of the immune system is difficult due 
to its ubiquitous and fluctuating distribution throughout tissues. From a metabolic 
perspective, both whole body energy expenditure and glucose utilization markedly increase 
during infection (Lang and Dobrescu, 1991; Lang et al., 1993; Plank et al., 1998), 
ostensibly because immune cells become substantial and obligate glucose consumers to 
support the energetic and substrate needs of activation (Calder et al., 2007; Maratou et al., 
2007; MacIver et al., 2008; Palsson-McDermott and O’Neill, 2013; Kelly and O’Neill, 
2015). For instance, in tissues with a large immune compartment (spleen, liver, lung, and 
ileum) LPS increases glucose utilization which is enhanced by maintaining euglycemia 
(Lang et al., 1993). Herein, we propose using a euglycemic clamp after LPS administration 
in order to estimate the amount of glucose utilized during an intense immune response. 
Immunoactivation was successfully induced in the current study as indicated by 
increased circulating levels of acute phase proteins haptoglobin, SAA, and LBP. While the 
increase in acute phase proteins is consistent with the literature, there is substantial 
variation in baseline, temporal pattern, and severity of increase (Jacobsen et al., 2004; 
Carroll et al., 2009; Graugnard et al., 2013; Moyes et al., 2014). This may be the result of 
different experimental models, route of LPS administration, animal variation, and/or 
laboratory procedures, but the variation (even from the same laboratory; Khafipour et al., 
2009a,b) highlights why repeated sampling from the same animal pre and post-
immunoactivation is necessary to put the magnitude of change into perspective and context. 
Ionized calcium was severely decreased (46%) following LPS administration, which 
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agrees with others (Griel et al., 1975; Elsasser et al., 1996; Waldron et al., 2003b), and is 
presumably due to calcium’s involvement with immune system activation (Hendy and 
Canaff, 2016). 
Severe hypoglycemia (30% decrease; Figure 20A) and hyperlactemia (160% 
increase; Figure 23A) developed ~180 min postbolus and continued through 720 min. 
These indications of glucose dyshomeostasis are similar to other models of endotoxemia 
in ruminants (Giri et al., 1990; Gerros et al., 1995; Elasser et al., 1996; Yates et al., 2012; 
Burdick Sanchez et al., 2013; Zarrin et al., 2014) and other species (Wolfe et al., 1977; 
Bruin et al., 2003; Michaeli et al., 2012). Glucose infusion initiation, coinciding with 
development of hypoglycemia, was fairly consistent between cows (143 ± 18 min post-
LPS administration; range 60-170). Interestingly, ROGI was maximum at 210 min 
postbolus and decreased to ~20 g/h between 360 and 540 min before increasing steadily to 
a plateau of ~40 g/h at 650 min (Figure 20B). Urine was not a source of glucose disposal 
as it was almost similarly immeasurable (< 1.5 mg/dL) from cows in all treatments. Milk 
yield was acutely decreased ~80% in both LPS-administered treatments and this ostensibly 
represents a strategy to spare glucose for immune cell utilization. Admittedly, this is an 
extreme decrease, but similar magnitudes of milk synthesis cessation are frequent during 
E. coli mastitis (Gröhn et al., 2004) and the acute model was necessary to achieve 
appreciable hypoglycemia in order to employ the euglycemic clamp. In CON cows, the 
~30% decrease in milk yield can be solely attributed to fasting. The decrease in milk yield 
allows us to estimate the amount of glucose conserved (milk glucose deficit) due to both 
reduced feed intake and glucose utilization by the immune system. The milk glucose deficit 
was 461, 1259, and 1288 g for CON, LPS-C, and LPS-Eu cows, respectively. In CON and 
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LPS-C cows, milk glucose deficit makes up the entirety of the total glucose deficit 
calculation. In LPS-Eu cows, the accumulated ROGI was ~265 g, which provides a total 
glucose deficit of 1553 g in LPS-Eu cows. Taking into account the reduction of feed intake 
by subtracting the 461 g deficit observed in CON cows, we estimate the activated immune 
system uses approximately 1092 g of glucose in a 720-min period. This calculation is likely 
underestimated as it does not incorporate glucose use by immune cells during the 
hyperglycemic phase. On a metabolic bodyweight basis, the glucose requirement is 
approximately 0.66 g/kg BW0.75/h which is comparable with data we have generated in 
other LPS-euglycemic clamp experiments in growing steers and pigs (1.0 and 1.1 g/kg 
BW0.75/h, respectively; Kvidera et al., 2016a; Kvidera and Baumgard, unpublished data). 
The immune system utilizes a large quantity of glucose following immunoactivation and 
the rate is seemingly conserved across species and life stages.  
 An additional reason for increased fuel oxidation (glucose in particular) following 
LPS administration could be to facilitate a febrile response. However, increased glucose 
utilization continues independently of rectal temperature during sepsis in experimental 
animal models (Lang et al., 1987a). In support of this, we observed only mild and transient 
pyrexia in LPS-administered cows (between 30 and 90 min postbolus) despite marked 
metabolic changes that existed for the entire experiment. This agrees with Giri et al. (1990) 
who also observed short-lived fever post-LPS despite large and prolonged changes in 
glucose homeostasis. Moreover, the fever response to LPS in ruminants is inconsistent and 
not dose dependent as sometimes higher doses attenuate the febrile response (Lohuis et al., 
1988a; Gerros et al., 1995; Waldron et al., 2003a; Jacobsen et al., 2005), while high LPS 
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doses consistently causes hypoglycemia. Regardless, increased glucose utilization during 
this experiment does not appear to be an attempt to mount a fever. 
The current experimental design has some limitations. First, the extent of peripheral 
tissue glucose consumption limits our capacity to accurately estimate immune system 
glucose utilization. However, insulin sensitivity and/or glucose utilization is reduced in 
both muscle and adipose tissue (typically large glucose consumers) during endotoxemia 
both in vivo (Raymond et al., 1981; Ling et al., 1994; Poggi et al., 2007; Mulligan et al., 
2012) and in vitro (Song et al., 2006; Liang et al., 2013). As mentioned before, tissues with 
a large immune compartment (spleen, liver, lung, and ileum) actually increase glucose 
utilization following LPS administration (Lang et al., 1993). Further, Mészáros and 
colleagues (1991) examined different cell fractions within the liver after an i.v. LPS 
challenge and demonstrated glucose uptake did not change in parenchymal cells but 
markedly increased in Kupffer cells (i.e., resident hepatic macrophages) and neutrophils. 
Overall, these results highlight the relative importance of activated immune cells to tissue 
specific glucose consumption. In addition, immune cell distribution radically changes after 
LPS administration as demonstrated by leukopenia observed in this and other studies (Griel 
et al., 1975; Bieniek et al., 1998), which is likely due to tissue leukocyte sequestration, 
especially tissues with important immune functions (Mészáros et al., 1991; Lang and 
Dobrescu, 1991). Endotoxemia also likely causes macrophage infiltration into adipose and 
muscle (Caesar et al., 2012; Pillon et al., 2013). The aforesaid studies demonstrate glucose 
incorporation into immune cells increases while extraimmune cells decrease glucose 
utilization following LPS administration and this supports our assumption glucose was 
primarily utilized by immune cells rather than peripheral tissue. 
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A second drawback to our experimental model is the lack of hepatic glucose output 
measurements which prevents us from estimating the liver’s contribution to the circulating 
glucose pool. However, endotoxemia-induced increased hepatic glycogenolysis and 
gluconeogenesis has been reported in multiple species (Wolfe et al., 1977; Filkins, 1978; 
Spitzer et al., 1985; Lang et al., 1985; McGuinness, 1994, McGuinness, 2005) including 
ruminants (Waldron et al., 2003a). Hepatic glycogenolysis is likely the primary contributor 
to the acute hyperglycemia observed following LPS administration in the current study 
(Figure 20A), but we are unable to calculate the amount of endogenous glucose utilized by 
the immune system prior to the initiation of glucose infusion (~180 min). The 
hyperglycemic phase results from orchestrated peripheral insulin insensitivity coupled with 
enhanced hepatic glucose production which provides glucose in surplus of immune cell 
utilization capacity. The hypoglycemic phase represents the inability of such glucose 
sparing mechanisms to keep pace with the activated immune system’s glucose 
consumption. If increased rates of hepatic glycogenolysis and gluconeogenesis described 
in ruminants and nonruminants apply to the current model, then we are further 
underestimating the quantity of glucose entering the circulating pool and subsequently the 
total amount of glucose utilized by the activated immune system. 
 There were little or no overall metabolic, production, or immune differences 
detected between LPS-C and LPS-Eu cows, indicating a similar response following LPS 
regardless of glycemic status. Most notably, maintaining euglycemia did not rescue milk 
yield or lactose content, indicating that decreased milk synthesis is not due to LPS-induced 
hypoglycemia. It is likely LPS induces a direct effect on mammary tissue, as mammary 
epithelial cells express Toll-like receptor 4, an LPS receptor (Ibeagha-Awemu et al., 2008). 
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Alternatively, endotoxin-induced increases in proinflammatory cytokines and hormonal 
changes (e.g., cortisol) may indirectly inhibit milk synthesis (Verheijden et al., 1983). 
Interestingly, LPS reduces the integrity of the mammary epithelial barrier (Wellnitz et al., 
2016) and cows from the LPS-C treatment had increased milk SCC, which agrees with a 
previous i.v. LPS report (Shuster et al., 1991). Further, euglycemia appeared to attenuate 
the LPS-induced mammary permeability as milk SCC from LPS-Eu cows was not different 
from either treatment. Markers of inflammation in the mammary gland post-LPS 
administration are increased when euglycemia is maintained compared to hypoglycemic 
cows (Vernay et al., 2012), suggesting glucose may be a limiting factor in mammary 
immune cell activation and subsequent pathogen clearance. Likewise, the reduction in 
circulating LBP at 540 and 720 min coupled with the increase in circulating neutrophils at 
720 min in LPS-Eu relative to LPS-C cows indicates that glucose availability may be a 
bottleneck to mounting a full immune response.  
Despite fasting, administering LPS induced acute and sustained hyperinsulinemia 
which has been previously observed in cattle (Waldron et al., 2003a; Burdick Sanchez et 
al., 2013; Zarrin et al., 2014; Kvidera et al., 2016a) and pigs (Stoakes et al., 2015a). 
Contrary to our previous results in growing steers (Kvidera et al., 2016a), infusing glucose 
did not exacerbate hyperinsulinemia to levels above LPS-C. An interaction between LPS 
and glucose infusion has been recently proposed (Baumgard et al., 2016) and may be due 
to either direct action of LPS on the pancreas (Vives-Pi et al., 2003; Bhat et al., 2014), 
LPS-induced hyperglycemia (Figure 20A), or LPS-stimulated secretion of the insulin 
secretagogue glucagon-like peptide 1 (Nguyen et al., 2014). Circulating insulin remained 
increased (~4 fold) during the hypoglycemic phase (180-720 min postbolus) so the acute 
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hepatic glycogenolysis is not likely the cause. Rationale for why circulating insulin 
increases are not clear, but insulin is important for immune cell glucose uptake and 
development during activation (Shimizu et al., 1983; Helderman, 1984; Calder et al., 2007; 
Maratou et al., 2007). Severe hyperinsulinemia likely contributes to decreased plasma 
NEFA observed in LPS-administered cows relative to controls, as insulin is a potent 
antilipolytic hormone (Vernon, 1992). Interestingly, despite the gradual increase in NEFA 
over time in all treatments (more pronounced in the controls), BHB was markedly 
decreased (>50%) throughout the experiment. This agrees with other ruminant models 
(Waldron et al., 2003a; Graugnard et al., 2013; Kvidera et al., 2016a), yet contradicts our 
pig results where BHB was increased following LPS administration (Stoakes et al., 2015a). 
Reasons for decreased circulating ketones are not clear. A majority of circulating BHB in 
ruminants in positive energy balance (akin to the current study) originates from the rumen 
epithelium as opposed to the liver (Pennington, 1952). Administrating LPS decreases 
rumen motility (Jing et al., 2014), and whether or not this gastrointestinal stasis affects 
ketone synthesis is not known. An additional reason could be reduced liver production, as 
data from rodent models have demonstrated a decreased capacity for hepatic ketone 
synthesis during endotoxemia (Takeyama et al., 1990; Gitomer et al., 1995). However, 
Waldron et al. (2003a) observed no LPS effects on ketone synthesis in incubated liver slices 
obtained from lactating cows. Additionally, an increased rate of BHB infusion was required 
to maintain hyperketonemia in lactating cows challenged with LPS (Zarrin et al., 2014), 
indicating increased circulating BHB clearance and peripheral tissue utilization could help 
explain the decrease as this may be a strategy utilized to spare glucose for immune cells. 
Nevertheless, having a better understanding of how endotoxemia influences NEFA and 
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ketone metabolism likely has practical implications to a variety of dairy cow pathological 
conditions (e.g., ketosis). 
Hyperlactemia is another characteristic of endotoxemia (Wolfe et al., 1977; 
Michaeli et al., 2012), which is likely due to enhanced glucose utilization via aerobic 
glycolysis in activated immune cells (Palsson-McDermott and O’Neill, 2013). In the 
current study, LPS-administered cows had >150% increase in circulating L-lactate. Other 
potential sources include skeletal muscle, which may export L-lactate as an oxidative fuel 
for non-immune cells in an attempt to “spare” glucose for the immune system, a process 
akin to the Warburg Effect (Tannahill and O’Neill, 2011). Muscle proteolysis is another 
adaptation employed during immunoactivation in order to support the demand for 
gluconeogenic precursors and amino acids for acute phase protein production (Klasing and 
Austic, 1984a; Doyle et al., 2011; Michaeli et al., 2012, Johnson, 2012). Similar to results 
of Zarrin and colleagues (2014) in lactating cows, we detected no treatment differences in 
circulating BUN concentrations but did observe a similar progressive increase over time. 
This is in contrast to findings in LPS-administered non-lactating ruminants (Elasser et al., 
1996; Ballou et al., 2008; Kvidera et al., 2016a) and other species (Myers et al., 1997; 
Bruins et al., 2003, Rose et al, 2007), where LPS administration markedly increases BUN. 
Relatively little data exists on circulating BUN following endotoxin challenge in lactating 
animals and why there appears to be differences between growing and lactating 
physiological states is not clear. 
Regarding immune parameters, leukopenia was evident at 180 min post-LPS and 
WBC count gradually increased to ~50% of CON levels by 720 min. Lymphocytes, 
neutrophils, and monocytes were the main contributors as they all followed the same 
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temporal pattern. Leukopenia has been observed in other ruminant endotoxemia studies 
(Griel et al., 1975; Bieniek et al., 1998; Jacobsen et al., 2005) and is likely due to 
accelerated leukocyte extravasation into tissues. Samples obtained beyond 720 min have 
observed leukocytosis following an initial period of leukopenia (Griel et al., 1975; 
Jacobsen et al., 2005; Horst and Baumgard, unpublished data), indicating circulating 
immune cells eventually exceed baseline levels. In summary, concentrations of circulating 
immune cells are highly dependent on time relative to immune activation. Leukopenia in 
the current study indicated immune cell mobilization into tissue, and the current 
experimental duration was likely not long enough to observe the characteristic leukocytosis 
in later stages of immunoactivation. 
Glucose is obviously a critically important metabolite in all species, but it is 
especially pertinent to lactating dairy cows as ruminants rely almost exclusively on hepatic 
gluconeogenesis instead of dietary carbohydrate digestion/absorption to meet their glucose 
requirements. Further, glucose is the substrate for lactose synthesis and lactose production 
is the primary osmoregulator of milk yield (Chaiyabutr et al., 1980), so extramammary 
processes which increase glucose utilization have the potential to decrease glucose supply 
to the mammary gland and thus decrease productivity. Herein we describe the immune 
system as a substantial glucose utilizer and this has implications to several practical 
scenarios. Metritis and mastitis are common infections, especially in early lactation, which 
prevent optimal productivity. There are two less overt situations where immune system 
glucose utilization limits maximum milk yield. The first is heat stress as heat-stressed 
animals have a compromised intestinal barrier function and thus intestinal derived LPS 
infiltration (Baumgard and Rhoads, 2013). Immune system glucose consumption during 
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heat stress likely explains why decreased feed intake is only responsible for about 50% of 
reduced milk yield. The second is maladaptation to lactation as the transition period is 
associated with increased inflammatory markers (Bertoni and Trevisi, 2013; Bradford et 
al., 2015), although a source of blatant infection is often unclear. We have extended this 
and recently demonstrated increased circulating inflammatory biomarkers in periparturient 
cows diagnosed with ketosis and no other obvious disorder (i.e. mastitis or metritis; 
Abuajamieh et al, 2016). We hypothesize dietary shifts and/or inadequate feed intake 
associated with the transition period cause leaky gut and thus endotoxin infiltration 
(Abuajamieh et al., 2016), a scenario similar to heat stress (Kvidera et al., 2016b). Having 
a better understanding of how the immune system influences nutrient partitioning may 
allow for developing strategies to ameliorate production losses and reduce morbidity. 
 
Conclusion 
Our experiment demonstrates the induction of acute endotoxemia induces 
hypoglycemia resulting from the immune system’s rate of glucose utilization exceeding 
whole-body glucose sparing mechanisms. From the combination of reduced milk 
carbohydrate output and ROGI, we estimate the activated immune system uses > 1 kg of 
glucose within 720 min. This is ostensibly underestimated because we are unable to 
account for immune system glucose utilization during the acute hyperglycemic phase and 
the liver’s increased contribution to the circulating pool. The consistency between glucose 
utilization in the current experiment and other LPS-Eu clamps we have performed, despite 
differences in animal ages, physiological status, and species, suggests the reprioritization 
and extent of fuel utilization by immune cells upon activation is a conserved response. 
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Whether glucose can become a limiting factor in the immune response is not clear and thus 
the benefits of supplemental glucose to sick animals remains unknown. However, from an 
animal production perspective, infection and inflammation noticeably redirect resources 
toward the immune system and away from utilization and synthesis of economically 
relevant products. Having a better understanding of the energetic and nutrient requirements 
of the immune response is critical to developing strategies to minimize productivity losses 
when physiological states or environmental conditions activate the immune system. 
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Figure 19. Rectal temperature in cows administered a bolus of saline (CON), 
lipopolysaccharide (LPS-C), or lipopolysaccharide accompanied with a euglycemic clamp 
(LPS-Eu).  
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Figure 20. (A) Blood glucose levels in cows administered a bolus of saline (CON), 
lipopolysaccharide (LPS-C), or lipopolysaccharide accompanied with a euglycemic clamp 
(LPS-Eu) during both hyperglycemic (0-150 min) and hypoglycemic (180-720 min) phases 
and (B) the average rate of glucose infusion in LPS-Eu cows. 
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Figure 21. (A) Milk yield at 360 and 720 min postbolus and (B) milk and/or total glucose 
deficit from 0-360, 360-720, and accumulated over 720 min in cows administered a bolus 
of saline (CON), lipopolysaccharide (LPS-C), or lipopolysaccharide accompanied with a 
euglycemic clamp (LPS-Eu). *,** Represent differences between milk glucose deficits (P ≤ 
0.05). a-c Represents differences between total glucose deficits (P ≤ 0.05; total glucose 
deficit = milk glucose deficit in CON and LPS-C cows; total deficit = milk glucose deficit 
+ infused glucose in LPS-Eu cows). 
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Figure 22. Circulating (A) insulin, (B) non-esterified fatty acids (NEFA), (C) BHB, and 
(D) ionized calcium during the hypoglycemic phase (180 -720 min) in cows administered 
a bolus of saline (CON), lipopolysaccharide (LPS-C), or lipopolysaccharide accompanied 
with a euglycemic clamp (LPS-Eu). 
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Figure 23. Circulating (A) L-lactate, (B) haptoglobin, (C) serum amyloid A (SAA), and 
(D) lipopolysaccharide-binding protein (LBP) during the hypoglycemic phase (180 -720 
min) in cows administered a bolus of saline (CON), lipopolysaccharide (LPS-C), or 
lipopolysaccharide accompanied with a euglycemic clamp (LPS-Eu). 
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Figure 24. Circulating (A) white blood cell (WBC), (B) lymphocyte, and (C) neutrophil 
counts during the hypoglycemic phase (180 -720 min) in cows administered a bolus of 
saline (CON), lipopolysaccharide (LPS-C), or lipopolysaccharide accompanied with a 
euglycemic clamp (LPS-Eu). 
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Table 11. Ingredients and composition of diet 
Ingredient % of DM1,2 
    Corn Silage 20.5 
    Alfalfa Hay 10.2 
    Lactation Grain 8.9 
    Ground Corn 4.7 
    Whole Cotton 4.6 
    Soy Plus 1.8 
    Soy 48 2.3 
  
Chemical analysis, % of DM  
    Starch 25.3 
    CP 16.6 
    NDF 31.4 
    ADF 22.2 
  
NEL Mcal/kg DM 1.62 
1Diet moisture averaged 42.32%. 
2Average nutrient levels: 4.72% Fat, 0.81% Ca, 
0.47% P, 0.36% Mg, 0.19% S, 1.20% K, 0.45% 
Na, 0.47% Cl, 56.05 ppm of Zn, 62.79 ppm of 
Mn,  129.60 ppm of Fe, 17.54 ppm of Cu, 0.22 
ppm of Co, 0.28 ppm Se, 0.84 ppm of I, 4453.3 
IU/kg of vitamin A, 1190.5 IU/kg of vitamin D, 
and 26.5 IU/kg of vitamin E 
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Table 12. Milk composition parameters in cows given a bolus of saline (CON), lipopolysaccharide (LPS-C), or 
lipopolysaccharide accompanied with a euglycemic clamp (LPS-Eu) at 360 and 720 min post-LPS administration 
 Treatment1    P-value  Contrasts 
Parameter2 CON LPS-C LPS-Eu 
 
SEM 
 
Treatment Time 
Treatment x 
Time 
 
CON v 
LPS3 
LPS v 
LPS-Eu 
Milk solids             
Fat, % 3.4 3.4 3.2  0.3  0.91 0.02 0.86  0.81 0.71 
Protein, % 3.1 2.9 3.1  0.1  0.13 0.36 0.75  0.14 0.15 
Lactose, % 4.7a 4.1b 4.3b  0.1  0.01 <0.01 0.08  0.01 0.29 
TS, % 12.2 11.2 11.3  0.3  0.14 0.02 0.78  0.05 0.80 
MUN, 
mg/dL 
18.1 16.8 16.4 
 
0.6 
 
0.26 <0.01 0.68  
0.12 0.67 
Milk SCC 54a 108b 81ab  13  0.03 0.01 0.23  0.02 0.15 
1CON = saline bolus; LPS-C = LPS bolus; LPS-Eu = LPS bolus and euglycemic clamp 
2Data are presented as least square means from milk samples collected 360 and 720 min postbolus 
3LPS-C and LPS-Eu treatments 
 
  
1
6
3
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Table 13. Complete blood count parameters in cows given a bolus of saline (CON), lipopolysaccharide (LPS-C), or lipopolysaccharide 
accompanied with a euglycemic clamp (LPS-Eu) during the hypoglycemic phase 180-720 min post LPS-administration 
 Treatment1    P-value  Contrasts 
Parameter CON LPS LPS-Eu  SEM  Treatment Time 
Treatment 
x Time 
 
CON v  
LPS2 
LPS-C v  
LPS-Eu 
Monocytes, *103/μL 0.24a 0.04b 0.05b  0.03  <0.01 0.02 0.07  <0.01 0.80 
Eosinophils, *103/μL 0.35 0.36 0.23  0.05  0.25 0.03 <0.01  0.43 0.13 
Basophils, *103/μL 0.05a 0.02b 0.02b  0.01  0.01 <0.01 0.24  <0.01 0.67 
Red blood cells, *106/μL 6.2a 6.6b 6.5b  0.1  0.04 0.08 0.58  0.02 0.65 
Hemoglobin, gm/dL 10.8a 11.9b 11.5b  0.2  0.02 0.04 0.36  0.01 0.23 
Hematocrit, % 28.9a 32.3b 31.3b  0.7  0.02 0.60 0.24  0.01 0.39 
Platelets, *103/μL 323a 136b 102b  15  <0.01 0.02 0.62  <0.01 0.12 
Mean platelet volume, fl 6.6a 13.4b 13.7b  1.0  <0.01 0.22 0.37  <0.01 0.84 
NLR3 1.05a 0.65b 0.56b  0.13  0.05 <0.01 0.02  0.02 0.63 
1CON = saline bolus; LPS-C = LPS bolus; LPS-Eu = LPS bolus and euglycemic clamp 
2LPS-C and LPS-Eu treatments 
3Neutrophil to lymphocyte ratio 
 
  
1
6
4
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CHAPTER 6: EFFECTS OF CONTINUOUS AND INCREASING 
LIPOPOLYSACCHARIDE INFUSION ON BASAL AND STIMULATED 
METABOLISM IN LACTATING HOLSTEIN COWS 
 
S. K. Kvidera, M. J. Dickson, E. A. Horst, C. S. Shouse, K. L. Bidne, E. J. Mayorga, M. 
Al-Qaisi, H. A. Ramirez, A. F. Keating, and L. H. Baumgard 
 
Iowa State University Department of Animal Science, Ames, Iowa, 50011 
 
Abstract 
Immunoactivation via an acute lipopolysaccharide (LPS) bolus elicits well-
characterized immune and metabolic responses in experimental settings. However, 
conventional immunoactivation situations rarely mimic the nature of a LPS bolus. 
Therefore, experimental objectives were to characterize the basal and stimulated metabolic 
response to continuous LPS infusion in mid-lactation Holstein cows (169 ± 20 DIM; 681 
± 16 kg BW; parity 3.1 ± 0.4). Following 3 d acclimation, cows were enrolled in 2 
experimental periods (P). During P1 (3 d), cows were fed ad libitum and baseline data was 
collected. Starting P2 (8 d), cows were assigned to 1 of 2 treatments: 1) saline-infused and 
pair-fed (CON-PF; 1 L i.v. sterile saline at 40 mL/h; n=6) or 2) LPS-infused and ad libitum-
fed (LPS-AL; E. coli O55:B5; 0.017, 0.020, 0.026, 0.036, 0.055, 0.088, 0.148, and 0.148 
µg/kg BW/h for d 1 through 8, respectively; n=6). During P2, CON-PF cows were pair-fed 
to LPS-AL cows to eliminate confounding effects of dissimilar nutrient intake. Following 
the P2D8 0600h milking, feed was removed and all cows received an i.v. glucose tolerance 
166 
 
 
test (GTT) to assess glucose disposal. Feed was returned following the challenge. Four 
hours following the GTT feed was again removed and cows received an epinephrine 
challenge (EC). Blood samples for both challenges were collected -30, -20, -10, 0, 5, 10, 
20, 30, 45, 60, and 90 min relative to bolus.  LPS reduced DMI (28%) on d 1 but DMI 
gradually returned to pre-infusion levels by the end of P2, and overall milk yield was 
reduced similarly (17%) between treatments. Blood samples were collected on d 1 and 2 
of P1 and 1, 3, 5, and 7 d of P2. There were no differences in basal circulating glucose. 
Plasma insulin during P2 was increased 140% in LPS-AL relative to CON-PF cows. 
Circulating non-esterified fatty acids were increased from d 1 to 3 and subsequently 
decreased from d 3 to 7 in cows from both treatments. Relative to P1, CON-PF cows had 
a 29% decrease in plasma β-hydroxybutyrate (BHB) while it did not change in LPS-AL 
cows, thus during P2, LPS-AL cows had overall increased (41%) BHB relative to CON-
PF cows. Blood urea nitrogen (BUN) gradually decreased in CON-PF cows and increased 
in LPS-AL cows from d 1 to 5 of P2, resulting in an overall 25% increase in LPS-AL versus 
CON-PF cows. In response to the GTT, the glucose and insulin AUC were increased 33 
and 56%, respectively in LPS-AL relative to CON-PF cows. There were no observable 
treatment differences in the glucose or non-esterified fatty acid response to the EC. In 
conclusion, chronic LPS exposure induces peripheral insulin resistance but does not affect 
adipocyte and hepatocyte sensitivity to a catabolic signal. Chronic LPS-induced changes 
in metabolism are suggestive of altered protein, lipid, and carbohydrate metabolism and 
overall nutrient partitioning. 
Key words: inflammation, insulin, lipopolysaccharide 
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Introduction 
An activated immune system requires a large amount of energy (Kvidera et al., 
2017a), which is reallocated from profitable purposes to support the immune system, 
resulting in decreased growth, inefficient feed utilization, poor reproduction, and increased 
health care costs (Lochmiller and Deerenberg, 2000). Immunoactivation begins when 
pathogen associated molecular patterns (PAMPs) from invading pathogens (e.g., bacteria, 
viruses, yeast, and parasites) are recognized by leukocytes, eliciting the transcription and 
production of inflammatory cytokines, including tumor necrosis factor α (TNFα). 
Inflammation is further characterized by pyrexia, changes in circulating leukocyte 
numbers, and hepatic acute phase protein synthesis (Ceciliani et al., 2012). Metabolic 
disturbances also occur in response to immunoactivation including: hyperglycemia or 
hypoglycemia (depending upon the stage and severity of infection), increased circulating 
insulin and glucagon, skeletal muscle catabolism and subsequent nitrogen loss 
(Wannemacher et al., 1980), and hypertriglyceridemia (Filkins, 1978; Wannemacher et al., 
1980; Lanza-Jacoby et al., 1998; McGuinness, 2005). These metabolic perturbations are 
presumably strategies employed to ensure adequate glucose delivery to the immune 
system, which becomes an obligate glucose utilizer following activation (Maratou et al., 
2007; Palsson-McDermott and O’Neill, 2013). However, the aforementioned response to 
LPS can vary in magnitude as repeated or continuous exposure to endotoxin causes 
hyporesponsiveness (i.e., tolerance; Beeson, 1947). 
Immunoactivation is often experimentally modeled by administering a bolus 
containing the PAMP lipopolysaccharide (LPS), a cell wall component of gram-negative 
bacteria that elicits a well-described and robust immune response (van Miert and Frens, 
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1968; Lohuis et al., 1988a,b). Yet during natural infection, endotoxin release is 
concomitant with dynamics of bacterial growth and proliferation (Crutchley et al., 1967; 
Tsuji and Harrison, 1978). Therefore, key knowledge gaps remain in distinguishing how 
accurate single or repeated LPS boluses mimic chronic, naturally-occurring pathogen 
exposure. Human data suggests continuous LPS infusion prompts a less aggressive and 
more sustained release of inflammatory mediators; likely a more appropriate model of 
chronic inflammation than an acute bolus (Taudorf et al., 2007). Having a better 
understanding of how continuous LPS infusion affects immunometabolism is critical to 
developing strategies to minimize production losses in naturally immunoactivated farm 
animals. Therefore, experimental objectives were to characterize the effect of continuous 
and exponentially increasing LPS infusion on basal and stimulated metabolism in order to 
better understand how chronic LPS affects nutrient partitioning and productivity. 
 
Materials and Methods 
Animals and Experimental Design 
Iowa State University Institutional Animal Care and Use Committee approved all 
procedures involving animals. Twelve lactating Holstein cows (169 ± 20 DIM; 681 ± 16 
kg BW; parity 3.1 ± 0.4, range 2-5) were utilized and housed in individual box-stalls (4.57 
by 4.57 m) at the Iowa State University Dairy Farm. Cows were allowed to acclimate for 
3 d during which bilateral jugular catheters were implanted, and were then enrolled in two 
experimental periods. Period 1 (P1) lasted 3 d and served as the baseline (data generated 
for covariate analysis) for period 2 (P2). Period two lasted 8 d during which cows received 
one of two treatments 1) control (1 L sterile saline infused constantly at a rate of 40 mL/h; 
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jugular i.v.; n = 6) or 2) LPS-infused (0.017, 0.020, 0.026, 0.036, 0.055, 0.088, 0.148, and 
0.148 µg/kg BW/h for d 1 through 8, respectively; Figure 25; n = 6). The LPS dose and 
increasing daily infusion rate were selected based on data from a similar experimental 
design utilizing pigs (Kvidera et al., 2016b; Huntley et al., 2017). A stock solution of 
lipopolysaccharide (Escherichia coli O55:B5; Sigma Aldrich, St. Louis, MO) was made at 
a concentration of 300 μg/mL, passed through a 0.2 μm sterile syringe filter (Thermo 
Scientific; Waltham, MA), and stored in a sterile glass bottle 24 h prior to P2. Each day, 
the amount of stock solution needed for each cow’s daily dose was calculated and injected 
into a 1 L bottle of sterile saline. The i.v. infusion system was incubated overnight with 
LPS solution (3 µg/mL) 1 d prior to initiation of infusion to saturate potential plastic LPS 
binding sites.  
Control animals were pair-fed (PF) to the LPS-treated cows to eliminate the 
confounding effects of dissimilar nutrient intake as we have previously described 
(Wheelock et al., 2010). All cows were individually fed a TMR once daily at 0800 h, and 
orts were recorded prior to feeding. The TMR (consisting primarily of corn silage) was 
formulated by Dynamic Nutrition Systems (Pierz, MN) to meet or exceed the predicted 
requirements of energy, protein, minerals, and vitamins (NRC, 2001; Table 14). 
Reductions in daily feed intake by LPS-treated cows during P2 were determined as a 
percentage of their mean daily ad libitum intake during P1. Due to space constraints and to 
allow for pair-feeding calculations and implementation, control cows were 9 d behind LPS-
cows in experimental protocol. Throughout the experiment, cows were milked twice daily 
at 0600 and 1800 h, and yields were recorded at each milking. Body weights were recorded 
on d 1 of acclimation and were used to calculate LPS dosage. Plasma samples were 
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collected daily at 0600 h during both P1 and P2. Whole blood was collected from the 
jugular catheter contralateral to the LPS-infusion catheter using EDTA as the anticoagulant 
(K2 EDTA, BD Vacutainer, Franklin Lakes, NJ). Plasma was harvested following 
centrifugation at 1500 x g for 15 min at 4°C, and subsequently frozen at -20°C until 
analysis. 
Metabolic Challenges 
 For both metabolic challenges, feed was removed immediately prior to the 
challenge and was returned upon challenge conclusion. Lipopolysaccharide infusion was 
paused temporarily (~5-10 min) to administer glucose or epinephrine bolus. Prior to bolus 
administration, ~5 mL of blood was drawn and discarded to prevent infusion of any LPS 
remnant in the catheter line. Infusing LPS resumed following bolus administration, and all 
blood samples were collected from the contralateral catheter. On P2D8, a glucose tolerance 
test (GTT) was performed following the morning milking at 0600 h. A 50% dextrose 
solution bolus (VetOne; MWI Veterinary Supply, Boise, ID) was administered at 0.25 g/kg 
BW via the jugular catheter as previously described (Wheelock et al., 2010). Blood samples 
were collected at -30, -20, -10, 0, 5, 7.5, 10, 20, 30, 45, 60, and 90 min relative to glucose 
administration. Four hours after the conclusion of the GTT an epinephrine challenge (EC; 
1.4 µg/kg BW; VetOne; MWI Veterinary Supply, Boise, ID) was performed as previously 
described (Baumgard et al., 2002a), and blood samples were collected -30, -20, -10, 2.5, 5, 
7.5, 10, 20, 30, 45, 60, 90, and 120 min relative to the epinephrine administration. All blood 
samples were collected in disposable tubes containing EDTA as the anticoagulant (K2 
EDTA, BD Vacutainer, Franklin Lakes, NJ). Plasma was harvested following 
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centrifugation at 1500 x g for 15 min at 4°C, and subsequently frozen at -20°C until 
analysis. 
Laboratory Analyses 
 Plasma glucose, insulin, non-esterified fatty acids (NEFA), β-hydroxybutyrate 
(BHB), L-lactate, and blood urea nitrogen (BUN) were determined using commercially 
available kits according to manufacturers’ instructions (glucose, Wako Chemicals USA 
Inc., Richmond, VA; insulin, Mercodia AB, Uppsala, Sweden; NEFA, Wako Chemicals 
USA, Richmond, VA; BHB, Pointe Scientific Inc., Canton, MI; L-lactate, Biomedical 
Research Service Center, Buffalo, NY; BUN, Teco Diagnostics, Anaheim, CA). The inter- 
and intra-assay coefficients of variation for glucose, insulin, NEFA, BHB, L-lactate, and 
BUN assays were 1.4 and 6.9%, 5.9 and 15.3%, 2.2 and 18.3%, 4.0 and 17.1%, 5.3 and 
9.7%, and 9.1 and 10.6%, respectively. 
Calculations and Statistical Analyses 
 Production and immunological data as well as molecular aspects of insulin action 
are reported elsewhere (Dickson and Keating, unpublished; Horst and Baumgard, 
unpublished). Metabolic responses to the GTT and EC were calculated as area under the 
curve (AUC) by linear trapezoidal summation between successive pairs of metabolite 
concentrations and time coordinates after subtracting baseline values. For the GTT, area 
under the curve (AUC) was calculated through the 90 and 45 min sample for glucose and 
insulin, respectively. For the EC, AUC was calculated through the 60 min sample for both 
glucose and non-esterified fatty acids. The AUC data was analyzed with SAS version 9.3 
(SAS Inst. Inc., Cary, NC) using PROC MIXED and treatment as a fixed effect. 
172 
 
 
For all other measurements, each animal’s respective parameter was analyzed using 
repeated measures with an autoregressive covariance structure. The repeated effect was 
day of LPS administration. Each specific variable’s prebolus value (when available) served 
as a covariate. Effects of treatment, time, and treatment by time interaction were assessed 
using PROC MIXED (SAS Inst. Inc., Cary, NC). All data are reported as LSmeans and 
considered significant if P ≤ 0.05 and a tendency if 0.05 < P ≤ 0.10. 
 
Results 
Basal circulating glucose concentration did not differ between treatments (P = 0.42; 
Figure 26A). Relative to baseline values, P2 circulating insulin tended to be decreased in 
CON-PF cows (47%; P = 0.08) while LPS-AL cows did not change (P = 0.42). Overall, 
this resulted in 140% increased circulating insulin in LPS-AL versus CON-PF cows (P = 
0.01; Figure 26B). Circulating basal NEFA were increased from d 1 to 3 and subsequently 
decreased from d 3 to 7 in both treatments (P < 0.01; Figure 26C). Relative to P1, CON-
PF cows had a 29% decrease in plasma β-hydroxybutyrate (BHB; P = 0.04) while BHB in 
LPS-AL did not change (P = 0.40), thus LPS-AL cows had overall increased (41%) BHB 
relative to CON-PF cows (P = 0.01; Figure 27A). Circulating BUN gradually decreased in 
CON-PF cows and increased in LPS-AL cows from d 1 to 5 (P = 0.04), resulting in an 
overall 25% increase in LPS-AL versus CON-PF cows (P = 0.02; Figure 27C).  
In response to the GTT, glucose AUC was increased (33%; 2523 vs. 3367 
mg/dL·min) in LPS-AL cows relative to CON-PF cows (P = 0.02; Figure 28A). Similarly, 
LPS-AL cows had a 56% increase in insulin AUC relative to CON-PF cows (265 vs. 414 
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µg/L·min; P = 0.03; Figure 28B). In response to the EC, neither glucose nor NEFA AUC 
differed between treatments (P ≥ 0.53; Figure 29A and 29B). 
  
Discussion 
Infection and inflammation impede efficient animal agriculture, and both begin 
when PAMPs from invading pathogens (e.g., bacteria, viruses, yeast, parasites) are 
recognized by immune cells, eliciting transcription and production of inflammatory 
cytokines. One of the most common ways to model immune activation is through bolus 
LPS administration, which elicits a well-characterized and robust immune response (van 
Miert and Frens, 1968; Lohuis et al., 1988a,b). Another strategy is to infuse the 
inflammatory cytokine TNFα, a method effectively bypassing both PAMP recognition and 
the signaling cascade that results in an array of inflammatory cytokine production. 
However, the metabolic effects of TNFα injection are unexplainably variable (Bradford et 
al., 2009; Yuan et al., 2013; Martel et al., 2014) which limits its utilization as an appropriate 
model. Compared to TNFα administration techniques, i.v. LPS infusion is a more systemic 
model and avoids the inflammation and cytokine production associated with surgical 
insertion of TNFα infusion pumps. Further, LPS infusion, rather than TNFα administration, 
includes PAMP recognition and NFĸB pathway initiation which elicits production of 
several cytokines, including IL-1β and IL-6 in addition to TNFα (Murphy et al., 2012). 
Additionally, each unique PAMP can produce distinctive cytokine profiles which in turn 
influence the pattern and production of acute phase proteins (Gabay and Kushner, 1999). 
Thus, the current model of continuous LPS infusion over several days is an attempt to more 
accurately model the inflammatory milieu that accompanies real infections and the 
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dynamic release of endotoxin upon bacterial overgrowth and proliferation (Crutchley et al., 
1967; Tsuji and Harrison, 1978). Inherently, living microorganisms replicate 
exponentially, and thus in vivo endotoxin exposure can (if not controlled and remedied by 
the immune system) also become exponential (Goris et al., 1988). Consequently, we chose 
to increase the daily LPS dose exponentially in an attempt to mimic endotoxin exposure 
during bacterial overgrowth (Figure 25). Metabolic alterations to bolus or short-term 
endotoxin infusion have been well-described in cattle (Lohuis et al., 1988b; Giri et al., 
1990; Waldron et al., 2003a); however, the effects of continuous and chronic systemic LPS 
infusion on basal and stimulated energetic metabolism in a lactating ruminant model are 
unknown. 
Basal hyperinsulinemia was one of the most marked treatment differences observed 
in the current study, and it agrees with LPS bolus models in a variety of species (Toribio 
et al., 2005; Waggoner et al., 2009b; Yates et al., 2011; Kvidera et al., 2016a; Kvidera et 
al., 2017a) and when LPS is infused over 100 min (Waldron et al., 2003a). Incidentally, 
this agrees with long-term (10 d) continuous TNFα infusion which increases circulating 
insulin in rodents (Raina et al., 1994). The changes in basal insulin were not reflected by 
decreased circulating glucose, which suggests that long-term LPS exposure induces whole-
body insulin resistance. This is corroborated by decreased glucose disposal rates following 
the GTT (Figure 28A). Whole-body insulin resistance following an LPS bolus has been 
previously reported in mid-lactation dairy cows using a hyperinsulinemic-euglycemic 
clamp (Vernay et al., 2012). Additionally, the 56% increase in insulin AUC in LPS-infused 
cows is interesting as we and others have shown that glucose infusion exacerbates LPS-
induced hyperinsulinemia (Blackard et al., 1976; Kvidera et al., 2016a) and suggests an 
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interaction between LPS and glucose stimulated insulin secretion as recently proposed 
(Baumgard et al., 2016). Similarly, heat stressed animals have an increased insulin 
response to glucose, presumably due to heat-induced intestinal barrier dysfunction and 
subsequent LPS infiltration into portal circulation (Wheelock et al., 2011; Baumgard and 
Rhoads, 2013; Sanz Fernandez et al., 2015). Insulin becomes important for leukocyte 
glucose uptake and development during immunoactivation (Shimizu et al., 1983; 
Helderman, 1984; Calder et al., 2007; Maratou et al., 2007) and hyperinsulinemia coupled 
with peripheral insulin resistance may be a homeorhetic strategy employed to ensure 
adequate glucose delivery to the immune system. Immune cells require significant amounts 
of glucose upon immunoactivation due to a metabolic switch from oxidative 
phosphorylation to aerobic glycolysis (Palsson-McDermott and O’Neill, 2013), resulting 
in generation and export of lactate. Interestingly, circulating lactate levels did not differ 
between treatments which is surprising as immunoactivation is frequently characterized by 
hyperlactemia (Michaeli et al., 2012; Kvidera et al., 2017a). This may be explained by the 
relatively low-dose and chronic nature of the model, as LPS enhances gluconeogenesis 
(Filkins, 1978); thus, hepatic lactate uptake and subsequent gluconeogenesis is likely able 
to keep pace with the increase in lactate pool entry.  
Skeletal muscle is catabolized during infection to provide amino acids as substrates 
for gluconeogenesis (Wannemacher et al., 1980) as well as to provide the building blocks 
for the synthesis of leukocytes and acute phase proteins (Iseri and Klasing, 2013). The 
profile of the immune system’s amino acid requirement differs from that of skeletal muscle, 
thus surplus amino acids are mobilized and unutilized amino acids are deaminated (Reeds 
et al., 1994). Therefore, not surprisingly, circulating BUN is consistently increased in pig 
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models of endotoxemia (Myers et al., 1997; Bruins et al., 2003), presumably due to 
increased skeletal muscle protein catabolism. Results from ruminants generally agree 
(Burdick Sanchez et al., 2014), but are more variable (Waggoner et al., 2009a,b; Zarrin et 
al., 2014), probably because interpreting circulating BUN is complicated by the 
contribution of rumen derived ammonia. In addition, endotoxin-induced hypophagia 
reduces substrate (amino acids) delivery to the liver as changes well as rumen microbiota 
profile and function (Galyean et al., 1981; Jing et al., 2014), and this potentially masks any 
catabolic-induced changes in BUN. Thus, it is important in ruminant studies to utilize pair-
feeding models to account for decreased feed intake. However, this again is complicated 
by the rumen, as it takes 4 or more days to truly fast a ruminant (Blaxter and Wainman, 
1966). Regardless, data from the current study corroborates monogastric reports as BUN 
decreased gradually in CON-PF cows but increased in LPS-AL cows (Figure 27C). Thus, 
endotoxemia-induced increased muscle catabolism likely occurs in lactating dairy cows as 
well. It would be of interest to study alternative markers (e.g., 3-methylhistidine, urine 
creatinine, etc.) to confirm whether muscle catabolism occurs during immunoactivation in 
ruminants. 
 Patterns of unstimulated circulating NEFA were similar between LPS-infused and 
pair-fed animals. This is surprising as basal circulating insulin was increased 140% in LPS-
animals and insulin is a potent antilipolytic hormone (Vernon, 1992). Previous studies 
conducted by our group demonstrated increased basal NEFA relative to baseline in LPS 
bolus-administered animals, but this response is blunted relative to the NEFA pattern of 
pair-fed animals (Kvidera et al., 2016a; Kvidera et al., 2017a). Other studies have observed 
an increase in NEFA following LPS bolus (Waldron et al., 2003a) while others have 
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reported no changes in circulating NEFA (Waldron et al., 2006; Zarrin et al., 2014).  
Reasons for why basal NEFA levels are inconsistent amongst studies is not clear but likely 
stems from differences in the dose, timing, and route of LPS administration. Circulating 
BHB were decreased in pair-fed cows, but were maintained at baseline levels in LPS-
infused cows. Interestingly, the discordant BHB patterns occurred despite cows from both 
treatments having similar concentrations of circulating NEFA. The majority of circulating 
BHB during positive energy balance originates form the rumen epithelium as opposed to 
the liver (Pennington, 1952). The maintenance of ketone levels in LPS-infused cows 
relative to pair-fed controls could be caused by 1 of 3 factors: 1) decreased ketone 
utilization by peripheral tissue, 2) increased absorption efficiency by the rumen epithelium, 
or 3) increased hepatic ketone production. A decrease in ketone utilization is not likely, as 
ketones provide an energy source for non-immune tissues during LPS-induced insulin 
resistance. Furthermore, an increased rate of BHB infusion was required to maintain 
hyperketonemia in lactating cows challenged with LPS (Zarrin et al., 2014), indicating 
increased circulating BHB clearance. Administrating LPS also decreases rumen motility 
and increases rumen butyrate concentrations, changes indicative of poor rumen ketone 
absorptive capacity (Jing et al., 2014). Lastly, Waldron and colleagues (2003a) observed 
no LPS effects on ketone synthesis in incubated liver slices obtained from lactating cows, 
indicating ketogenesis remains functional. However, other animal models demonstrate 
reduced hepatic ketogenesis during inflammation, attributed to either circulating insulin’s 
lipogenic role in both hepatic cells and adipocytes (therefore reducing substrate delivery 
for ketogenesis; Beisel et al. 1980, Neufeld et al., 1980) or direct antiketogenic effects of 
inflammatory cytokines (Memon et al., 1992). We and others have shown reduced 
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circulating BHB following bolus endotoxin administration (Graugnard et al., 2013; Zarrin 
et al., 2014; Kvidera et al., 2016a; Kvidera et al., 2017a) and LPS infused over 100 min 
(Waldron et al., 2003a), which contrasts with the current study. One factor potentially 
responsible for these differences may be the LPS dose. Larger LPS doses cause more robust 
metabolic changes (Lohuis et al., 1988b; Waldron et al., 2003a); therefore, most bolus 
studies use a large LPS dose in order to accurately observe and measure changes. In the 
current study, a relatively low dose was initially used (0.4 µg/kg BW over 24 h) and was 
gradually increased to what would be considered a high dose if given as a bolus (3.56 µg/kg 
BW over 24 h on d 7 and 8) because 2.0 µg/kg BW can be fatal in lactating cows (Waldron 
et al., 2003a). With this dose schedule, metabolic shifts were certainly not as dramatic, and 
endotoxin tolerance obviously developed, so it is very likely ketone metabolism differs in 
this model compared to bolus administration.  Very little literature exists (in any species) 
on the effect of chronic inflammation on ketone metabolism over several days, and 
maintenance of ketone levels during continuous low-dose LPS infusion in lactating cows 
appears to be a novel discovery. 
 Previous data has demonstrated both blunted lipolysis and a blunted glucose 
response to adrenergic stimulation during sepsis (Hargrove et al., 1989; Forse et al., 1994). 
Hargrove et al. (1990) suggested this was primarily due to increased circulating insulin, 
which is a strong inhibitor of both adipose lipolysis and hepatic glucose output (Halter et 
al., 1984; Vernon, 1992). Elevated circulating insulin also occurs in heat-stressed animals, 
and they also have an attenuated NEFA response to lipolytic signals (Baumgard et al., 
2011; Sanz Fernandez et al., 2015). The blunted response to adrenergic stimulation could 
also be due to desensitization of adrenergic receptors, as epinephrine is increased during 
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heat stress (Alvarez and Johnson, 1973) and endotoxin challenge in humans, cattle, and 
sheep (Richardson et al., 1989; Williams et al., 2009; Burdick Sanchez et al., 2011). 
Chronically increased circulating levels of epinephrine can downregulate and desensitize 
adrenergic receptors (Briggs et al., 1983; Snavely et al., 1985), potentially inducing 
tolerance to adrenergic signaling. Surprisingly, despite the LPS-induced hyperinsulinemia, 
no changes in adipose lipolysis or hepatic glucose output in response to the EC were 
detected in the current study. It would be of interest to evaluate the temporal pattern of both 
liver and adipose tissue responsiveness to catabolic signals during endotoxemia. 
  
Conclusion 
 A variety of studies have characterized LPS-induced metabolic effects using bolus 
or repeated bolus models. We attempted to more accurately represent chronic in vivo 
infection by infusing LPS continuously with exponentially increasing doses for 7 d. The 
most striking effect of continuous low-dose LPS infusion was chronically elevated 
circulating insulin. The lack of changes in basal circulating glucose coupled with the 
decrease in glucose disposal following the GTT strongly suggests that chronic LPS 
infusion causes insulin resistance. Furthermore, because both treatments had a similar 
catabolic response to epinephrine despite increased insulin in LPS-infused animals, it 
appears chronic LPS infusion may diminish insulin’s inhibitory role on both hepatic 
glucose output and adipose tissue lipolysis. Increased circulating BUN and BHB in LPS-
infused cows also suggests protein and lipid metabolism are altered during continuous LPS 
exposure. Futures studies delineating mechanisms regulating endotoxin-induced altered 
nutrient partitioning would help to understand nutrient requirements during illness. 
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Table 14. Ingredients and composition of diet 
Ingredient % of DM2 
    Corn Silage 33.58 
    CGF 16.01 
    Alfalfa Hay 12.74 
    Lactation  Grain 11.19 
    Ground Corn 9.58 
    Whole Cotton 5.09 
    QLF 2.38 
    Soy Plus 1.04 
    Soybean Meal 4.75 
      
Chemical analysis, % of DM  
    Starch 22.86 
    CP 16.95 
    NDF 31.09 
    ADF 20.28 
  
NEL Mcal/kg DM 1.44 
1Values represent an average of ration nutrient summary reports collected 
throughout the trial.   Diet moisture averaged 52.49%. 
2Average nutrient levels: 5.02% Fat, 0.91% Ca, 0.47% P, 0.36% Mg, 0.23% S, 
1.32% K, 0.53% Na, 0.59% Cl, 69.39 ppm of Zn, 38.09 ppm of Mn,  3.02  ppm 
of Fe, 11.61 ppm of Cu, 0.65 ppm of Co, 0.28 ppm Se, 0.65 ppm of I, 6005.6 
IU/kg of vitamin A, 477.9 IU/kg of vitamin D, and 15.7 IU/kg of vitamin E 
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Figure 25. Daily dose schedule of lipopolysaccharide (LPS) administered intravenously 
via a jugular catheter in LPS-AL cows. Rate of infusion remained constant at 40 mL/h 
while LPS solution concentration was adjusted to achieve the predetermined daily dose. 
Control cows were infused with sterile saline at a rate of 40 mL/h. 
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Figure 26. Circulating daily levels of (A) glucose, (B) insulin, and (C) non-esterified fatty 
acid in cows administered a continuous and increasing dose of lipopolysaccharide (LPS-
AL) or sterile saline and pair-fed (CON-PF) to LPS-infused cows. 
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Figure 27. Circulating daily levels of (A) β-hydroxybutyrate, (B) L-lactate, and (C) blood 
urea nitrogen in cows administered a continuous and increasing dose of lipopolysaccharide 
(LPS-AL) or sterile saline and pair-fed (CON-PF) to LPS-infused cows. *Indicates 
treatment differences at the indicated time point (P < 0.05). 
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Figure 28. Circulating (A) glucose and (B) insulin response to an intravenous glucose 
tolerance test during day 8 of continuous and increasing lipopolysaccharide infusion (LPS-
AL) or sterile saline and pair-fed (CON-PF) to LPS-infused cows. 
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Figure 29. Circulating (A) glucose and (B) non-esterified fatty acids (NEFA) response to 
an intravenous epinephrine challenge during day 8 of continuous and increasing 
lipopolysaccharide infusion (LPS-AL) or sterile saline and pair-fed (CON-PF) to LPS-
infused cows. 
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CHAPTER 7: INTEGRATIVE SUMMARY 
 Infection and inflammation are likely experienced by all animals in varying degrees 
at some point in their lifetime. Inflammation has negative economic consequences to 
animal agriculture due to decreased production, inefficient feed utilization, poor 
reproduction, and increased health care costs. An activated immune system demands a 
large amount of energy and nutrients (Lochmiller and Deerenberg, 2000; Johnson, 2012) 
which reprioritizes the hierarchy of nutrient partitioning away from productive purposes. 
For example, skeletal muscle proteolysis is an important source of amino acids for different 
components of the immune response. The amino acid requirement during 
immunoactivation has been studied extensively (Klasing and Austic, 1984a,b; Reeds et al., 
1994; Grimble and Grimble, 1998; Reeds and Jahoor, 2001; Li et al., 2007; Johnson, 2012). 
Accurately quantifying energetic requirements of the immune system is more difficult 
because there are immune cells within virtually every tissue, and leukocyte distribution and 
flux changes during immunoactivation. Whole-body expenditure and glucose utilization 
are estimated to increase approximately 50% during an infection (Lang and Dobrescu, 
1991; Lang et al., 1993; Plank et al., 1998). Recently, Huntley et al. (2017) estimated that 
immune system stimulation increases maintenance requirements of growing pigs by ~ 
25%. Thus, it is very clear that an activated immune response increases whole-body energy 
consumption. Increased energy expenditure is partially explained by the febrile response 
which accompanies immunoactivation; however, increased glucose utilization continues 
independently of rectal temperature changes (Lang et al., 1987a). Therefore, we believe 
glucose utilization by an activated immune system is comprising a majority of this 
increased energy cost. As previously discussed, activated immune cells switch their 
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metabolism from oxidative phosphorylation to aerobic glycolysis, which substantially 
increases glucose consumption to support energetic and substrate demand (Calder et al., 
2007; Maratou et al., 2007; MacIver et al., 2008; Palsson-McDermott and O’Neill, 2013; 
Kelly and O’Neill, 2015). This is especially important to the dairy industry because glucose 
is the precursor to lactose, the primary osmoregulator of milk yield (Chaiyabutr et al., 
1980). Thus, extramammary processes that increase glucose utilization have the potential 
to decrease glucose supply to the mammary gland and limit milk synthesis. Elucidating the 
bioenergetics of an immune response is an important prerequisite to developing strategies 
aimed at minimizing production losses. As this research progresses, the practical 
implications will have clear benefits, particularly in lactating dairy cattle where glucose 
drives milk productivity. 
Obvious sources of inflammation in dairy cattle include metritis and mastitis 
(Sheldon et al., 2008; Ballou, 2012). A more inconspicuous source of inflammation is 
increased gastrointestinal barrier dysfunction which can be a consequence of different 
stressors including dietary changes (e.g., grain-induced acidosis; Khafipour et al., 2009a) 
or environmental factors like heat stress (Baumgard and Rhoads, 2013). Additionally, we 
hypothesize the periparturient period is a time characterized by intestinal dysfunction 
(Abuajamieh et al., 2016) and have also shown in the current dissertation that feed 
restriction contributes to intestinal dysfunction in lactating dairy cows (chapter 3).  
Gastrointestinal tract luminal content is technically extrinsic to the animal and is 
colonized with bacteria which increase in concentration from the proximal to distal 
intestine. Therefore, it is not surprising that a large majority of the immune system resides 
in the splanchnic bed (van der Heijden et al., 1987). Barrier importance is heightened in 
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cattle as both the size of the GIT and potential toxin exposure are more extensive in 
ruminants due to pre-gastric fermentation compartments. Exposure to immunogenic 
compounds and the initiation of inflammation certainly has implications on a variety of 
productive and metabolic aspects. However, studying the direct consequences of intestinal 
barrier dysfunction is difficult as the natural situations characterized by leaky gut are 
accompanied by a number of other behavioral and endocrine changes, which greatly 
increases variability and makes developing a repeatable leaky gut model arduous. 
Additionally, gastrointestinal dysfunction in dairy cattle remains less studied relative to 
other production animals. This is, in part, due to research costs and inability to perform gut 
health tests such as the lactulose/mannitol test due to rumen degradation of these unique 
sugars (Ahmed et al., 2013). Therefore, accurately characterizing the direct effects of leaky 
gut, developing an adequate and repeatable model, and characterizing the metabolic cost 
of immune activation and consequence of long-term inflammation are prerequisites for the 
development of strategies to mitigate intestinal dysfunction and its negative consequences. 
Impaired intestinal barrier function occurs in a wide variety of human and animal 
diseases despite different underlying etiologies (see Chapter 1 ‘Situations of increased 
intestinal permeability’ section). However, discerning the direct metabolic and production 
consequences of leaky gut is difficult because conditions responsible for reducing intestinal 
barrier integrity can differ widely and affect multiple tissues and systems. For example, 
heat stress and the periparturient period are both situations where decreased barrier 
function occurs, yet both are characterized by other homeorhetic adaptations to support a 
new dominant physiological state (i.e., heat dissipation and milk production). Therefore, 
the objective of chapter 2 was to evaluate the metabolic, inflammatory, and production 
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consequences of intentionally-induced intestinal dysfunction in otherwise healthy mid-
lactation cows. We hypothesized that intestinal tract dysfunction would negatively affect 
production and would alter metabolism and inflammatory parameters to resemble 
characteristic biomarkers during heat stress and the periparturient period. Our results 
confirmed our hypothesis, as intentionally damaging gut morphology reduced dry matter 
intake (~70%) and milk production (~40%) over time. Cows with intentionally-induced 
intestinal dysfunction had increased insulin, peak circulating ketones, and tended to have 
increased LBP relative to pair-fed cows. Interestingly, we discovered that pair-fed controls 
also had increased circulating acute phase proteins relative to their baseline values. This 
indicated that feed restriction itself causes intestinal barrier dysfunction, and this agrees 
with a variety of other models. 
Feed intake reduction is frequently experienced by livestock either voluntarily (e.g., 
heat stress, immunoactivation, psychological stress, etc.) or involuntarily (e.g., shipping, 
poor management, drought, overcrowding, etc.). Therefore, when studying different stress 
situations, it is important to distinguish between their direct (i.e., the stressor) and indirect 
(i.e., via reduced feed intake) effects. For example, heat-stressed animals drastically 
decrease feed intake and exhibit reduced intestinal barrier integrity, leading to 
inflammation and poor performance. Similarly, we have administered gamma-secretase 
inhibitor in cows and observed intestinal damage and reduced intake. However, due to pair-
fed controls in these experiments, we have also determined these negative effects are 
partially explained by reduced intake and its independent role in reducing intestinal barrier 
function (Pearce et al., 2013a; Baumgard and Rhoads 2013; Kvidera et al., 2017a). 
Therefore, objectives of chapter 3 were to determine if simply feed restricting cows would 
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negatively affect intestinal histology, to identify a magnitude of feed restriction that affects 
circulating inflammatory markers, and to assess GLP2’s ability to mitigate intestinal 
dysfunction caused by feed restriction. We discovered that feed restriction affects ileum 
morphology in cows fed 40% of their ad-libitum intake. Furthermore, incremental feed 
restriction linearly increased circulating markers of inflammation. Administration of GLP2 
in cows restricted to 40% of their ad libitum feed intake improved intestinal morphology 
variables above the level of control animals, clearly demonstrating a beneficial effect of 
GLP2 on gut health during reduced feed intake. Therefore, in this study we concluded that 
a simple feed restriction of ≤ 40% ad libitum intake in lactating cows is a viable model for 
intestinal dysfunction, as it caused marked changes in intestinal architecture and increased 
inflammatory biomarkers. Furthermore, we successfully tested GLP2 as a mitigation 
strategy using this model. Administering GLP2 ameliorated intestinal damage caused by 
feed restriction and actually improved intestinal growth beyond ad libitum control values. 
Thus, future studies delineating production responses to GLP2 administration are 
warranted. 
Chapters 2 and 3 successfully demonstrated altered metabolism and increased 
markers of inflammation during intestinal dysfunction. How these alterations contribute to 
productivity were the objectives of the remaining chapters in the dissertation. As discussed 
previously, estimating glucose requirements of an activated immune system is difficult due 
to the fluctuating nature of immune cells within immune and non-immune tissue. 
Therefore, the objective of chapter 4 was to describe a model where glucose requirements 
of an activated immune system could be estimated using an LPS bolus followed by a 
euglycemic clamp. Administration of the LPS bolus caused hypoglycemia (~30% below 
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baseline levels) in control animals within 3 h. Approximately 516 g of glucose were infused 
within the 12 h period in order maintain blood glucose levels. This model has obvious 
limitations because glucose uptake by adipose and muscle tissue, two of the largest glucose 
disposal sites, is unknown. However, insulin insensitivity has been well-characterized in 
both adipose and muscle during endotoxemia both in vivo (Raymond et al., 1981; Ling et 
al., 1994; Poggi et al., 2007; Mulligan et al., 2012) and in vitro (Song et al., 2006; Liang et 
al., 2013). Furthermore, our model is limited because we are not able to calculate hepatic 
glucose output, including the ~180 min period of hyperglycemia due to hepatic 
glycogenolysis immediately following LPS infusion. The contribution of gluconeogenesis 
to the glucose pool is also unclear in our model. Acute endotoxemia seems to inhibit 
gluconeogenesis while more chronic inflammatory situations increase gluconeogenesis 
(Filkins, 1978; McGuiness, 2005). Therefore, knowing the gluconeogenic contribution to 
our model would be of interest. The lack of endogenous glucose contribution 
measurements means we are underestimating the quantity of glucose entering the 
circulating pool and subsequently the total amount of glucose utilized by the immune 
system. Quantifying this would refine our model and make it more accurate. 
Using this model, we quantified glucose consumption by an activated immune 
system in both Holstein steer calves (chapter 4) and lactating Holstein dairy cows (chapter 
5). We found that glucose utilization by the activated immune system was 1.0 g/kg 
BW0.75/h and 0.66 g/kg BW0.75/h in steer calves and lactating cows, respectively. Data we 
have also generated in pigs (1.1 g/kg BW0.75/h; Appendix A) and in a separate lactating 
cow study (1.0 g/kg BW0.75/h; Horst and Baumgard, unpublished data) appears comparable 
and thus conserved across species and life stages, although this needs to be investigated 
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further. The aforementioned data comprises all our knowledge of glucose consumption of 
the immune system using this newly developed model. Therefore, it would be of interest 
to test the LPS-euglycemic clamp in different stages of lactation or during heat stress to 
see if these altered physiological states influence glucose consumption by the immune 
system.  
Modeling immunoactivation, such as we have done in chapters 4 and 5, is 
frequently done using an acute LPS bolus. A high dose inducing a robust response was 
required for the development of hypoglycemia in order to quantify activated immune 
system glucose requirements; however, this acute i.v. bolus is not a great model of naturally 
occurring inflammation as cows would likely not experience such an intense immediate 
systemic exposure. During natural infection, endotoxin release is directly tied to bacterial 
growth and proliferation because LPS is shed through bacterial growth or death (Crutchley 
et al., 1967; Tsuji and Harrison, 1978). Therefore, we wanted to compare and contrast 
metabolic changes due to chronic versus acute LPS exposure. Similar to acute LPS 
exposure, we found chronic exposure increases circulating levels of insulin. In contrast, 
chronic exposure elevated circulating BUN and BHB levels relative to pair-fed animals. 
Control animals were pair-fed throughout the study, so this model helps to rid ambiguity 
within ruminant literature as BUN is complicated by the contribution of rumen derived 
ammonia. Furthermore, this data agrees with monogastric models of increased BUN 
following LPS exposure, likely due to muscle catabolism. However, BUN is certainly not 
a perfect biomarker of muscle catabolism, and investigating more specific markers of 
muscle catabolism is justified.  
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Reasons behind the circulating BHB differences in chapter 6 are unclear and 
certainly warrant further investigation into altered lipid metabolism following LPS 
exposure in both acute and chronic situations. A variety of studies have demonstrated 
decreased BHB following acute LPS infusion (see Table 4), including Zarrin et al. (2014) 
who observed significantly decreased BHB levels despite increasing BHB infusion in an 
attempt to maintain hyperketonemic levels. These studies suggest increased BHB 
utilization by peripheral tissue. Circulating BHB is also likely affected by decreased rumen 
motility and butyrate absorptive capacity (Jing et al., 2014). Waldron et al. (2003a) reported 
hepatic ketogenesis during LPS infusion remains functional in lactating cows, yet various 
other animal models show impaired hepatic ketogenesis due to high circulating insulin 
levels (Neufeld et al., 1980). Hepatic steatosis can be a consequence of infection or 
inflammation (Hirsch et al., 1964; Ilan, 2012; Fukunishi et al., 2013; Wenfeng et al., 2014; 
Damms-Machado et al., 2017) because NEFA accumulation into hepatic triglycerides is 
accelerated during immunoactivation (Guckian, 1973; Fiser et al., 1974; Lanza-Jacoby and 
Tabares, 1990). Normally, increased liver lipid content and reduced glucose availability 
contribute to ketogenesis in order to continue producing energy for extrahepatic tissues. 
Thus, the relationship between inflammation, ketone metabolism, and hepatic steatosis 
remain ill-defined in lactating cows and further studies investigating ketone metabolism 
and flux throughout tissues may be beneficial. 
Interestingly, decreased circulating calcium is another hallmark of acute LPS 
exposure (see Table 4). Calcium is involved in immune activation (Hendy and Canaff, 
2016), but where circulating calcium is redistributed or mechanistic reasons for 
hypocalcemia are unclear. Others have found calcium accumulates in ascites during i.v. 
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endotoxin infusion, and administering exogenous calcium i.v. has no benefit during sepsis 
(Carlstedt et al., 2008). Infusing glucose did not rescue milk yield following an acute LPS 
challenge (chapter 5); however, milk production is also dependent on calcium, which was 
reduced 46% and did not return to baseline levels within the 12 h period of the study. 
Perhaps infusion of both glucose and calcium could work synergistically to rescue milk 
yield during acute inflammation. Temporally characterizing circulating calcium following 
an LPS bolus would also give a better idea of how severely calcium homeostasis is affected. 
While calcium metabolism is not the focus of this dissertation, understanding the role 
inflammation and endotoxin plays in milk fever may also be of interest. Due to the 
magnitude of change observed by us and others, it is clear calcium homeostasis is severely 
affected by acute LPS and merits further research. 
A portion of the current dissertation’s focus was glucose consumption by the 
immune system. Glucose is certainly an important substrate for immune cells and glucose 
availability may limit the immune response (Kimura et al., 1999; Vernay et al., 2012; 
Garcia et al., 2015). However, in addition to glucose availability, circulating NEFA and/or 
BHB may affect immune function.  A variety of studies have evaluated how NEFA and/or 
BHB affect various immune cells and their functions such as cytokine and immunoglobulin 
secretion, proliferation, phagocytic activity, and chemotaxis (Targowski and Klucinski, 
1983; Kluciński et al., 1988; Lacetera et al., 2004; Renner et al., 2013). Contrary to these 
findings, some studies demonstrate no change or an enhanced immune response to 
increasing levels of BHB and/or NEFA (Bouchard et al., 1999; Lessard et al., 2004; Valko 
et al., 2007; Dänicke et al., 2012; Schulz et al., 2015). Differences in cell culture conditions 
and the difficulty of simulating the complex metabolic environment of a transition cow 
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likely contribute to these conflicting results. Of particular interest is a set of in vitro studies 
by Franklin, Nonnecke, and Young (Franklin et al., 1991; Nonnecke et al., 1992) which 
demonstrated no change in lymphocyte proliferation or B cell IgM secretion with glucose 
and ketone body concentrations representative of a clinically ketotic cow. In conclusion, 
the literature is conflicting and more decisive in vivo research is needed to fully 
comprehend the dynamic relationship of glucose, insulin, NEFA, and BHB with immune 
cell function, particularly in transitioning dairy cows. 
Neutrophil function during the periparturient period is thought to be compromised, 
although a complete understanding of the mechanisms governing this are not entirely clear. 
As discussed above, postpartum immune dysfunction has been attributed in part to 
increased circulating metabolites such as BHB and NEFA. Furthermore, metabolic stresses 
associated with milk production are thought to contribute to immune cell dysfunction 
(Kimura et al., 1999) and cows with retained placental also exhibit depressed neutrophil 
function (Kimura et al., 2002). The immune cell functional assays in the aforementioned 
studies utilize leukocytes from peripheral circulation and do not include extravasated 
neutrophils or neutrophils in the marginated pool (i.e., neutrophil accumulation within 
organs or neutrophils adhered to blood vessel endothelial cells). During acute LPS infusion, 
changes in leukocytes are very dynamic with leukopenia occurring immediately, ostensibly 
increasing the fraction extravasated and marginated pool neutrophils. It would be of interest 
to somehow characterize function of this non-circulating fraction, although this would be 
difficult as the lifespan of a neutrophil within tissue is influenced by inflammation and 
neutrophil extracellular traps in vitro lead to neutrophil death within 4 h (Fuchs et al., 2007; 
Kolazkowska and Kubes, 2013). It may be that during parturition and peripheral 
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inflammatory situations (such as retained placenta), leukocyte distribution changes include 
functional leukocyte extravasation while less functional leukocytes remain in circulation. 
While we did not characterize circulating leukocyte dynamics past 12 h in the current 
dissertation, recent data our lab has generated indicates leukopenia is followed by 
leukocytosis by ~18 h (Horst and Baumgard, unpublished data). Characterizing neutrophil 
function at these different time points would help us to elucidate whether depressed 
neutrophil function during the periparturient period is related to changes in leukocyte 
distribution between the circulating and non-circulating pools. 
Finally, animal models outside lactating dairy cows have demonstrated systemic or 
peripheral inflammation (Ziegler et al., 1988; Russell et al., 1995; Hietbrink et al., 2009; 
Epple and Zeitz, 2012) and psychological stress (Wallon et al., 2008; Vanuytsel et al., 
2014) can contribute to gastrointestinal dysfunction. These aforementioned situations 
certainly have practical implications to dairy farm management. It would be of interest to 
study the effects of non-intestinal inflammation sources (i.e., mastitis, metritis, and 
laminitis) on intestinal health. Likewise, the social stresses of pen moves and overcrowding 
are frequently observed on-farm and create an unpredictable feeding environment which is 
associated with inflammation (Proudfoot et al., 2014). Understanding the impact of these 
stressful situations on intestinal health is worthy of additional study. 
In conclusion, intestinal barrier dysfunction is a situation likely more ubiquitous 
than previously thought. Continued study of intestinal dysfunction in lactating cows is 
necessary in order to develop mitigation strategies to curb inflammation and prevent 
production losses. The current dissertation elucidated direct metabolic and inflammatory 
consequences and also characterized feed restriction’s effects on intestinal dysfunction. 
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Furthermore, cost of immunoactivation in terms of glucose utilization was explicated. 
Future directions to expand upon this work include a greater understanding of calcium and 
lipid metabolism during inflammation, better characterization of immune cell function and 
how it is impacted by circulating metabolites and inflammation, and additional situations 
which may compromise intestinal integrity and cause inflammatory situations in practical 
dairy settings. With a greater appreciation for the metabolic and inflammatory changes, we 
can move forward in developing mitigation strategies aimed at increasing intestinal barrier 
integrity and limiting the negative influence of immunoactivation on metabolism and 
production. 
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APPENDIX A: ESTIMATING GLUCOSE REQUIREMENTS OF AN 
ACTIVATED IMMUNE SYSTEM IN GROWING PIGS 
 
An abstract presented in 2015 at the ASAS-ADSA Joint Annual Meeting: J. Anim. Sci. 
93(E-Suppl. S3):634. 
 
Abstract 
Activated immune cells are obligate glucose utilizers and a large lipopolysaccharide (LPS) 
IV dose causes severe hypoglycemia. Therefore, study objectives were to use the quantity 
of glucose needed to maintain euglycemia following an endotoxin challenge as a proxy of 
immune cell glucose requirement. Fifteen fasted crossbred gilts (30 ± 2 kg) were jugular 
catheterized bilaterally and assigned one of two IV bolus treatments: control (CON; 10 mL 
sterile saline; n=7) or LPS-infused + euglycemic clamp (LPS-Eu; E. coli 055:B5; 5 μg/kg 
BW; 50% dextrose infusion to maintain euglycemia; n=8). Following infusion, blood 
glucose was determined every 10 min and dextrose infusion rates were adjusted in LPS-Eu 
pigs to maintain euglycemia for 8 h. Rectal temperature was increased in LPS-Eu pigs 
relative to control (39.8 vs 38.8°C, P<0.01). After 3 h, blood glucose content gradually 
declined for CON pigs while LPS-Eu glucose levels remained unchanged (P=0.01). Plasma 
insulin, BUN, BHB, and L-lactate were increased in LPS-Eu pigs compared to CON (69, 
57, 21, and 60%, respectively; P<0.05). By 8 h, plasma LPS binding protein was increased 
24% in LPS-Eu pigs relative to controls (P<0.01). Plasma NEFA increased with time in 
CON pigs, but remained unchanged in the LPS-Eu pigs (P<0.01). White blood cells, 
lymphocytes, monocytes, eosinophils, and basophils were decreased in LPS-Eu pigs 
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relative to CON (P<0.01). Additionally, the neutrophil-to-lymphocyte ratio was increased 
in LPS-Eu pigs relative to CON (72%, P<0.01). During the 8 h, 116 ± 8 g of infused glucose 
was required to maintain euglycemia. If the amount of glucose required to maintain 
euglycemia can be used as a proxy, then the glucose requirements of an activated immune 
system are approximately 1.1 g/kg BW0.75/hr. 
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Figure 30. Effects of saline (CON; 10 mL i.v. saline bolus; n=7) or lipopolysaccharide 
infusion + euglycemic clamp (LPS-Eu; 5 µg/kg BW lipopolysaccharide i.v. bolus; E. coli 
055:B5 in saline; n=8) on (A) rectal temperature (Tr), (B) blood glucose and (C) rate of 
glucose infusion (ROGI) in fasted growing pigs (30.3 ± 2 kg BW)  
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Table 15. Effects of saline (CON) or LPS infusion + euglycemic clamp (LPS-Eu) on 
circulating metabolites and markers of inflammation in fasted growing pigs (30.3 ± 2 kg BW) 
 Trt1  P 
Parameter CON LPS-Eu SEM Trt Time Trt x Time 
Insulin, µg/L 0.04 0.13 0.02 <0.01 <0.01 <0.01 
NEFA2, µEq/L 326 147 22 <0.01 <0.01 <0.01 
β-hydroxybutyrate, µmol 61.2 77.6 3.9 0.01 <0.01 0.02 
L-lactate, mM 1.3 3.2 0.2 <0.01 <0.01 <0.01 
LBP3, µg/mL 14.9 16.3 0.5 0.04 0.34 0.27 
Blood urea N, mg/dL 7.3 14.0 1.6 0.01 <0.01 <0.01 
1Treatment: CON = 10 mL i.v. sterile saline bolus (n=7); LPS-Eu = 5 µg/kg BW 
lipopolysaccharide i.v. bolus; E. coli 055:B5 in saline (n=8) 
2Non-esterified fatty acids 
3Lipopolysaccharide binding protein 
 
  
Table 16. Effects of saline (CON) or LPS infusion + euglycemic clamp (LPS-Eu) on 
complete blood count parameters in fasted growing pigs (30.3 ± 2 kg BW) 
 Trt1  P 
Parameter CON LPS-Eu SEM Trt Time Trt x Time 
White blood cells, x 103/µL 14.8 6.7 1.0 <0.01 0.01 0.03 
Neutrophils, x 103/µL 5.69 4.56 0.70 0.29 <0.01 <0.01 
Lymphocytes, x 103/µL 7.72 1.94 0.47 <0.01 0.94 0.71 
Monocytes, x 103/µL 0.92 0.12 0.07 <0.01 0.83 0.58 
Eosinophils, x 103/µL 0.23 0.07 0.03 <0.01 0.63 0.06 
Basophils, x 103/µL 0.04 0.02 0.01 0.05 0.08 0.64 
Unidentified cells, x 103/µL 0.20 0.05 0.03 <0.01 0.70 0.67 
Red blood cells, x 106/µL 5.53 6.18 0.07 <0.01 <0.01 <0.01 
Hemoglobin, gm/dL 9.77 10.89 0.09 <0.01 <0.01 <0.01 
Hematocrit, % 30.84 34.63 0.42 <0.01 <0.01 <0.01 
Platelets, x 103/µL 491 211 21 <0.01 0.39 0.38 
Neutrophil:Lymphocytes 0.74 2.60 0.27 <0.01 <0.01 <0.01 
1Treatment: CON = 10 mL i.v. sterile saline bolus (n=7); LPS-Eu = 5 µg/kg BW 
lipopolysaccharide i.v. bolus; E. coli 055:B5 in saline (n=8) 
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APPENDIX B: EFFECTS OF REPEATED LIPOPOLYSACCHARIDE INFUSION 
ON HEMATOLOGIC, METABOLIC, AND INTESTINAL HISTOLOGY 
PARAMETERS 
 
An abstract presented in 2016 at Experimental Biology: FASEB J. 30:925.14. 
 
Abstract 
Objectives were to characterize effects of repeated LPS infusion on circulating metabolites, 
white blood cells, and intestinal histology in pigs. Ten crossbred female pigs (168 ± 2 kg) 
were reproductively synchronized and jugular catheterized. The experimental period, 
during the follicular phase of the estrous cycle, lasted 5 d and pigs were assigned to either 
control (CON; 3 mL i.v. saline; n=4) or lipopolysaccharide (LPS; 0.1 µg/kg BW LPS i.v.; 
Escherichia coli 055:B5 Sigma, St. Louis, Missouri; n=6) treatments administered 4x/d at 
0000, 0600, 1200, and 1800h. Each animal was limit-fed 2.7 kg of feed once daily at 0600 
h. Blood samples for metabolites and a complete blood count were obtained daily at 1730h. 
Rectal temperatures were measured 2x/d at 0530 and 1730h and condensed into daily 
averages. Animals were sacrificed on d 6 beginning at 0600h and segments of jejunum, 
ileum, and colon were collected and analyzed for morphology and were stained for 
myeloperoxidase (a measure of neutrophil infiltration). Circulating platelets were 
decreased 31% (P<0.01) and total white blood cell count tended to be decreased 10% 
(P=0.07) in LPS relative to CON pigs. Lipopolysaccharide binding protein was increased 
37% in LPS pigs relative to CON pigs (P=0.05) and was increased 60% on d 1 of the 
experiment relative to CON pigs (P=0.02). There was a treatment by day interaction for 
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neutrophils, lymphocytes, monocytes, and eosinophils where on d 1 only, neutrophils were 
increased 58% in LPS pigs relative to CON (P<0.01) and lymphocytes, monocytes, and 
eosinophils were decreased by 61, 93, and 81%, respectively in LPS pigs relative to CON 
(P<0.01 for all). Likewise, treatment by day differences in blood metabolites were 
observed where on d 1, insulin, blood urea nitrogen, β-hydroxybutyrate, and ionized 
calcium increased 36, 14, 13, and 7%, respectively, in LPS pigs relative to CON pigs 
(P=0.03, P=0.07, P=0.02,  and P<0.01, respectively). There was no treatment by day 
interaction for blood glucose; however, it tended to be increased 6% in LPS pigs on d 1 
relative to controls (84 vs 79 mg/dL; P=0.08). Rectal temperature did not differ between 
the two treatments throughout the entire study (38.5 vs 38.6°C; P=0.71). In the jejunum, a 
tendency for reduced goblet cell area was observed (2.2 vs 5.6%; P=0.06) as well as an 
increase in myeloperoxidase stained area (1.03 vs 0.87%; P<0.01) in LPS pigs relative to 
CON. No other differences in histological measurements were observed. In conclusion, 
LPS only altered metabolism on d 1 of the 5 d injection period. Platelets were the only 
measurement consistently affected throughout the 5 d. Jejunum was the only intestinal 
segment which seemed to be affected by repeated LPS exposure as determined by a 
tendency for reduced goblet cell area and an increase in myeloperoxidase stained area. 
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Table 17. Effects of 5-day lipopolysaccharide or saline administration on rectal temperature and 
circulating metabolic and inflammatory parameters 
 Treatment1 
 
 
 
P 
Parameter CON LPS 
 
SEM 
 
Trt Day Trt x Day 
Glucose, mg/dL 79 84  3  0.33 0.74 0.36 
Rectal Temperature, °C 38.5 38.6  0.1  0.71 <0.01 0.68 
Insulin, μg/L 0.392 0.519  0.06  0.12 0.20 0.03 
NEFA2, mEq/L 83.1 89.7  14.6  0.76 0.61 0.54 
β-hydroxybutyrate, mg/dL 0.69 0.73  0.02  0.25 0.02 0.02 
Blood urea nitrogen, mg/dL 9.0 9.6  0.4  0.41 0.02 0.07 
L-lactate, µM 2006 1879  53  0.11 0.25 0.08 
LBP3, µg/mL 12.5 19.9  2.3  0.05 0.01 0.02 
1Treatments: CON = control pigs receiving 3 mL saline i.v. 4x/d for 5 d; LPS = pigs receiving 0.1 µg/kg 
BW lipopolysaccharide Escherichia coli 055:B5 i.v. 4x/d for 5 d 
2Non-esterified fatty acids 
3Lipopolysaccharide binding protein 
 
 
Table 18. Effects of 5-day lipopolysaccharide or saline administration on blood gases, hematology, and 
electrolytes 
 Treatment1    P 
Parameter CON LPS  SEM  Trt Day Trt x Day 
pH 7.44 7.45  0.01  0.09 <0.01 0.42 
CO2 partial presure, mmHg 47.2 44.9  0.6  0.03 <0.01 0.36 
O2 partial pressure, mmHg 37.7 42.6  1.7  0.07 <0.01 0.78 
Base excess, mmol/L 7.9 7.0  0.4  0.17 0.08 0.73 
HCO3, mmol/L 32.0 31.0  0.4  0.12 0.01 0.72 
Total CO2, mmol/L 33.5 32.4  0.4  0.11 0.01 0.49 
O2 saturation, % 71.9 78.8  1.6  0.02 <0.01 0.35 
Hemoglobin, g/dL 10.3 10.6  0.3  0.53 0.42 0.42 
Hematocrit, % 30.4 31.2  0.8  0.52 0.42 0.71 
Sodium, mmol/L 142.4 141.6  0.2  0.05 0.06 <0.01 
Potassium, mmol/L 4.1 4.1  0.1  0.45 0.34 0.30 
Ionized Calcium, mmol/L 1.40 1.39  0.01  0.63 <0.01 <0.01 
1Treatments: CON = control pigs receiving 3 mL saline i.v. 4x/d for 5 d; LPS = pigs receiving 0.1 µg/kg 
BW lipopolysaccharide Escherichia coli 055:B5 i.v. 4x/d for 5 d 
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Table 19. Effects of 5-day LPS or saline administration on complete blood count parameters 
 Treatment1    P 
Parameter CON LPS  SEM  Treatment Day 
Trt x 
Day 
White blood cells, x 103/μL 18.5 16.7  0.6  0.07 <0.01 0.14 
Neutrophils, x 103/μL 4.6 5.1  0.4  0.42 <0.01 <0.01 
Lymphocytes, x 103/μL 11.5 10.3  0.7  0.27 <0.01 <0.01 
Monocytes, x 103/μL 0.77 0.56  0.08  0.13 <0.01 <0.01 
Eosinophils, x 103/μL 1.2 0.9  0.1  0.09 0.55 <0.01 
Basophils, x 103/μL 0.08 0.07  0.01  0.74 0.30 0.21 
Unidentified cells, x 103/μL 0.08 0.08  0.01  0.83 0.06 0.54 
Red blood cells, x 106/μL 6.1 6.3  0.1  0.18 0.25 0.86 
Platelets, x 103/μL 292 201  20  0.01 <0.01 <0.01 
Neutrophils:Lymphocytes 0.42 0.76  0.1  0.09 <0.01 <0.01 
1Treatments: CON = control pigs receiving 3 mL saline i.v. 4x/d for 5 d; LPS = pigs receiving 0.1 µg/kg 
BW lipopolysaccharide  Escherichia coli 055:B5 i.v. 4x/d for 5 d 
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Table 20. Effects of 5-day lipopolysaccharide or saline administration on intestinal 
morphology 
 Treatment1    P 
Parameter CON LPS  SEM  Trt 
Jejunum       
Crypt depth, μm 359 306  21  0.12 
Villous height, μm 387 410  32  0.62 
Villous width, μm 170 177  9  0.60 
Goblet cell area, %2 5.6 2.2  1.0  0.06 
Mucosal surface area, M index3 6.3 5.9  0.3  0.49 
MPO Area, %4 0.9 1.0  0.1  <0.01 
Ileum       
Crypt depth, μm 165 179  20  0.63 
Villous height, μm 330 328  23  0.95 
Villous width, μm 134 132  11  0.87 
Goblet cell area, %2 6.3 4.9  1.8  0.61 
Mucosal surface area, M index3 6.4 6.3  0.4  0.92 
MPO Area, %4 4.9 5.0  0.3  0.85 
Colon       
Goblet cell area, %2 16.2 13.6  3.0  0.57 
MPO Area, %4 0.5 0.4  0.1  0.19 
1Treatments: CON = control pigs receiving 3 mL saline i.v. 4x/d for 5 d; LPS = pigs receiving 
0.1 µg/kg BW lipopolysaccharide Escherichia coli 055:B5 i.v. 4x/d for 5 d  
2Expressed as a percentage of epithelial area 
3M-index = (villous surface + unit bottom – villous bottom)/unit bottom, where villus surface = 
π ∙ (villous length ∙ villous width), unit bottom = π ∙ (villous width/2 + crypt width/2)2, and 
villous bottom = π∙(villous width/2)2 as described by Kisielinski et al., 2002. 
4Percentage of positive myeloperoxidase relative to total stained area 
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APPENDIX C: EFFECT OF SUPPLEMENTAL CITRULLINE ON THERMAL, 
PRODUCTION, AND INTESTINAL HEALTH PARAMETERS DURING HEAT 
STRESS AND NUTRIENT RESTRICTION IN GROWING PIGS 
 
A combination of two abstracts presented in 2016 at the ASAS-ADSA Joint Annual 
Meeting: J. Anim. Sci. 94(E-Suppl. 5):995 and in 2017 at the ASAS-ADSA Midwest 
Meeting: J. Anim. Sci. 95(E-Suppl. 2):20. 
 
Abstract 
Heat stress (HS) compromises intestinal barrier function, and citrulline improves intestinal 
health in rodent models. Therefore, objectives were to characterize effects of citrulline 
supplement (CIT) on physiological and production responses during HS. Supplements 
were fed twice daily at 0600 and 1800 h and consisted of 20 g of cookie dough without 
citrulline (CON) or with 0.13 g/kg BW L-citrulline (CIT; 99.3% purity; MP Biomedicals, 
Santa Ana, CA). Forty crossbred gilts (30 ± 2 kg) were assigned to 1 of 5 supplemental-
environmental treatments: 1) thermoneutral (TN; 23.6 ± 0.1°C) ad libitum feed (AL) with 
CON (TNAL; n=8), 2) TN pair-fed (PF) with CON (PF-CON; n=8), 3) TN PF with CIT 
(PF-CIT; n=8), 4) HS AL with CON (HS-CON; n=8), and 5) HS AL with CIT (HS-CIT; 
n=8). Acclimation lasted 4 d and all pigs received the CON supplement. During period 1 
(P1; 7 d), pigs were kept in TN, fed AL, and fed respective supplemental treatments. During 
period 2 (P2; 60 h), HS-CON and HS-CIT animals were fed AL and exposed to cyclical 
HS (33.6 to 38.3°C) while TNAL, PF-CON, and PF-CIT remained in TN and were fed 
either AL or PF to their HS counterparts to negate the effect of dissimilar nutrient intake. 
255 
 
 
Feed intake was measured daily and BW was obtained 1 d before P1, d 7 of P1, and at P2 
conclusion. Animals were sacrificed following P2 and segments of jejunum, ileum, and 
colon were collected and analyzed for morphology and were stained for myeloperoxidase 
(a measure of neutrophil infiltration). Rectal temperature (Tr), skin temperature (Ts), and 
respiration rate (RR) were obtained once daily at 1800 h during P1 and thrice daily at 0600, 
1200, and 1800 h during P2. Pigs exposed to HS had increased Tr (0.8°C), Ts (4.7°C), and 
RR (47 bpm) relative to TN pigs (P<0.01). HS-CIT pigs had decreased RR (7 bpm, P=0.04) 
and a tendency for decreased Tr (0.1°C, P=0.07). Feed intake decreased ~16% in HS 
relative to TNAL pigs (P<0.01) and did not differ between HS and PF pigs (P>0.10). P2 
ADG decreased 11 and 30% in HS and PF pigs, respectively, relative to TNAL pigs. PF-
CIT pigs tended to have increased (0.12 kg/d) ADG compared to PF-CON pigs (P=0.09). 
Gain:feed was similar between TNAL and HS pigs but decreased 30% in PF relative to 
TNAL pigs (P<0.01). No effects of CIT on production variables during HS were detected. 
Exposure to HS decreased both jejunum villus height and mucosal surface area (12 and 
15%, respectively; P<0.01) with no effect of CIT supplementation. In the ileum, exposure 
to HS decreased villus height and mucosal surface area (15 and 19 %, respectively P<0.01) 
in HS-CON relative to TNAL pigs, and supplementation with CIT ameliorated these 
changes (P<0.01). Pigs supplemented with CIT during HS had 53% increased circulating 
LBP concentrations relative to HS-CON (P=0.03). There were no treatment differences on 
neutrophil infiltration in the jejunum. Pigs exposed to HS tended to have increased ileum 
neutrophil infiltration relative to TNAL controls (30%; P=0.09), but did not differ from PF 
animals. Interestingly, PF-CON pigs had increased ileum neutrophil infiltration relative to 
TNAL and PF-CIT pigs (49 and 63%, respectively; P≤0.02). In the colon, HS increased 
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neutrophil infiltration 62% (P=0.02) relative to TNAL controls, but this did not differ from 
PF-CON pigs as colon neutrophil infiltration was also increased in PF-CON relative to 
TNAL and PF-CIT pigs (64 and 108%, respectively; P≤0.03). In summary, no effect of 
CIT supplementation on production variables during HS were detected. Supplementing 
CIT had minimal effects on physiological and production parameters during HS, but tended 
to increase ADG during limit-feeding. Exposure to HS had detrimental effects to both 
jejunum and ileum morphology, and CIT supplementation was only able to rescue changes 
in the ileum. Both HS and nutrient restriction increase neutrophil infiltration in the distal 
gastrointestinal tract. Supplemental citrulline did not diminish this immune response 
during HS but does ameliorate it under nutrient-restriction conditions. There may be 
beneficial effects of CIT on gut health during HS and nutrient restriction, but further 
investigation is needed. 
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Figure 31. Effect of citrulline supplementation on (A) rectal temperature (Tr), (B) skin temperature (Ts), (C) respiration rate 
(RR), and (D) circulating lipopolysaccharide binding protein (LBP) during heat stress or pair-feeding 
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Table 21. Effects of citrulline supplementation on production parameters during heat stress or pair feeding 
 Treatment1    P  Contrasts 
 TNAL PF-CON PF-CIT HS-CON HS-CIT  SEM  Trt  
TNAL v 
PF2 
TNAL v 
HS3 
PF-CIT v 
PF-CON 
HS-CIT v 
HS-CON 
Period 1               
End BW, kg 40.4 40.0 41.0 40.0 40.1  0.2  0.10  0.71 0.28 0.01 0.91 
FI, kg/d 2.05 1.96 2.16 1.92 1.94  0.07  0.15  0.94 0.15 0.04 0.82 
ADG4 0.89 0.84 0.98 0.84 0.85  0.04  0.10  0.71 0.28 0.01 0.91 
Gain:Feed 0.44 0.43 0.46 0.44 0.43  0.02  0.75  0.59 0.85 0.22 0.69 
Period 2               
End BW, kg 43.5 41.1 42.5 42.5 42.6  0.3  <0.01  <0.01 0.02 0.01 0.86 
FI, kg/60 h 5.28 4.03 4.77 4.08 4.20  0.26  <0.01  0.01 <0.01 0.05 0.72 
ADG4 1.01 0.36 0.48 0.82 0.83  0.10  <0.01  <0.01 0.08 0.34 0.93 
Gain:Feed 0.45 0.24 0.26 0.50 0.49  0.06  0.02  0.01 0.52 0.83 0.89 
1Treatments: TNAL = thermoneutral ad-libitum; PF-CON = pair-fed control; PF-CIT = pair-fed citrulline; HS-CON = heat stress control; HS-CIT = 
heat stress citrulline 
2PF-CON and PF-CIT pigs 
3HS-CON and HS-CIT pigs 
4Feed intake 
5Average daily gain 
2
5
8
 
